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ABSTRACT: 
The enzyme choline acetyltransferase (ChAT) mediates synthesis of the neurotransmitter 
acetylcholine required for cholinergic neurotransmission. ChAT mutations are linked to 
congenital myasthenic syndrome (CMS), a rare neuromuscular disorder. One CMS-related 
mutation, V18M, reduces ChAT enzyme activity and cellular protein levels, and is located 
within a highly-conserved N-terminal proline-rich motif at residues 14PKLPVPP20. It is 
currently unknown if this motif regulates ChAT function. In this thesis, I demonstrate that 
disruption of this proline-rich motif in mouse cholinergic SN56 cells reduces both the 
protein levels and cellular enzymatic activity of mutated P17A/P19A- and V18M-ChAT. 
The cellular loss of mutant ChAT protein appears to be a result of increased proteasome-
dependent degradation due to enhanced ChAT ubiquitination. Using a novel fluorescent-
biorthogonal pulse-chase protocol, I determined that the cellular protein half-life of 
P17A/P19A-ChAT (2.2 h) is substantially reduced compared to wild-type ChAT (19.7 h), 
and that proteasome inhibition by MG132 treatment increases the half-life and steady-state 
levels of ChAT protein. By proximity-dependent biotin identification (BioID), co-
immunoprecipitation, and in situ proximity-ligation assay (PLA), I identified the heat shock 
proteins HSC/HSP70 and HSP90 as novel ChAT protein-interactors that are enriched in 
cells expressing mutant P17A/P19A-ChAT. Pharmacological inhibition of these HSPs by 
treatment with the HSC/HSP70 inhibitors 2-phenylethynesulfonamide (PES) or VER-
155008, or the HSP90 inhibitor 17-AAG reduced cellular ChAT activity and solubility, and 
enhanced ubiquitination and proteasomal loss of ChAT protein. The effects of HSP 
inhibition were greatest for mutant P17A/P19A- and V18M-ChAT. While I observed that 
ChAT interacts in situ with the HSP-associated E3 ubiquitin ligase CHIP, siRNA-mediated 
knock-down of CHIP had no effect on ChAT protein levels. Inhibition of HSC/HSP70 by 
PES treatment sensitized ChAT to H2O2-induced insolubilization, and ChAT ubiquitination 
was enhanced following H2O2 treatment. Lastly, inhibition of the endoplasmic reticulum 
(ER)- and HSP-associated co-chaperone Cdc48/p97/Valosin-containing protein (VCP) 
prevented the degradation of ubiquitinated ChAT. Together my results identify novel 
mechanisms for the functional regulation of wild-type and CMS-related mutant ChAT by 
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multiple molecular chaperones and the ubiquitin-proteasome system that, importantly, may 
have broader implications for ChAT function during cellular stress and disease.  
 
 
 
KEYWORDS: 
Choline acetyltransferase (ChAT), molecular chaperones, protein degradation, protein 
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CHAPTER 1: INTRODUCTION 
1.1: Proteostasis and protein quality control mechanisms 
Preservation of protein homeostasis (i.e. proteostasis) is critical for the maintenance of 
cellular function under both physiological conditions and during cellular stress, whereas 
dysregulation of proteostatic mechanisms is a hallmark of many diseases. Regulation of 
cellular proteostasis relies on a complex interconnected network of cellular factors that 
collectively function as protein quality control mechanisms to promote protein function. 
These factors can be separated into four broadly defined systems (Figure 1.1); first, factors 
related to mRNA synthesis, processing, and stability, along with ribosome biogenesis 
regulate the synthesis of nascent proteins [1-3]. Second, nascent proteins are folded into 
mature, functional, and active proteins by various endoplasmic reticulum (ER)-associated 
and/or cytoplasmic molecular chaperones, such as heat shock proteins (HSPs), that 
cooperate with other cellular factors that regulate disulfide-bond formation, glycosylation, 
and protein phosphorylation [4-6]. Third, molecular chaperones play a critical role in the 
maintenance of protein function in cells exposed to various proteotoxic conditions, such as 
hyperthermia and oxidative stress, by preventing stress-induced protein misfolding and 
aggregation [7-10]. Fourth, and lastly, the proteolytic degradation of cellular proteins is 
essential for the timely turnover and attenuation of signalling proteins (e.g. transcription 
factors), and for the removal of excess, stress-damaged, misfolded, and dysfunctional 
proteins. Proteolysis of proteins is regulated through two major distinct cellular pathways, 
these being the autophagy-lysosome and the ubiquitin-proteasome systems [11-13], and, 
importantly, dysregulation of these proteolytic systems is known to be a critical feature of 
cancer and of various human neurodegenerative diseases [14-15]. Of note, many of these 
distinct protein quality control mechanisms not only work in tandem, but can also directly 
interact with one another, such as in the case for degradation of misfolded proteins by ER-
associated protein degradation (ERAD) via the ubiquitin-proteasome system [16]. This 
thesis will hereafter explore in detail cellular mechanisms related to the ubiquitin-
proteasome system and protein degradation, as well as various molecular chaperones that 
promote protein folding and stability and that target misfolded proteins for degradation. 
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Figure 1.1: Protein quality control overview. Regulation of protein homeostasis (i.e. 
proteostasis) is a critical process required for the maintenance of cellular function. Cellular 
proteostasis relies on protein quality control mechanisms that involve a complex 
interconnected network of cellular factors that regulate protein synthesis (e.g. ribosome 
biogenesis), maturation (e.g. endoplasmic reticulum (ER)-associated and cytoplasmic 
protein chaperones), protein maintenance during cellular stress, and protein degradation 
through, for example, the ubiquitin-proteasome system (UPS). Of note, many of these 
distinct cellular mechanisms not only work in tandem, but also interact with one another, 
such as in the case for ER-associated protein degradation (ERAD) of misfolded proteins 
via the ubiquitin-proteasome system. 
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1.2: The ubiquitin-proteasome system 
1.2.1: The proteasome 
The ubiquitin-proteasome system is one of two major cellular pathways responsible for the 
highly selective degradation of intracellular proteins in eukaryotic cells [11-12]. This 
system relies on two core components, the proteolytic 26S proteasome, and the small 8.5 
kDa signalling protein ubiquitin (Figure 1.2). The eukaryotic 26S proteasome is a multi-
subunit protein complex that consists of a hollow catalytic 20S core particle that is 
sandwiched between two ATP-dependent 19S regulatory particles [17-19]. The 20S core 
itself contains four stacked heptagonal rings consisting of two structural α-subunits that 
interact with the 19S regulatory particle and that are flank by two central β-subunits that 
impart threonine-dependent proteolytic activity to the 26S proteasome [20-22]. Multiple 
small molecule inhibitors that target the 20S proteasome core have been identified that are 
commonly used in cellular and molecular studies, such as MG132 and lactacystin [23-26], 
or that have been shown to have in vivo anti-tumorigenic properties such as bortezomib 
[27-28]. Substrate-specificity and activation of the 26S proteasome in regulated by the 
ATP-dependent 19S regulatory particles. These protein complexes contain multiple Rpt 
proteins, members of the ATPases associated with diverse cellular activities (AAA-
ATPase) family, and non-ATPase Rpn proteins that together form a “molecular lid” that 
gates entry of substrates into 20S core particle for proteolytic breakdown [22, 29-32]. 
Recognition of proteasome substrates is mediated through interaction of Rpn proteins 
within the 19S regulatory particle, specifically Rpn10 and Rpn13, with the small protein 
ubiquitin when it is covalently attached to cellular proteins destined for proteolysis [33-36].  
  
1.2.2: Ubiquitin 
Ubiquitin is a highly-conserved 76 amino acid (8.5 kDa) regulatory protein expressed 
ubiquitously across eukaryota [37-40]. In mammals, ubiquitin is expressed from four 
different genes as precursor proteins that are either bound to the ribosomal biogenic 
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Figure 1.2: The ubiquitin-proteasome system. Cellular proteins are selectively targeted 
for proteasomal degradation by ATP-dependent post-translational modification with the 
small 8.5 kDa protein ubiquitin (Ub). Construction of substrate-bound polyubiquitin chains 
targets ubiquitinated proteins for proteolytic degradation by the 26S proteasome, a large 
multimeric protein complex consisting of a hollow catalytic 20S core particle sandwiched 
between two 19S regulatory particles. Binding of polyubiquitin chains to the Rpn proteins 
Rpn10 and Rpn13 located within the 19S regulatory particles promotes the 
deubiquitination, unfolding, and uptake of proteasome-targeted proteins into the 20S core 
where they are subsequently degraded in an ATP-dependent manner. Small molecule 
inhibitors of the proteasome, such as MG132 and lactacystin, interfere with the 20S core 
β-subunits, leading to accumulation of ubiquitinated proteasome substrates [36]. 
 
proteins L40 or S27 [41-42] or are expressed as tandem repeats that are post-translationally 
processed into free monomeric ubiquitin by deubiquitinating enzymes (DUBs) [43]. In the 
cell ubiquitin can most often be found either in its free and unbound monomeric state or 
covalently bound to other cellular proteins as either monomers or as a polyubiquitin (poly-
Ub) chain [43-44]. Canonically, ubiquitination of cellular proteins occurs through the 
formation of a covalent isopeptide bond between residue Gly76 at the extreme C-terminus 
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of ubiquitin and the ε-amino group of a targeted lysine residue located either on a substrate 
protein or on a substrate-conjugated ubiquitin molecule [44-46]. Alternatively, protein 
ubiquitination has also been shown to occur on serine and threonine residues, as well as on 
N-terminal methionine residues [47-49]. Ubiquitination has been shown to have multiple 
diverse effects on protein function, including regulation of enzyme activity and subcellular 
trafficking, though is known foremost to promote the proteasome-dependent degradation 
of ubiquitinated proteins [44, 50-51].  
 
1.2.3: Ubiquitination mechanisms 
Conjugation of ubiquitin onto cellular proteins is a well-characterized multistep process 
that involves three distinct classes of enzymes in addition to ubiquitin (Figure 1.3). First, 
in an ATP-dependent manner monomeric free ubiquitin binds to and forms a thioester bond 
between the C-terminal residue Gly76 of ubiquitin and the catalytic cysteine residue of an 
E1 ubiquitin-activating enzyme. Second, the activated ubiquitin is transferred to the active 
site cysteine of an E2 ubiquitin-conjugating enzyme. Third, E3 ubiquitin ligases facilitate 
transfer of the active ubiquitin molecule onto a protein substrate by formation of a covalent 
isopeptide bond between reside Gly76 of ubiquitin and the ε-amino group of a substrate 
lysine residue. Conjugation of a single ubiquitin molecule on a protein substrate (i.e. 
monoubiquitination) can then serve as a primer for the construction of larger proteolytic 
poly-Ub chains by isopeptide attachment of free monomeric ubiquitin onto lysine residues 
within substrate-bound ubiquitin molecules. Alternatively, poly-Ub chains can be 
deconstructed and removed from substrate proteins by various DUBs [34, 44, 52-54]. While 
this process is known to exhibit a high degree of substrate specificity, it is believed that 
over 800 distinct cellular proteins are involved directly in the regulation of protein 
ubiquitination. Specifically, in humans two genes encode for two different E1 activating--
enzymes (UBA1 and UBA6) that are solely responsible for ubiquitin activation [55]. 
Conversely, it is estimated that approximately 40 different E2 conjugating-enzymes, over 
600 unique E3 ubiquitin ligases, and roughly 100 distinct DUBs are expressed in human  
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Figure 1.3: The ubiquitination pathway.  Ubiquitination of cellular proteins involves 
three distinct classes of enzymes. First, monomeric free ubiquitin (Ub) covalently binds to 
the catalytic cysteine residue of an E1 ubiquitin-activating enzyme in an ATP-dependent 
manner. Second, the activated ubiquitin molecule is transferred to the active site cysteine 
of an E2 ubiquitin-conjugating enzyme. Third, E3 ubiquitin ligases facilitate transfer of the 
active ubiquitin molecule onto protein substrates by promoting the formation of a covalent 
isopeptide bond between the C-terminal residue Gly76 of ubiquitin and the ε-amino group 
of a lysine residues on the substrate protein. Attachment of a single ubiquitin molecule (i.e. 
monoubiquitination) can then serve as a primer for the construction of larger proteolytic 
polyubiquitin (poly-Ub) chains by isopeptide attachment of free monomeric ubiquitin onto 
lysine residues located within substrate-bound ubiquitin molecules. Alternatively, poly-Ub 
chains can be deconstructed and monomeric ubiquitin can be removed from substrate 
proteins by various deubiquitinating enzymes (DUBs) [40, 43-44, 52, 61].  
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cells [56-59]. Subsequently, due to the substantial number of and their role in directly 
interacting with protein substrates, E3 ubiquitin ligases are thought to provide the majority 
of substrate specificity to the cellular ubiquitination system [44, 60-61].  
E3 ubiquitin ligases can be categorized into two major families defined by their 
sequence/structural homology and the mechanism by which they transfer ubiquitin from 
E2 conjugating-enzymes onto their substrates. First, members of the homologous to the E6-
AP carboxy terminus (HECT) family are characterized by their ability to first accept 
ubiquitin from E2 enzymes by formation of a covalent intermediate thioester bond via a 
conserved catalytic cysteine within the E3 HECT domain, then subsequently covalently 
transfer ubiquitin onto their substrates [62-63]. Of the over 600 estimated E3 ubiquitin 
ligases, to date only 28 HECT family members have been identified based on homology to 
the E3 ligase E6-associated protein (E6-AP) [57], with the WW-domain containing 
NEDD4 [64-66] and the BH3-domain containing HUWE1/Mule [67-68] representing two 
well-characterized HECT E3 ligases. Conversely, the large majority of E3 ubiquitin ligases 
belong to the really interesting new gene (RING) family that are characterized for their 
ability to facilitate direct conjugation of ubiquitin from E2 enzymes onto their substrates 
without forming covalent intermediates [69-70]. One notable feature of the RING family 
is the tendency of these E3 ubiquitin ligases to form large multi-protein heterocomplexes, 
particularly in collaboration with scaffolding Cullin proteins, with two well-documented 
examples being the Skp1-Cul1-F-box (SCF) complex and the anaphase-promoting 
complex (APC) [71-72]. Lastly, a smaller third family of RING-like E3 ubiquitin ligases 
has been identified that contain a conserved catalytic U-box domain [73-75], with the HSP-
associated C-terminus of HSC70-interacting protein (CHIP/Stub1) being a notable U-box 
E3 ubiquitin ligase critical to the chaperone-mediated degradation of misfolded proteins 
[76-78]. It is important to note that E3 ubiquitin ligases can contain aspects from both 
HECT and RING ligases, such as Parkin [79], and that members from all E3 families are 
capable of both mono- and polyubiquitination of their protein substrates [44, 59-60]. 
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1.2.4: The ubiquitin code 
Protein ubiquitination has been shown to have both proteolytic and non-proteolytic 
functions. For example, studies have shown that monoubiquitination can regulate various 
cellular processes including cell cycle progression, mitosis/meiosis, and transcriptional 
activity [80-81], as well as endocytosis of plasma membrane-bound receptors and channels 
[82-84] and viral budding [85-87]. Conversely, the construction of substrate-bound poly-
Ub chains canonically promotes the proteasome-dependent degradation of ubiquitinated 
cellular proteins, though polyubiquitination has also been shown to have non-proteolytic 
functions. The function of poly-Ub chains is dependent on the “lysine-linkages” between 
individual ubiquitin molecules within a substrate-bound poly-Ub chain, where ubiquitin 
contains seven lysine residues at positions K6, 11, 27, 29, 33, 48, and 63 that can be used 
to form differential ubiquitin-ubiquitin isopeptide linkages to construct poly-Ub chains 
(Figure 1.4). These different linkages produce structurally-distinct poly-Ub chains, such as 
for K48- and K63-linked chains, that allow for differential recognition by ubiquitin-binding 
proteins containing ubiquitin-binding domains (UBD) [88-90]. Classically, the proteolytic 
features of ubiquitination have been best characterized for K48-linked chains where 
modification of cellular proteins with poly-Ub chains containing at least four K48-linked 
ubiquitin molecules targets these polyubiquitinated proteins for proteasome-dependent 
degradation [44-45, 54, 60, 91-93]. Though, more recently K11-linked chains have also 
been shown to target substrates for proteasomal degradation and have been shown to 
regulate cellular processes such as cell cycle progression by the APC [94-96] or ERAD 
through interaction of K11-linked chains with the ER-associated AAA-ATPase 
cdc48/p97/Valosin-containing protein (VCP) [50, 97-98]. In contrast, K63-linked chains 
largely perform non-proteolytic functions and have been shown to regulate endocytic 
protein trafficking, DNA repair mechanisms, kinase activation, and ribosomal function [99-
102]. Interestingly, multiple studies have also documented the degradation of K63-linked 
substrates in a proteasome-independent nature via the autophagy-lysosome system [103-
105]. The remaining poly-Ub linkages (K6-, K27-, K29-, and K33-linked chains) have been 
less characterized and have unclear and/or unknown functions [44, 54, 60, 106].  
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Figure 1.4: The ubiquitin code. (A) Three-dimensional (3D) ribbon diagram of the crystal 
structure of human erythrocytic ubiquitin (PDB: 1UBQ) [107]. Ubiquitin contains seven 
lysine residues (shown in green) at positions K6, 11, 27, 29, 33, 48, and 63 that can all be 
used for the extension of poly-ubiquitin chains by formation of covalent isopeptide linkages 
between the C-terminal Gly76 residue (red) of a free ubiquitin molecule and lysine residues 
within substrate-bound ubiquitin. (B) Cellular proteins targeted for degradation are first 
monoubiquitinated by covalent attachment of monomeric ubiquitin (Ub) onto substrate 
lysine residues by E3 ubiquitin ligases. Monoubiquitination can then either alter substrate 
protein function (i.e. subcellular trafficking and/or protein signalling) or can serve as a 
primer for the construction of larger proteolytic poly-Ub chains. Classically, proteasome-
dependent degradation of cellular proteins requires recognition of substrate-bound K48-
linked poly-Ub chains by the 26S proteasome. Alternatively, K11-linked poly-Ub chains 
have also been implicated in the proteasomal degradation of cell cycle modulators by the 
anaphase-promoting complex (APC) and of endoplasmic-reticulum-associated protein 
degradation (ERAD) substrates. Conversely, K63-linked poly-Ub chains largely perform 
non-proteolytic functions (i.e. regulation of endosomal trafficking, kinase activation, and 
DNA repair mechanisms), though can also promote the lysosomal-dependent degradation 
of K63-linked proteins. K6-, 27-, 29-, and 33-linked poly-Ub chains have unclear and/or 
unknown functions [44, 50-51, 54, 60, 87]. 
 
1.2.5: Autophagy-lysosomal degradation 
In addition to the ubiquitin-proteasome system, the autophagy-lysosome system is another 
distinct cellular pathway that mediates degradation of intracellular proteins. Cytoplasmic 
materials destined for lysosomal degradation, such as damaged organelles and excess, 
foreign, insoluble, and/or aggregated proteins, are first enveloped into autophagosome 
vesicles through a process called autophagy [108-109]. Subsequently, autophagosomes 
fuse with the lysosome, a membrane-bound acidic organelle that contains various pH-
sensitive proteases with broad proteolytic activity, resulting in the gross proteolysis of 
cytoplasmic materials within autophagosomes [110-111]. Though multiple mechanisms 
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can direct cellular proteins to the lysosome, ubiquitination of lysosomal targets with K63-
linked poly-Ub chains is a well documented signal for lysosomal proteolysis [51, 103-105, 
112-113]. In addition, alternative poly-Ub chains, such as K27- or K29-linked chains, have 
been shown to target cellular proteins for lysosomal degradation [114-115]. Lastly, 
important to the molecular study of lysosome function, multiple lysosomal inhibitors have 
been identified, such as the vacuolar-type H+-ATPase inhibitor bafilomycin-A1 [116] and 
the lysosomotropic agent chloroquine [117]. 
 
1.3: Protein folding and molecular chaperones 
1.3.1: Molecular chaperones overview 
Cellular proteolytic pathways are essential to protein quality control and the maintenance 
of proteome integrity through the break-down of excessive, foreign, misfolded, and 
dysfunctional proteins, as well as for the turn-over of short-lived signaling proteins. To 
balance these pro-degradative pathways, cells also rely on opposing molecular mechanisms 
that promote the stabilization of cellular protein through protein folding, maturation, and 
maintenance. Proper and completed protein folding of not only newly synthesized nascent 
proteins, but also of misfolded proteins during cellular stress, represents a critical 
proteostatic mechanism as the stability and function of most cellular proteins is dependent 
on obtaining specific three-dimensionally folded structures. The cellular mechanisms that 
oversee protein folding are extensively varied, though central to this process are molecular 
chaperones that not only interact with and promote the folding of nascent and 
misfolded/aggregated proteins but can also “triage” terminally misfolded proteins for 
proteolytic degradation (Figure 1.5) [118-121]. As such, dysregulation of protein 
chaperones has been associated with the accumulation of mutated, misfolded, and/or 
aggregated proteins in several human diseases, such as cancer and age-related 
neurodegeneration [122-125].  
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Figure 1.5: Molecular chaperones regulate cellular proteostasis. Molecular chaperones 
interact with and promote the folding and stabilization of non-native nascent and semi-
folded proteins. Additionally, molecular chaperones assist in the refolding and 
disaggregation of misfolded and/or aggregated proteins following cellular stress (e.g. 
hyperthermia and oxidative stress) or in the case of mutated or disease-related aggregate-
prone proteins (e.g. poly-Q-expanded huntingtin, β-amyloid (Aβ), and α-synuclein). Lastly, 
molecular chaperones can promote ubiquitination and degradation of terminally misfolded 
and/or aggregated proteins through either the ubiquitin-proteasome system or the 
autophagy-lysosome system [119-121]. 
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The term protein chaperone was first introduced in 1978 to describe the ability of 
the nuclear protein nucleoplasmin to facilitate assembly of nucleosomes, the core subunits 
of chromatin [126-127]. Later, this term was extended to encompass both prokaryotic and 
eukaryotic proteins that actively promote the folding of nascent proteins and the assembly 
of oligomeric protein complexes [128-130]. Today, this classification has expanded to 
cover over 200 different molecular chaperones that are found throughout the cell, many of 
which are localized to specific organelles or subcellular regions, and that collectively 
regulate an exhaustive array of cellular process. Examples of these molecular chaperones 
include ribosome-binding chaperones (e.g. nascent-chain-associated and ribosome-
associated complexes) [131], ER-associated chaperones (e.g. 78 kDa glucose-regulated 
protein (GRP-78) and protein disulfide isomerase) [132-133], cytoplasmic chaperones (e.g. 
heat shock proteins (HSPs) and chaperonins) [134-135], mitochondrial chaperones (e.g. 
Ssc1 and Ssq1) [136], and the aforementioned nuclear chaperone nucleoplasmin [119-120]. 
Of these, HSPs represent a diverse family of molecular chaperones containing members 
that are localized throughout the cell and that are involved in the protein folding and 
stabilization of a multitude of differing cellular proteins [118-120, 135, 137-138]. 
 
1.3.2: Heat shock proteins and the heat shock response 
HSPs belong to a ubiquitous family of molecular chaperones that are involved in many 
diverse protein quality control functions, including nascent protein folding, refolding of 
stress-misfolded and/or aggregated proteins, subcellular trafficking, and in the degradation 
of terminally misfolded proteins [118, 120, 135]. Interestingly, HSPs were inadvertently 
discovered in 1962 when Dr. Ferruccio Ritossa first observed chromosome puffing in 
Drosophila larvae following exposure to elevated temperatures, suggesting the presence of 
heat-induced changes in gene transcription [139].  This was later confirmed in 1974 by 
Tissières et al. when Drosophila chromosome puffing was correlated with heat-induced 
protein expression [140], a response that has since been shown to be a universal response 
to acute heat shock from bacteria to humans [141-143]. To date numerous HSP family 
members have been identified that can be separated into six major subfamilies based on 
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function, homology, and molecular mass, including small HSPs such as HSP27 and HSP33, 
HSP40/DnaJs, HSP60s, HSP70s, HSP90s, and HSP100s [8, 144-145]. Importantly, though 
first discovered in the context of acute heat stress, many HSP are now known to be 
constitutively expressed under non-stressed physiological conditions, such as heat shock 
cognate 71 kDa protein (HSC70) and HSP90-β, whereas others, such as HSP70 and HSP90-
α, are expressed when cells are exposed to protein-misfolding stresses such as hyperthermia 
and oxidative stress [8, 135, 146].   
Elevated expression of stress-inducible HSPs during cellular stress is a critical event 
required to prevent stress-induced misfolding and aggregation of cellular proteins [8, 135, 
144]. The stress-induced expression of HSPs in mammalian cells, i.e. the heat shock 
response, is regulated by the transcription factor heat shock factor 1 (HSF1) which, under 
non-stressed conditions, is maintained as an inactive cytosolic monomer by interaction with 
various constitutively-expressed HSPs [147-149]. The accumulation of stress-denatured 
proteins following acute proteotoxic stress competes with HSF1 for interaction with these 
constitutively-expressed HSPs, thus relieving the HSP-mediated sequestration of HSF1 and 
allowing for trimerization and nuclear import of HSF1 and subsequent stress-induced 
expression of HSP70 and HSP90-α [150-153]. In turn, HSF1-mediated expression of HSPs 
protects cells from stress-induced accumulation of misfolded proteins, cellular dysfunction, 
and apoptosis by chaperoning stress-denatured proteins [8, 154-158]. Lastly, once cellular 
stress has been relieved HSPs can bind to, sequester, and inactivate HSF1, resulting in 
abrogation of the heat shock response and restoration of cellular proteostasis [159-161]. 
Importantly, while many HSP subfamilies contain both constitutive and stress-expressed 
members, many of these, such as inducible HSP90-α and constitutive HSP90-β, share a 
high degree of sequence, structural, mechanistic, and substrate homology.  
 
1.3.3: The HSP chaperone network 
Despite their name, most members of the HSP family are constitutively-expressed under 
non-stressed physiological conditions, such as HSP40/DnaJ, HSC70, and HSP90-β that act 
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together to promote the folding of nascent proteins and to prevent aggregation of misfolded 
and/or mutant proteins [120, 146, 162]. These HSPs have been shown to chaperone 
substrate proteins in a cooperative and processive manner (Figure 1.6) where non-native 
nascent proteins are first recognized by and bind to the co-chaperone HSP40 that then 
interacts with HSC/HSP70 to form a ternary chaperone-substrate complex [163-165]. 
Affinity of these HSPs for their protein substrates is mediated through interaction of their 
substrate-binding domains with exposed peptide sequences rich in hydrophobic amino 
acids that are located within non-native substrate proteins [166-169]. Next, HSP40 
stimulates hydrolysis of HSC/HSP70-bound ATP, causing HSC/HSP70 to adopt an ADP-
bound closed-conformation that secures the non-native substrate protein and promotes 
protein folding [164, 170-171]. Lastly, nucleotide exchange factors (NEF), such as BAG 
family molecular chaperone regulator 1 (BAG-1) [172] and HSP70-binding protein 1 
(HspBP1) [173], promote ADP-to-ATP exchange, causing HSC/HSP70 to adopt an ATP-
bound open-conformation that releases the folded substrate protein [174-175]. Though, if 
a native fully-folded state is not obtained, semi-folded HSP substrates can re-enter this 
chaperone cycle through repeated interaction with HSP40 and HSC/HSP70 [176-177]. 
Alternatively, semi-folded HSC/HSP70 substrates can be transferred to HSP90 for further 
processing by the HSP70-HSP90 organizing protein (HOP/STI1) that reversibly links and 
mediates transfer of proteins between these molecular chaperones [179-180]. In addition to 
nascent proteins, misfolded and aggregated proteins can also enter the HSP chaperone 
network through interaction with the disaggregases HSP104 and HSP110 in cooperation 
with HSP40 and HSC/HSP70 [181-183]. Lastly, if the native-folded state of a substrate 
protein cannot be obtained, HSC/HSP70 and HSP90 can triage terminally misfolded 
proteins for proteasome-dependent degradation through interaction with the HSP-
associated E3 ubiquitin ligase C-terminus of HSC70-interacting protein (CHIP) [76-78, 
184]. Though many HSPs regulate protein folding, both HSC/HSP70 and HSP90 are 
central to the maintenance of proteostasis, and as such this thesis will continue to review 
these HSPs with a focus on their dual roles in protein folding and promoting degradation 
of misfolded proteins. 
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Figure 1.6: The HSP chaperone network. (1) Non-native nascent and misfolded proteins 
bind via exposed hydrophobic regions to the co-chaperone HSP40/DnaJ that then interacts 
with HSC/HSP70 to form a ternary chaperone-substrate complex. (2) HSP40 stimulates 
hydrolysis of HSC/HSP70-bound ATP, causing HSC/HSP70 to adopt an ADP-bound 
closed-conformation that secures non-native protein substrates and promotes protein 
folding. (3) Nucleotide exchange factors (NEF), such as BAG-1 and HspBP1, promote 
ADP-to-ATP exchange of HSC/HSP70 (4), causing HSC/HSP70 to adopt an ATP-bound 
open-conformation that releases the folded substrate protein (5a). If folding is incomplete 
(5b), non-native semi-folded substrates can re-enter this chaperone cycle through repeated 
interaction with HSP40 and HSC/HSP70, or (6) can be transferred to HSP90 for further 
processing by the HSP70-HSP90 organizing protein (HOP/STI1), a tetratricopeptide repeat 
(TPR)-containing co-chaperone that reversibly links and mediates transfer of substrate 
proteins between HSC/HSP70 and HSP90. (7) Aggregated proteins can also enter the HSP 
chaperone network via interaction with the disaggregases HSP104/110 and HSP110 in 
cooperation with HSP40 and HSC/HSP70. (8) Lastly, HSC/HSP70 and HSP90 can 
alternatively triage terminally misfolded proteins for proteasome-dependent degradation 
through interaction with the HSP-associated and TPR-containing E3 ubiquitin ligase C-
terminus of HSC70-interacting protein (CHIP) [6, 118, 137, 176]. 
 
1.3.4: HSC/HSP70 
The HSC/HSP70 family is an extensively studied chaperone subfamily that consists of 
multiple highly-related proteins found through both prokaryota and eukaryota that range in 
molecular mass from 66 kDa to 78 kDa. While best know for their role in the co- or post-
translational folding of approximately 20% of all nascent proteins [185-187], HSC/HSP70 
proteins can also regulate the subcellular trafficking of substrate proteins [188-189] and the 
degradation of misfolded proteins [78, 184, 190]. Multiple genes in eukaryotes encode for 
HSC/HSP70 proteins that differ in their molecular mass, expression profile, and subcellular 
localization [146, 191-193]. For example, the prototypical 70-kDa stress-inducible HSP70-
1a/b (collectively termed HSP70) [191, 193] and the constitutively-expressed HSP70-8 (i.e. 
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HSC70) are primarily localized to the cell cytoplasm [194-195]. In comparison, the 
constitutively-expressed HSP70-5 and HSP70-9, known respectively as 78-kDa glucose-
regulated protein (GRP-78/BiP) [196-197] and mortalin (mtHSP70/GRP-75) [198], are 
localized to the ER lumen or mitochondrial matrix respectively. This contrasts with 
prokaryotes that express only three HSC/HSP70 homologs, including DnaK, Hsc66, and 
Hsc62 [199-200]. Of note, many eukaryotic HSC/HSP70 proteins have overlapping 
functions and share similar substrates, though also have distinct functions typically 
determined by their subcellular localization [146].  
Though differences in expression profile and subcellular localization exist, all 
known members of the HSC/HSP70 family share highly homologous amino acid sequences 
and conserved domain structures. These domains include an N-terminal nucleotide-binding 
domain (NBD) with weak ATPase activity, a hydrophobic linker region, a C-terminal 
substrate-binding domain (SBD), and an extreme C-terminal EEVD-motif that facilitates 
interaction of HSC/HSP70 proteins with various tetratricopeptide repeat (TPR)-containing 
co-chaperones such as HSP40, BAG-1, HspBP1, HOP/STI1, and CHIP [6, 146, 176]. The 
C-terminal SBD can be further subdivided into an α-helical lid that sits adjacent to a 
substrate-binding β-sandwich that recognizes label and solvent-exposed 4-7 amino acid 
sequences within substrate proteins enriched in hydrophobic residues [166-169, 201-202]. 
Mechanistically, ATP-ADP binding to the N-terminal NBD alters affinity of HSC/HSP70 
for non-native protein substrates by allosterically altering the C-terminal SBD. Specifically, 
cycling of HSC/HSP70 between a low-affinity ATP-bound state and a high-affinity ADP-
bound state by HSP40 and various NEFs is responsible, respectively, for the allosteric 
opening or closing of the C-terminal α-lid domain onto protein substrates bound to the C-
terminal substrate-binding β-sandwich [203-206]. Accordingly, HSC/HSP70-mediated 
protein folding is believed to function through a process of kinetic partitioning where non-
native hydrophobic regions within protein substrates transiently interact with the C-
terminal SBD of HSC/HSP70, thus preventing substrate aggregation by allowing for the 
unobstructed folding of hydrophilic domains and the subsequent burial of hydrophobic 
residues/domains upon substrate release [4, 6, 8, 176]. Importantly, the availability of 
exposed hydrophobic regions within HSC/HSP70 substrates can promote repeated HSP-
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substrate binding and folding either until a fully-folded native state is achieved or, if not, 
the non-native substrate is transferred to HSP90 for further processing or is targeted for 
proteolytic degradation [118, 137, 176]. 
Multiple small molecule inhibitors of HSC/HSP70 have been discovered and 
characterized that can bind to and alter the activity and function of HSC/HSP70 [195, 207-
208]. Due to the ATP-dependent nature of HSC/HSP70-mediated protein folding, 
inhibition of the N-terminal NBD has proven to be a successful route for the discovery and 
design of HSC/HSP70 inhibitors, including 3’-sulfogalactolipids [209], the allosteric small 
molecules MAL3-101 and MKT-007 [210-211], and the ATP mimetic VER-155008 [212-
214]. Alternatively, compounds that interfere with the C-terminal SBD of HSC/HSP70 
have also been characterized, including neutralizing peptide aptamers [215], and the small 
molecules 2-phenylethynesulfonamide (PES) and the modified PES-Cl [216-218]. Lastly, 
the small molecule 15-deoxyspergualin (15-DSG) and its associated derivatives have been 
shown to act through multiple means by inhibiting ATPase activity, substrate binding, and 
by blocking the extreme C-terminal EEVD-motif required for co-chaperone interaction 
with HSC/HSP70 [210, 219-220]. Importantly, inhibition of HSC/HSP70 substrate binding 
(e.g. PES) has been shown to result in the accumulation of misfolded and aggregated 
HSC/HSP70 substrates [216-217], while inhibition of HSC/HSP70 ATPase activity (e.g. 
VER-155008) results in enhanced degradation of HSC/HSP70 substrates [213-214, 221]. 
Altogether, the variety of available HSC/HSP70 inhibitors has greatly enhanced the 
molecular study of HSC/HSP70 function and of their protein substrates, and subsequently 
has impacted research into human diseases associated with dysregulation of HSPs and 
proteostasis [218, 222-225]. 
 
1.3.5: HSP90 
The HSP90 family is another well-conserved subfamily of both constitutive and stress-
induced molecular chaperones that make up an estimated 1-2% of all intracellular proteins 
under physiological conditions [162, 226-227]. Like HSC/HSP70, HSP90 proteins play a 
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critical role in both the folding and stabilization of nascent and stress-damaged proteins 
[149, 228-229], as well as in the degradation of misfolded proteins [184, 230-231]. HSP90s 
are believed to interact with and regulate the function of at least 200 different cellular 
proteins [232], though, despite this apparent promiscuity, HSP90 is thought to contain a 
greater substrate specificity compared to that of HSC/HSP70 which, respectively, interacts 
with a diverse and extensive range of non-native proteins [233-235]. Specifically, in the 
current model (Figure 1.6) HSP90 acts downstream of HSC/HSP70 to interact with semi- 
or pre-folded proteins and appears to play a notable role in the structural maturation and 
conformational activation of signalling proteins such as steroid receptors and kinases [236-
238]. Subsequently, a high proportion of identified HSP90 substrates are either enzymes 
and/or kinases involved in the regulation of cell cycle control [239-240], cell survival [241], 
epigenetics [242-243], or in hormone receptor and cell signalling [244-247]. Thus, HSP90 
functions as a critical regulator of a subset of the proteome that integrates together several 
cellular signalling pathways through its chaperoning function [232, 235, 248]. 
 Similar to HSC/HSP70, multiple genes in eukaryotes encode for HSP90 proteins 
that differ in their molecular mass, expression profile, and subcellular localization [249-
250]. Specifically, three cytoplasmic isoforms of the prototypical 90-kDa HSP90 have been 
identified including the constitutively-expressed HSP90-β and the stress-inducible HSP90-
α1/α2 [251-253]. Additionally, ER- and mitochondrial-localized isoforms of HSP90 have 
been identified, including ERp99/GRP-94 [254-255] and tumor necrosis factor receptor-
associated protein 1 (TRAP-1) respectively [256]. In contrast, prokaryotes express a single 
HSP90 homolog, high-temperature protein G (HtpG) [257].  
 All known members of the eukaryotic HSP90 family share highly conserved 
domains that consist of a nucleotide-binding N-terminal domain (NTD) with ATPase 
activity, a charged linker region, a substrate-binding middle domain (MD), and a C-
terminal domain (CTD) responsible for HSP90 dimerization [4, 162, 227, 235]. 
Furthermore, HSP90s contain an extreme C-terminal MEEVD-motif that allows for 
interaction with various TPR-containing co-chaperones such as HOP/STI1 [258-260], 
peptidyl-prolyl-isomerases (e.g. cyclophilin 40) [261], and serine/threonine-protein 
phosphatase type 5 (PP5) [262]. Mechanistically, HSP90 functions as a C-terminally-bound 
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homodimer where ATP-ADP cycling at the NTD causes allosteric conformational changes 
to the CTD that facilitates substrate folding (Figure 1.7). Specifically, HSP90 in the absence 
of nucleotide binding forms an early-stage “apo-open” complex that binds to semi-folded 
protein substrates in complex with HSC/HSP70 and HOP/STI1 [178-180, 263-264]. Like 
other HSPs, binding of non-native proteins to HSP90 is promoted by the availability of 
exposed hydrophobic sequences within protein substrates [234, 246. 265]. Next, ATP 
binding to the NTDs of HSP90, and subsequent ATP hydrolysis, causes dimerization of the 
NTDs with concomitant compaction of the HSP90 dimer into a “closed” conformation, 
securing and promoting the conformational folding of protein substrates [266-268]. 
Following ATP hydrolysis, the NTDs separate, release ADP, and the folded protein 
substrate is released, thus returning HSP90 to the apo-open state ready for new or repeated 
substrate binding [263, 268-269]. Multiple co-chaperones can directly influence the HSP90 
chaperone cycle, including HOP/STI1 and Cdc37/p50 which both stabilize HSP90 in its 
open conformation and inhibit ATP hydrolysis [270-271], while HOP/STI1 additionally 
facilitates substrate transfer from HSC/HSP70 to HSP90 [178-180]. Furthermore, 
following ATP and protein substrate binding to HSP90, two molecules of p23 can bind to 
the ATP-bound NTDs and stabilize the substrate-bound HSP90 dimer prior to ATP 
hydrolysis [272-273]. Conversely, the co-chaperone activator of 90 kDa heat shock protein 
ATPase homology 1 (Aha1) can stimulate the inherent ATPase activity of HSP90 by 
binding to the MD of HSP90, causing transition of HSP90 to its closed, pro-folding 
conformation [271, 274]. In addition, various TPR-containing co-chaperones can interact 
with HSP90 through its C-terminal MEEVD-motif, such as peptidyl-prolyl-isomerases, to 
assist in the final conformation folding and activation of HSP90 substrates [261-262]. 
Lastly, HSP90 can interact with the E3 ubiquitin ligase CHIP in a TPR-mediated fashion 
that promotes degradation of terminally misfolded protein substrates [230, 275-276]. 
Various small molecules have been discovered and characterized that can bind to 
and alter the activity and function of HSP90 [277-278]. Most of these inhibitors target the 
NTDs of HSP90 and their associated ATPase activity, such as the natural antibiotics 
radicicol [279-280] and geldanamycin, of which was instrumental in deciphering the 
structural and molecular mechanisms of the HSP90-ATP chaperone cycle [279-282]. 
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Figure 1.7: The HSP90 chaperone cycle: (1) In the absence of HSP90 nucleotide-binding 
semi-folded non-native protein substrates, in complex with HSC/HSP70 and HOP/STI1, 
interact with a HSP90 homodimer bound together by the C-terminal domains (CTD) of 
HSP90. The co-chaperone Cdc37 prevents binding of ATP to the N-terminal domains 
(NTD) of HSP90 and maintains an early-stage “apo-open” complex. (2) ATP binds to and 
induce dimerization of the HSP90 NTDs. The co-chaperone p23 stabilizes an 
“intermediate” substrate-bound HSP90 dimer prior to ATP hydrolysis by binding to the 
ATP-bound NTDs. (3) Binding of the co-chaperone Aha1 to the middle domain (MD) of 
HSP90 promotes ATP hydrolysis, causing an allosteric compaction of the HSP90 dimer 
into a “closed” conformation, securing and promoting conformational folding of protein 
substrates. Various tetratricopeptide repeat (TPR)-containing co-chaperones, such as 
peptidyl-prolyl-isomerases (PPI) and serine/threonine-protein phosphatase type 5 (PP5), 
interact with the HSP90 C-terminal MEEVD-motif to aid in substrate folding. Following 
ATP hydrolysis, the HSP90 NTDs separate, release ADP, and the folded protein substrate 
is released (4), returning HSP90 to the apo-open state where it is ready for new or (5a) 
repeated protein substrate binding. Alternatively, (5b) HSP90 can interact with the TPR-
containing E3 ubiquitin ligase CHIP to promote degradation of terminally misfolded 
HSP90 substrates [162, 227, 235].  
 
Subsequently, a geldanamycin derivative, 17-allylamino-17-demethoxygeldanamycin (17-
AAG), has been shown to be a potent inhibitor of HSP90 activity [283-284], resulting in 
enhanced proteasomal degradation of HSP90 substrates [230, 285-287]. Lastly, coumarin 
antibiotics, such as novobiocin, have been shown to interfere with the dimerization function 
of the HSP90 CTD, resulting in proteolytic loss of cellular HSP90 substrates [288-289]. 
 
1.3.6: Ubiquitin E3 ligase CHIP 
Degradation of dysfunctional, mutated, and misfolded/aggregated proteins is a critical 
event required to maintain cellular proteostasis. Importantly, both HSC/HSP70 and HSP90 
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can triage misfolded proteins for proteolytic degradation through interaction with the E3 
ubiquitin ligase CHIP/Stub1 [184, 276, 290]. CHIP is a cytosolic member of the U-box 
family of RING-like E3 ubiquitin ligases that contains a C-terminal U-box domain with E3 
ligase activity [77, 291-292] and three tandem N-terminal TPR domains that facilitate 
interaction of CHIP with the C-terminal EEDV-motifs of HSC/HSP70 and HSP90 [76-78, 
293]. CHIP has been shown to regulate diverse cellular functions due to its capacity to 
ubiquitinate a multitude of HSC/HSP70 and HSP90 substrates, including the glucocorticoid 
receptor [184, 294], hypoxia-inducible factor 1-alpha (HIF-1α) [295], the receptor tyrosine 
kinase ErbB2 [230, 285], the transcription factors Foxp3 and RFX1 [296-297], and the 
cystic fibrosis transmembrane conductance regulator (CFTR) [298-299]. Importantly, 
CHIP can target its protein substrates to distinct proteolytic pathways through the synthesis 
of either K48- or K63-linked poly-Ub chains. Specifically, interaction of CHIP with the E2 
ubiquitin-conjugating enzyme UbcH5 promotes K48-linked polyubiquitination and 
proteasome-dependent degradation of CHIP substrates [292, 300-301], whereas interaction 
with the E2 enzyme Ubc13 has been shown to promote K63-linked polyubiquitination and 
endocytosis of growth hormone receptors [302-303]. Owing to its regulatory roles in a 
range of diverse cellular processes, CHIP mutations are associated with development of 
hereditary cerebellar ataxias, including Gordon Holms spinocerebellar ataxia syndrome 
[304-305], as well as widespread multisystemic neurodegeneration [306].  
The substrate specificity of CHIP is dependent on interaction with HSPs where it 
preferentially ubiquitinates HSP-bound misfolded proteins [77, 184, 291]. Of note, various 
HSP-interacting co-chaperones have also been shown to affect CHIP function, including 
BAG-1 which cooperates with CHIP to target HSC/HSP70 substrates for degradation [307-
308], as well as BAG-2 and HspBP1 which, conversely, inhibit CHIP ligase activity [299, 
309-310]. To date no small molecule inhibitors of CHIP have been identified, though 
siRNA-mediated knock-down of CHIP has proven to be an effective means for 
investigating CHIP-substrate dynamics [296, 311-312]. In addition to HSP-bound protein 
substrates, CHIP can also directly ubiquitinate and regulate both the activity and the 
degradation of HSC/HSP70 and HSP90 under non-stressed conditions [291, 313-315], and 
furthermore plays a key role in restoring cellular proteostasis following cellular stress by 
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degrading stress-induced HSPs [316-317]. Though CHIP is well-known for its role in 
chaperone-mediated proteolysis, one intriguing and yet unclear question is which factors 
regulate the triage decisioning between folding or degradation of HSP substrates. One 
leading theory stipulates that CHIP can compete through its tandem N-terminal TPR 
domains with other pro-folding TPR-containing co-chaperones for binding to the C-
terminal EEVD-motif of HSC/HSP70 and HSP90. In support, CHIP has been shown to 
compete with HOP/STI1 for binding to C-terminus of HSP70 and HSP90, and subsequently 
that C-terminal phosphorylation of these HSPs regulates the alternate binding of pro-
folding HOP/STI1 and pro-degradative CHIP [276, 315, 318].  
 
1.4: Molecular chaperones in human disease 
1.4.1: HSPs in Cancer  
Provided their essential role in maintaining cellular proteostasis, HSPs have been 
implicated in the pathogenesis of many human cancers and neurodegenerative diseases. In 
respect to cancers, one of the defining features and drivers of tumorigenesis is the build-up 
of mutated and dysregulated proteins, especially those associated with regulation of cell 
cycle and cell survival mechanisms [319-321]. Importantly, HSPs such as HSC/HSP70 and 
HSP90 have been shown to chaperone and stabilize mutant and dysregulated cancer-related 
proteins, such as mutated and inactive p53, thereby promoting cell cycle dysregulation and 
tumorigenesis [322-323]. Additionally, HSPs play a critical anti-apoptotic role during 
tumorigenesis by preventing stress-induced apoptosis due to hypoxic build-up of oxidative 
and proteotoxic stress within the microtumor environment [324-325]. Consequently, 
dysregulated and heightened expression of both constitutive and stress-induced HSPs is a 
common feature of many cancers which often correlates with poorer clinical prognosis and 
can promote resistance to chemotherapy [323, 326]. Therefore, an area of intense study for 
cancer therapy is the development of clinically-relevant inhibitors of HSPs, such as the 
HSP90 inhibitor 17-AAG that has shown promising results in clinical trial [327-328].  
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1.4.2: HSPs in aging and neurodegeneration 
The functions of HSPs have also been implicated during the aging process and in the 
pathology of human neurodegenerative diseases [10, 329]. One significant feature of 
cellular aging is a decline in both the constitutive and stress-inducible expression of HSPs, 
resulting in a diminished capacity of aging cells to chaperone non-native proteins, as well 
as respond to cellular and proteotoxic stress [330-332]. In turn, this age-related decline in 
chaperoning capacity can lead to the accumulation of misfolded aggregate-prone proteins, 
loss of cellular proteostasis, and accelerated cell death [332-333]. Importantly, increased 
aberrant protein misfolding and accumulation of protein aggregates during aging has been 
associated with the development of type 2 diabetes mellitus [334] as well as various 
neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s and 
Huntington’s disease, and amyotrophic lateral sclerosis (ALS) [4, 6, 10]. Although the 
mechanisms responsible for these different age-related diseases are varied, one common 
pathological feature is the accumulation of cytotoxic amyloid or amyloid-like oligomers 
and aggregates [335-336].  
The cytotoxic properties of these age-related misfolded and aggregated proteins 
have been foremost attributed to their ability to directly impair organelle function, such as 
mitochondria [337], the ER [338], and autophagosomes [339]. To exacerbate this issue, 
protein aggregates can inadvertently interact with exposed hydrophobic regions found 
within non-native nascent proteins and in numerous structurally-labile proteins, such as 
enzymes, kinases, and transcription factors, thereby co-aggregating with and sequestering 
these cellular proteins from performing their normal functions, resulting in multifactorial 
cytotoxicity [122, 340-341]. Lastly, protein aggregates can directly impair activity of the 
ubiquitin-proteasome system, leading to the establishment of an aggregate-driven positive 
feedback system that promotes the build-up of pathogenic protein aggregates, resulting in 
gross proteostatic dysregulation, induction of proteotoxic cellular stress, and enhanced cell 
death [4, 124, 342-343]. Of note, multiple studies have demonstrated that HSPs have 
cytoprotective properties in multiple neurological protein misfolded diseases [10, 344-
345]. Specifically, in the case of Huntington’s disease, HSP70 and HSP40 have been shown 
to chaperone and prevent the assembly of mutant polyglutamine-expanded proteins, such 
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as huntingtin, into cytotoxic aggregates [346-347]. Additionally, HSPs can interfere with 
the toxic accumulation of AD-associated hyperphosphorylated tau protein or β-amyloid 
(Aβ) [348-349], or with Parkinson’s-associated α-synuclein [350]. Consequently, 
pharmacological upregulation of HSP expression or chaperone activity [351-352], 
enhancement of proteasome activity [353-354], or stimulation of the ubiquitination of 
misfolded and aggregated protein [15, 355-356] represent exciting new avenues for the 
treatment of protein misfolding neurodegenerative diseases. 
 
1.4.3: HSPs and oxidative stress 
Common to both cancer and neurodegenerative diseases is the build-up of oxidative stress 
and concomitant acceleration of protein misfolding and cell death [357-358]. A powerful 
and significant source of cellular oxidative stress is the generation of free reactive oxygen 
species (ROS) that have the capacity to oxidize cellular components, including cellular 
proteins, lipids, and DNA [359-361]. For example, ROS-mediated oxidation of thiol-
containing cysteine residues within cellular proteins can either promote the formation of 
aberrant intra- and intermolecular disulfide bonds or can stimulate modification of oxidized 
proteins with various protective antioxidant modifications such as glutathione or 
thioredoxin [362-364]. Though the formation of disulfide bonds during the synthesis of 
nascent proteins is often required for proper protein function, the formation of stress-
induced disulfide bonds during oxidative stress can induce protein misfolding with severe 
and damaging functional consequences [361, 364-365]. Therefore, provided the critical role 
of cysteine residues in disulfide bond formation and protein folding, it is reasonable to 
hypothesize that cysteine-rich proteins may be more susceptible to oxidative misfolding 
and dysfunction. One such protein, the disease-associated E3 ubiquitin ligase Parkin, has a 
higher-than-average cysteine content of 7.5% compared to 2.26% for the global human 
proteome [366] or 1.6% for intracellular mammalian proteins [367]. Importantly, studies 
have demonstrated that exposure of Parkin to H2O2, a potent inducer of cellular oxidative 
damage, can induce misfolding, inactivation, and aggregation of Parkin [368-370].  
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Interestingly, HSPs play a key role in mitigating the cytotoxic and pro-apoptotic 
effects of oxidative stress by chaperoning stress-damaged and aggregate-prone proteins [7, 
371]. Of note, prolonged cellular exposure to oxidative stress can lead to the induction of 
the heat shock response through oxidative depletion of glutathione, an antioxidant and 
redox modulator that can compete with and prevent the formation of aberrant oxidative 
disulfide bonds [372-374]. Oxidative depletion of glutathione in turn promotes the 
oxidation of cellular proteins and formation of non-native disulfide bonds, causing gross 
cellular protein misfolding that subsequently stimulates activation of HSF-1 and the heat 
shock response [375-377]. Consequently, stress-induced HSP70 and HSP90 can either bind 
to and chaperone oxidized proteins to maintain and/or restore protein function, or 
alternatively can promote proteasomal degradation of oxidatively damaged proteins [371, 
378-379]. In addition to their stress-induced functions, HSPs have also been found to 
constitutively maintain an available pool of reduced glutathione that can buffer against 
acute oxidative stress [380-381]. Lastly, in the case of neurodegenerative diseases various 
HSPs have been shown to suppress the oxidative properties of mutant and misfolded 
huntingtin, Aβ1-42, and the ALS-associated DNA-binding protein TDP-43 [382-384]. Taken 
together, these studies establish a critical role for HSPs not only in the regulation of nascent 
protein folding, but also in the maintenance of cellular proteostasis during exposure to 
cellular stress and in human disease. 
 
1.5: Cholinergic neurobiology 
1.5.1: The cholinergic synapse 
Build-up of oxidative stress and dysregulation of cellular proteostasis are common cellular 
events observed during aging and in many age-related neurodegenerative diseases, 
including AD, and may represent mechanisms that are critical to the pathogenesis of these 
diseases. Work in the Rylett Laboratory is primarily focused on the role of cholinergic 
neurons in the brain during aging and AD [385-386] as these neurons appear to be 
particularly sensitive to oxidative stress and to AD-related dysfunction and degeneration 
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[387-388]. Cholinergic neurons are critical components of the central, autonomic, and the 
somatic nervous system where they are essential to the regulation of bodily homeostasis 
through their ability to synthesize and release the neurotransmitter acetylcholine (ACh) 
[389-390]. In turn, ACh regulates diverse processes throughout the human body, including 
cognitive functions such as behaviour and memory, as well as autonomic (e.g. heart rate, 
pupil dilation, and gastric function) and neuromuscular processes. Consequently, 
dysregulation of ACh synthesis and/or neurotransmission has been observed in multiple 
neurodegenerative and neuromuscular disorders [388, 391].  
Cholinergic neurotransmission has been extensively studied over the past fifty-plus 
years and is known now to involve the cooperative actions of multiple presynaptic proteins 
that oversee the synthesis and release of ACh, as well as postsynaptic ACh receptors that 
relay cholinergic neural activity into discreet post-synaptic signalling events (Figure 1.8). 
Briefly, in this system ACh is first produced in the presynaptic terminals of cholinergic 
neurons by the cytoplasmic enzyme choline acetyltransferase (ChAT) using the substrates 
choline and acetyl coenzyme A (acetyl-CoA) [392]. ACh is then transported and stored in 
presynaptic lipid-bound vesicles by the vesicular acetylcholine transporter (VAChT) [393]. 
Depolarization and activation of cholinergic neurons induces calcium-dependent fusion of 
ACh-containing vesicles with the presynaptic terminal plasma membrane, resulting in 
release of ACh into the synaptic cleft [394-395]. Subsequently, released ACh then binds to 
postsynaptic membrane-bound receptors, such as nicotinic and muscarinic ACh receptors, 
that then initiate downstream postsynaptic signalling events [396-397]. To attenuate 
cholinergic signalling, ACh is broken down into choline and acetate by the enzyme 
acetylcholinesterase (AChE) located within the synaptic cleft [398]. Lastly, extracellular 
choline is transported back into the presynaptic terminals of cholinergic neurons by the 
high-affinity choline transporter (CHT) where it can be used by ChAT for the renewed 
synthesis of ACh [390, 399]. Importantly, many of these cholinergic proteins have been 
found to be dysregulated in neurodegenerative and neuromuscular diseases [400-402], 
prompting researchers to develop treatment-oriented cholinergic modulators, such as the 
acetylcholinesterase inhibitors donepezil and rivastigmine for the treatment of AD [403].  
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Figure 1.8: The cholinergic synapse. (1) In the presynaptic terminals of cholinergic 
neurons, the enzyme choline acetyltransferase (ChAT) synthesizes the neurotransmitter 
acetylcholine (ACh) using the substrates choline and acetyl-CoA. (2) ACh is transported 
into and stored in lipid-bound synaptic vesicles by the vesicular acetylcholine transporter 
(VAChT). (3) Depolarization and activation of cholinergic neurons induces Ca2+ influx into 
the presynaptic terminals through voltage-gated calcium channels (VGCCs), resulting in 
fusion of ACh-containing vesicles with the terminal plasma membrane and release of ACh 
into the synaptic cleft. (4) ACh binds to postsynaptic membrane-bound nicotinic and/or 
muscarinic acetylcholine receptors (n/mAChRs), resulting in the opening of ligand-gated 
ion channels (nicotinic) and/or activation of G-coupled protein signalling (muscarinic) that 
alters postsynaptic ion dynamics and downstream subcellular signalling. (5) Cholinergic 
signalling is attenuated by breakdown of ACh in the synaptic cleft into choline and acetate 
by the enzyme acetylcholinesterase (AChE). (6) Lastly, free choline is transported back 
into cholinergic presynaptic terminals by the high-affinity choline transporter (CHT) where 
it can be used again as a substrate for ChAT in the repeated synthesis of ACh [389, 392]. 
 
1.5.2: Choline acetyltransferase (ChAT) 
The enzyme ChAT holds a particularly vital role in cholinergic neural function as it is the 
sole protein responsible for the synthesis of ACh. ChAT is a member of the CoA-dependent 
superfamily of acyltransferases that includes, for example, carnitine and chloramphenicol 
acetyltransferases [404-405], and is a phenotypic marker of central, autonomic, and somatic 
cholinergic neurons [389-390]. To date, multiple ChAT transcripts have been identified in 
both human and rodents that are formed by alternative splicing and differential use of the 
non-coding exons R, N, M, S and H [392, 406-408]. All transcripts encode a common 69-
kDa ChAT enzyme that is localized predominantly to the neuronal cytoplasm where it 
generates ACh, while the spinal cord-isolated S-transcript also encodes for a 74-kDa 
isoform [407, 409-411]. Additionally, unique to humans and non-human primates the M-
transcript also encodes for an 82-kDa ChAT protein in addition to 69-kDa ChAT due to the 
presence of a unique in-frame translation initiation codon located 5’ to the common 
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translation initiation site for 69-kDa ChAT [407, 411, 412-413]. This primate-specific 82-
kDa ChAT protein contains a nuclear localization signal (NLS) located within its extended 
118 amino acid N-terminus that directs it to the nuclei in human brain and spinal cord 
cholinergic neurons [385, 414-415]. While our laboratory has shown that 82-kDa ChAT 
can synthesize ACh [386, 414-415], the function/s of this nuclear ChAT isoform remain 
under investigation, though more recent studies have gathered evidence that 82-kDa ChAT 
may be involved in regulating chromatin organization and the gene expression of important 
amyloid precursor protein (APP) processing proteins such as GGA3 [386, 416-417].  
Though different molecular mass ChAT protein isoforms exist, the cytoplasmic 69-
kDa variant is considered the canonical ChAT enzyme responsible for ACh synthesis due 
to its shared expression from the aforementioned mRNA transcripts in multiple animal 
species. Consequently, provided its essential role in cholinergic neurotransmission, 
multiple studies have investigated the regulation of ChAT enzyme activity with a focus on 
the structural and/or molecular and biochemical properties of 69-kDa ChAT. Importantly, 
the crystal structures of both rat [418-419] and human 69-kDa ChAT [420] have been 
solved. Structurally, human ChAT contains two functional domains, a substrate-binding 
domain that binds to its two substrates choline and acetyl-CoA, and a catalytic domain with 
an interfacial active site tunnel that runs between these two domains [420]. An active site 
histidine residue, His324, catalyzes transfer of the acetyl group from acetyl-CoA to choline 
in a sequential reaction resulting in ACh synthesis [420-422]. Impaired in vitro activity of 
purified recombinant ChAT has been demonstrated under oxidative conditions and when 
ChAT is exposed to either sulfhydryl-reactive or arginine-modifying reagents [423-424]. 
Subsequently, the arginine residues Arg442 and Arg443 have been shown to be indirectly 
involved in CoA-binding through interactions with a surface “P-loop” that stabilizes acetyl-
CoA within the active site [420, 425]. In addition to these structural determinants of ChAT 
activity, post-translational phosphorylation of ChAT has also been shown to regulate its 
enzymatic activity where phosphorylation by protein kinase C (PKC) and casein kinase II 
(PK2) increases the in vitro activity of recombinant human ChAT [426]. Importantly, in 
human HEK293 or IMR32 neuroblastoma cells residues Ser440 and Ser476 of human 69-kDa 
ChAT have been shown to be phosphorylated by PKC in a hierarchical fashion such that 
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phosphorylation of Ser476 regulates the basal activity of ChAT and where PKC activation 
promotes phosphorylation of residue Ser440, subsequently enhancing ChAT activity [410, 
427]. Interestingly, mutation of residue Arg442 not only prevents PKC-mediated 
phosphorylation of ChAT at residue Ser440 but also dramatically reduces basal ChAT 
enzymatic activity [427]. Analysis of the human ChAT crystal structure reveals that these 
residues, Ser440 and Arg442, can form hydrogen bonds between each other [420], suggesting 
a potential biochemical link between ChAT phosphorylation and protein structural changes 
that may influence acetyl-CoA binding and subsequent enzymatic activity of human ChAT. 
 
1.5.3: ChAT in neurodegenerative diseases 
Alterations in ChAT activity have been found in multiple neurological disorders, including 
AD [428-429], ALS [430] and in Huntington’s disease [431]. Of significance, impairment 
of ChAT activity [432-435] and reduced ChAT mRNA expression [436-437] have been 
associated with the clinical progression of AD. Furthermore, exposure of cells to AD-
related and cytotoxic Aβ1-42 oligomers results in calcium/calmodulin-dependent kinase II 
(CaMKII)-mediated phosphorylation of ChAT on residue Thr456, altering ChAT activity, 
and promoting interaction of ChAT with the ER- and HSP-associated co-chaperone 
Cdc48/p97/VCP [438-440]. VCP is a critical mediator for the proteasome-dependent 
degradation of ubiquitinated ERAD substrates [50, 97, 441-442], as well as for the 
maturation of ubiquitin-containing autophagosomes that are critical to the autophagy-
lysosome system [443-445]. While it is currently unknown whether ChAT protein stability 
and function is regulated by either the ubiquitin-proteasome and/or autophagy-lysosome 
system, these studies collectively suggest that ChAT ubiquitination and protein stability 
may be altered following exposure to cytotoxic Aβ stress. Lastly, aggregated forms of Aβ 
have been found to reduce ChAT activity in vivo in the striatum of aged rats [446]. These 
studies detailing alteration in ChAT enzyme activity during AD or following exposure to 
cytotoxic Aβ, together with the observation that significant loss of cholinergic neurons 
occurs in patients with AD [447-449], forms the basis for the cholinergic hypothesis of AD 
and suggest a critical role for ChAT during AD [450-451]. Subsequently, studies have 
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investigated whether coding and non-coding single-nucleotide polymorphisms (SNPs) 
within the human ChAT gene are genetically linked to the development of AD, though 
comparison of these studies reveals variable results [452-456]. 
 
1.5.4: Congenial myasthenic syndrome (CMS)  
Though alterations in ChAT activity and mRNA expression have been correlated with the 
progression of AD and other neurodegenerative diseases, direct and conclusive genetic 
linkage of ChAT missense mutations with these neurodegenerative diseases has yet to be 
observed. Conversely, ChAT mutations have been causatively-linked to the development 
of the rare neuromuscular disorder congenital myasthenic syndrome (CMS) [411, 457-
458]. CMS is an inheritable and heterogeneous disorder with an early-childhood onset in 
which neuromuscular synaptic mechanisms are compromised, resulting in chronic muscle 
weakness (i.e. myasthenia), difficulties in movement, eating, and breathing, and in severe 
cases of CMS periods of episodic apnea that can be fatal without medical intervention [402, 
459]. Of note, CMS differs from other myasthenic diseases, such as myasthenia gravis and 
Lambert-Eaton syndrome, due to the genetic/mutational origins of CMS compared to the 
non-genetic autoimmune features of these other myasthenic diseases [402, 460-461]. 
Myasthenic syndromes, including CMS, are often highly-treatable disease, though 
treatment efficacy specifically for CMS patients is highly dependent on the underlying 
genetic cause for a patients CMS diagnosis. Importantly, to date mutations in no fewer than 
20 different neuromuscular proteins, including cholinergic proteins, have been causatively-
linked to CMS development [402, 462-463].  
While mutations in various proteins localized either pre- and/or postsynaptically at 
neuromuscular junctions are linked to CMS [402, 459], early in vitro electrophysiological 
studies of CMS patients revealed that ACh synthesis can be directly impaired, suggesting 
a role for ChAT in the pathogenesis of CMS [464-466]. Subsequently, multiple studies 
have identified over 40 unique CMS-related missense mutations in the human 69-kDa 
ChAT protein, many of which have been biochemically characterized [411, 457-458, 467-
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473]. The severity of CMS-related ChAT mutations has been associated with the position 
of the mutated residues within the three-dimensional structure of ChAT where, in general, 
mutations involving the ChAT active site can severely impair enzymatic activity, often 
through alterations in acetyl-CoA binding. Furthermore, these active site mutations often 
display a concomitant reduction in ChAT protein levels, resulting in a synergistic loss in 
ACh synthesis associated with development of severe CMS (Figure 1.9) [411, 457-458]. 
One CMS-related mutations located within the ChAT active site tunnel is an arginine-to-
histidine mutation of residue Arg442, a residue our laboratory has shown to regulate both 
basal ChAT activity and the PKC-mediated phosphorylation of ChAT on residue Ser440 
[420, 427]. Residue Arg442 is hypothesized to indirectly stabilize acetyl-CoA binding to 
ChAT, and while the CMS-related R442H mutation does not appear to affect ChAT protein 
levels in cells [411, 427], this mutation does dramatically reduce the in vitro affinity of 
recombinant R442H-ChAT for acetyl-CoA, causing a 99% loss in catalytic activity [411].  
 
1.5.5: V18M-ChAT and the ChAT N-terminus  
Interestingly, several catalytically-deficient CMS-related ChAT mutations have been found 
that are positioned distal to the ChAT active site and are hypothesized to work through 
allosteric mechanisms, though these mutations tend to produce less severe catalytic defects 
and often do not affect protein expression of ChAT [411, 457-458]. One notable exception 
is a valine-to-methionine mutation of the N-terminal residue Val18 that was identified in 
four unrelated CMS patients with severe myasthenic symptoms [457-458]. Biochemical 
characterization of this mutation not only revealed a notable decrease in the in vitro affinity 
of recombinant V18M-ChAT for acetyl-CoA, leading to a 30-75% loss in overall catalytic 
efficiency, but also a remarkable 30-40% reduction in the steady-state protein levels of 
mutant V18M-ChAT compared to wild-type ChAT when transiently expressed in either 
BOSC 23 or HEK293 cells (Figure 1.9) [457-458]. Furthermore, this V18M mutation was 
found to have negligible effects on the in vitro thermal stability of the enzyme [457], 
suggesting that the loss of V18M-ChAT catalytic activity and cellular protein expression 
is not likely due to gross alterations in ChAT protein folding.  
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Figure 1.9: Missense mutations within human ChAT are associated with development 
of the neuromuscular disorder congenital myasthenic syndrome (CMS). CMS-related 
ChAT mutations disrupt ChAT function by (A) reducing the steady-state protein levels of 
mutant ChAT in cells and/or (B) by altering choline (chol) and/or acetyl-CoA (AcCoA) 
binding. In general, mutations involving the ChAT active site (red asterisks) severely 
impair ChAT enzymatic activity, frequently due to a loss in AcCoA affinity, and are often 
accompanied by a concomitant reduction in ChAT protein levels resulting in a synergistic 
loss in ACh synthesis that is associated with development of severe CMS. Interestingly a 
valine-to-methionine mutation of the N-terminal residue Val18 has been identified in four 
unrelated CMS patients with severe myasthenic symptoms. This residue is positioned distal 
to the ChAT active site where mutation of Val18 has been found to reduce both the cellular 
steady-state levels protein levels of and the in vitro AcCoA affinity of mutant V18M-ChAT 
(green asterisks; D and E). Shown are anti-ChAT immunoblot from transfected COS cells 
(A), in vitro kinetic parameters (B), and mutation summaries (C, D, and E) for various 
CMS-related ChAT mutants collated from three independent studies completed previously 
by other laboratories [A-C, 411; D, 457; E, 458]. Amino acid numbering corresponds to 
the human 82-kDa ChAT protein sequence (+118 amino acids vs. 69-kDa ChAT).  
 
The mechanisms by which this CMS-related V18M mutation enacts its effects on 
cellular ChAT function remains to be elucidated. One hypothesis provided by the authors 
of the above studies is that mutation of residue Val18 may disrupt a hydrogen-bond network 
that involves other active site-localized residues that contribute to acetyl-CoA binding, such 
as residue Ser440 [457-458]. Importantly, in silico analysis of the human 69-kDa ChAT 
amino acid sequence revealed that residue Val18 is positioned within a highly-conserved N-
terminal proline-rich motif with sequence 14PKLPVPP20 (Figure 1.10). This motif is 
positioned distal to the ChAT active site, is surface-exposed, and forms part of a stably-
folded domain (Figure 1.11) where neither Val18 nor any other residue in this motif 
participates directly in acetyl-CoA binding [420, 457-458]. Interestingly, this highly-
conserved proline-rich motif of ChAT shares structural and sequence homology with the 
core PxxP-binding motif for Src homology 3 (SH3)-binding domains [420, 474-475].  
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Figure 1.10: Comparative sequence alignment of the highly-conserved N-terminal 
proline-rich motif of ChAT from multiple divergent animal species. An in silico NCBI 
Blastp search with downstream sequence alignment using Clustal Omega (EMBL-EBI) 
was completed to compare the first 50 N-terminal amino acids of human 69-kDa ChAT to 
the indicated animal species. The sequence for the N-terminal proline-rich motif of human 
ChAT (14PKLPVPP20), including the CMS-related residue Val18 (i.e. V18M), is indicated. 
Sequence alignment revealed either complete (green) or a high degree (yellow) of amino 
acid conservation within the ChAT proline-rich motif between multiple species, with 
residues differing from the human 69-kDa ChAT sequence highlighted in purple.  
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Figure 1.11: Three-dimensional crystal structure of human 69-kDa ChAT. Shown is a 
space-fill 3D model of the human 69-kDa ChAT structure, bound to acetyl-CoA, that was 
solved previously in the Rylett Laboratory (PDB: 2FY4) [420]. ChAT contains a highly-
conserved N-terminal proline-rich motif at residues 14PKLPVPP20 (green) that shares 
homology with the core PxxP-binding motif for Src homology 3 (SH3)-binding domains. 
SH3-mediated protein-protein interactions are abundant within intracellular signalling 
networks and regulate diverse protein and cellular functions [474-479]. A CMS-related 
valine-to-methionine mutations of residue Val18 (red) has been identified from four 
unrelated CMS patients with severe myasthenia.  This mutation is located within the ChAT 
N-terminal proline-rich motif and has been shown previously to reduce the cellular steady-
state protein levels and in vitro catalytic activity of mutant V18M-ChAT [457-458]. 
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Protein-protein interactions between SH3-motifs and SH3-domain-containing proteins are 
abundant within intracellular signalling networks and have been shown to regulate the 
subcellular trafficking, phosphorylation, activity, and stability of multiple cellular proteins 
[475-479]. To date only a handful of protein-protein interaction involving human ChAT 
has been identified, including the protein kinases PKC and CaMKII and the co-chaperone 
VCP [438]. As such, it is currently unknown whether ChAT engages in SH3-mediated 
protein-protein interactions that may alter ChAT function, or furthermore if the ChAT N-
terminal proline-rich motif may play a functional role in the regulation of ChAT enzyme 
activity and/or protein stability.  
 
1.6: Study rationale, aims, and hypothesis 
Maintenance of cellular proteostasis represents an intricate, ongoing, and critical process 
required for the preservation of cellular function and cell survival. To accomplish this, cells 
utilize a complex network of pro-stabilizing molecular chaperones, such as HSPs, and pro-
degradation proteins, such as those involved with the ubiquitin-proteasome system, to 
efficiently triage cellular proteins between these two opposing cellular fates. In addition, 
HSPs play a significant role in the protection against cellular proteotoxic stress (e.g. 
hyperthermia and oxidative stress) by either chaperoning stress-misfolded proteins to 
promote their folding and stability or, conversely, to triage terminally misfolded proteins 
for proteolytic degradation, thereby maintaining proteostasis and preventing stress-induced 
cell death. Chronic exposure to oxidative stress, and the associated dysregulation of 
molecular chaperones and cellular proteostasis is a common factor in the pathogenesis of 
multiple human diseases, including cancer and many neurodegenerative diseases such as 
AD. Work in our laboratory is focused on the regulation of cholinergic neural function 
during aging as cholinergic neurons appear to be especially sensitive to oxidative stress and 
AD-related dysfunction. The cholinergic enzyme ChAT is responsible for the synthesis of 
the neurotransmitter ACh and is essential to cholinergic neural function. Missense 
mutations found within human 69-kDa ChAT protein have been causatively-linked to the 
rare inheritable neuromuscular disorder CMS. One CMS-related ChAT mutation, V18M, 
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reduces both in vitro enzyme activity and cellular steady-state protein levels, and is 
positioned within a highly-conserved, surface-exposed, N-terminal proline-rich motif at 
residues 14PKLPVPP20 that share homology with SH3-binding motifs. It is currently 
unknown what cellular factors regulate ChAT protein stability, and whether the N-terminal 
proline-rich motif of ChAT regulates ChAT function. 
  The specific aims of my present study were to two-fold. First, I was to assess the 
role of the ChAT N-terminus, and in particular the proline-rich motif surrounding the CMS-
related residue Val18, in the regulation of ChAT protein function. Second, and in 
conjunction with my first aim, I was to determine cellular mechanisms involved in the 
regulation of ChAT protein stability, potentially through alteration of the ChAT N-
terminus. Thus, I hypothesized that ChAT protein stability and enzyme activity are 
regulated by the highly-conserved N-terminal proline-rich motif of ChAT, and 
furthermore that ChAT protein stability is regulated by molecular chaperones in 
collaboration with the ubiquitin-proteasome system. 
 Briefly, to evaluate these hypothesises I addressed the cellular protein expression, 
enzymatic activity, and the degradation of both wild-type and CMS-mutant ChAT protein 
in transiently transfected mouse cholinergic SN56 neural cells. To assess the role of the 
proline-rich motif on ChAT protein function, CMS-related V18M-ChAT was compared to 
an engineered proline-to-alanine ChAT mutant, P17A/P19A-ChAT. Initial assessment was 
carried out by anti-ChAT immunoblotting and by radioenzymatic assay to assess cellular 
ChAT protein levels and activity respectively. Additionally, mechanisms that regulate the 
degradation of ChAT were determined using the proteasome inhibitor MG132 and the 
lysosome inhibitor chloroquine, and subsequently ChAT ubiquitination was tested by anti-
ubiquitin immunoblotting from anti-ChAT immunoprecipitation protein samples. Together 
these experiments formed the basis for further experimentation into the regulation of ChAT 
protein stability and function.   
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CHAPTER 2: MATERIALS AND METHODS 
2.1: Protein expression plasmids 
For expression in mammalian cells, cDNA encoding wild-type human 69-kDa ChAT, 
ligated to pcDNA3.1+ vector [440], was used as a template for preparation of N-terminally 
truncated, proline-mutant, and CMS-mutant ChAT. Multiple N-terminally truncated ChAT 
isoforms (1-5, 1-10, 1-15, 1-20 and 1-30) were prepared by PCR amplification and 
ligated to pcDNA3.1+ vector. Additionally, multiple proline-to-alanine ChAT mutants 
(P14A, P17A, P19A, P20A and P17A/P19A) and CMS-mutant ChAT (V18M, A513T and 
T490N) [457-458] were prepared by site-directed mutagenesis according to the 
QuikChange II Kit (Agilent/Stratagene). For bacterial expression, cDNA encoding wild-
type human 69-kDa ChAT, ligated to pProEXHTa vector [480], was used as a template for 
preparation of P17A-, P19A- and P17A/P19A-ChAT mutants by site-directed mutagenesis. 
Plasmids encoding wild-type and mutant HA-tagged ubiquitin [481-482] were purchased 
from Addgene: wild-type (#17608), K0 (#17603), K11 (#22901), K48 (#17605), K48R 
(#17604), and K63 (#17606). For BioID experiments, pcDNA3.1/MCS-BirA(R118G)-HA 
(BirA*; Addgene #36047) [483] served as a template for the ligation of PCR-amplified 
wild-type and P17A/P19A-ChAT cDNA. For the heterologous expression of wild-type and 
CHIP mutants (ΔTPR and ΔU-box), plasmids were kindly provided by Dr. Yosef Shaul 
(Weizmann Institute of Science) [484] with permission by Dr. Cam Patterson (UNC School 
of Medicine). CHIP cDNA was PCR amplified with the addition of a C-terminal FLAG-
tag and ligated to pcDNA3.1+ vector. Expression plasmids were validated by full-length 
DNA sequencing prior to use for mammalian/bacterial expression.  
 
2.2: Cell culture, experimental treatments, and cell lysis 
Mouse cholinergic SN56 neural cells (gift from Dr. J.K. Blusztajn, Boston University) 
[485] or human HEK293 cells (ATCC) were grown as monolayers in DMEM 
supplemented with 5-10% FBS (Invitrogen) and 1% Pen-Strep at 37C with 5% CO2. Prior 
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to experimental treatments, cells were transiently transfected with protein expression 
plasmids (detailed above) by either calcium phosphate [486] or using Lipofectamine 
2000/3000 (Invitrogen) at ~50% confluence for 18-24 h at 37C. All laboratory procedures 
were conducted with Biosafety Approval BIO-RRI-0022. 
For determination of ChAT steady-state protein levels and cellular ChAT activity of 
wild-type or mutant ChAT, ChAT-expressing SN56 cells were collected and lysed on ice 
in ChAT assay lysis buffer (10 mM Na2HPO4; pH 7.4, 0.87 mM EDTA, 0.5% Triton X-
100 and 1.5 mM eserine sulphate) supplemented with mammalian protease inhibitor 
cocktail (Sigma), phosphatase inhibitor cocktail (10 mM NaF, 1 mM Na3VO4, 20 mM 
Na2HPO4, 3 mM -glycerolphosphate, 5 mM sodium pyrophosphate), and 50 µM MG132 
(Enzo Life Sciences). Lysates were centrifuged for 10 min at 21,000 g at 4C and protein 
concentrations were measured by Bradford Protein Assay (Bio-Rad). Lysate supernatants 
were prepared for analysis of ChAT protein levels by denaturing aliquots of cell lysate in 
1x Laemmli sample buffer (63 mM Tris-HCl; pH 6.8, 10% glycerol, 2% SDS, 0.005% 
bromophenol blue, 2.5% 2-mercaptoethanol) at 95C for 10 min followed by anti-ChAT 
immunoblotting. Additionally, cell lysates were used to determine cellular ChAT activity 
by modified radioenzymatic assay [487-488]. To investigate the effect of proteasome 
and/or lysosome inhibitors on ChAT steady-state protein levels and cellular ChAT activity, 
SN56 cells transiently expressing wild-type, P17A/P19A-ChAT, or CMS-mutant ChAT 
were treated with 5 µM MG132, 25 µM chloroquine (Sigma), or vehicle (DMSO or water 
respectively) for 18 h at 37C prior to immunoblotting or radioenzymatic assay.  
The impact of inhibition of HSC/HSP70, HSP90, or p97/VCP function on ChAT 
steady-state protein levels was determined in SN56 cells expressing either wild-type or 
mutant ChAT proteins that were treated with varying concentrations of the HSC/HSP70 
inhibitor VER-155008 (5 – 50 µM; Sigma),  the HSP90 inhibitor 17-AAG (0.5 – 2 µM; 
StressMarq Biosciences), or the p97/VCP inhibitor Eeyarestatin-I (Eer1; 5 – 10 µM; 
Sigma) for 18 – 24 h at 37°C. Cells were collected and lysed on ice in RIPA buffer (50 mM 
Tris-HCl; pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) 
supplemented with protease/phosphatase inhibitors (above), 50 µM MG132, 10 mM N-
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ethylmaleimide (NEM; Calbiochem), and 800 U/ml DNase I (Invitrogen). Lysates were 
centrifuged for 10 min at 21,000 g at 4C, protein concentrations were measured by BCA 
protein assay (Thermo), and lysate supernatants were denatured in 1x Laemmli sample 
buffer at 95C for 10 min then analyzed by anti-ChAT immunoblotting. 
To measure cellular ChAT activity following HSC/HSP70 and/or HSP90 inhibition 
SN56 cells expressing wild-type or mutant ChAT proteins were treated with either 40 µM 
VER-155008 or 1 µM 17-AAG either alone or in combination at 37°C for 24 h. Cells were 
collected and lysed on ice in ChAT assay lysis buffer (above) supplemented with 
protease/phosphatase inhibitors and 50 µM MG132. Lysates were centrifuged for 10 min 
at 21,000 g at 4C and used for analysis of cellular ChAT activity as described above.  
The effects of either proteasome or lysosome inhibition on ChAT steady-state protein 
levels during HSC/HSP70 and HSP90 inhibition were investigated in SN56 cells 
expressing wild-type or mutant ChAT. Cells were treated either alone with 40 µM VER-
155008 or 1 µM 17-AAG at 37°C for 24 h or co-treated for 18 h with either 5 µM MG132 
or 50 µM chloroquine. To lyse cells and release aggregated proteins following HSP and 
proteasome inhibition, cells were boiled at 95°C for 5 min and sonicated in 1% SDS lysis 
buffer (50 mM Tris-HCl; pH 8.0, 150 mM NaCl, 1% SDS) supplemented with 
protease/phosphatase inhibitors, 50 µM MG132 and 10 mM NEM. Protein samples were 
prepared for anti-ChAT immunoblotting as above.  
For ubiquitination studies, SN56 cells were transiently transfected to express wild-
type, P17A/P19A-ChAT or CMS-mutant ChAT alone, or in combination, with HA-tagged 
wild-type, K0, K11, K48, K48R or K63-ubiquitin, then treated with either 5 µM MG132, 
2.5 µM lactacystin (EMD), or 25 µM chloroquine for 18 h at 37C. For oxidative stress 
studies SN56 cells transiently co-expressing wild-type ChAT with HA-ubiquitin were pre-
treated for 18 h with 5 µM MG132 then co-treated for an additional 30 or 60 min with 1 
mM H2O2. Alternatively, SN56 cells transfected to express either wild-type or mutant 
ChAT were treated at 37°C with 40 µM VER-155008 for 24 h, 1 µM 17-AAG for either 8 
or 24 h, or 10 µM Eer1 for 18 h to inhibit HSC/HSP70, HSP90, or p97/VCP respectively. 
To block degradation of ubiquitinated ChAT following HSP inhibition cells were co-treated 
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with 20 µM MG132 for 6 h prior to being collected; MG132 co-treatment was omitted 
when cells were treated with Eer1. Cells were collected and lysed on ice in RIPA buffer 
(above) or in RIPA buffer supplemented with 0.5% SDS. Lysates were sonicated to shear 
DNA, centrifuged for 10 min at 21,000 g at 4C, then either anti-HA or anti-ChAT 
immunoprecipitations were completed and analyzed by immunoblotting. 
 
2.3: Immunoprecipitation (IP) to assess ChAT ubiquitination 
For anti-HA IPs, 1 mg aliquots of cleared whole cell lysate were diluted to a final volume 
of 1 ml in supplemented RIPA buffer (above), pre-cleared by incubation with 30 µl of anti-
mouse IgG-agarose beads (Sigma) for 1 h at 4C, then HA-tagged ubiquitinated proteins 
were immunocaptured onto 25 µl of monoclonal anti-HA-agarose beads (Sigma) for 3 h at 
4C. For anti-ChAT IPs, 2-4 mg aliquots of cleared whole cell lysate were diluted to a final 
volume of 1 ml in supplemented RIPA buffer, incubated with 25 µg/mg cellular protein of 
anti-ChAT primary antibody (CTab) [440] at 4C for 18 h, then immune complexes were 
captured onto 50 µl of protein-G Dynabeads (Invitrogen) for 1 h at 4C. For both anti-HA 
and anti-ChAT IPs, immunocaptured samples were washed 4-6 times with ice-cold RIPA 
buffer and immune complexes were eluted into 50 µl of 2x Laemmli sample buffer (above) 
by heating samples at 85C for 15 min with intermittent mixing. IP samples were analyzed 
by immunoblotting with anti-ChAT, anti-HA, and anti-ubiquitin primary antibodies. Total 
protein samples were prepared by denaturing whole cell lysates in 1x Laemmli sample 
buffer at 95C for 5-10 min prior to immunoblotting. 
 
2.4: Co-immunoprecipitation (co-IP) of ChAT with CHIP or HSPs 
For co-IP of ChAT with endogenous HSPs, endogenous CHIP, or heterologous FLAG-
tagged CHIP either HEK293 or SN56 cells were transfected to transiently express either 
wild-type or mutant ChAT protein alone or to be co-expressed with either FLAG-CHIP or 
with mutant FLAG-CHIP-ΔTPR or FLAG-CHIP-ΔU-box. For co-IP of ChAT with 
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endogenous HSPs following oxidative stress, SN56 cells transiently expressing wild-type 
ChAT were treated with either 100 µM H2O2 for 1 – 8 h or with 1 mM H2O2 for 1 h at 
37°C. Cells were collected on ice and lysed in co-IP lysis buffer (10 mM HEPES; pH 7.4, 
5 mM MgCl2, 1 mM EGTA, 50 mM NaCl, 5% glycerol, 0.5% Triton X-100) supplemented 
with protease/phosphatase inhibitors, 50 µM MG132, and 10 mM NEM. Lysates were 
centrifuged for 15 min at 15,000 g at 4C, protein concentrations were measured by 
Bradford protein assay, then aliquots of cleared whole cell lysates containing either 2 mg 
(FLAG-CHIP) or 4 mg (endogenous proteins) of protein were incubated with CTab primary 
antibody at 4C for 18 h. Immune complexes were captured onto 50 µl of protein-G 
Dynabeads for 1 h at 4C, washed 4-6 times in co-IP lysis buffer, then eluted into 50 µl of 
2x Laemmli sample buffer by heating samples at 85C for 15 min with intermittent mixing. 
Co-IP samples were analyzed by immunoblotting. Total protein samples were prepared by 
denaturing whole cell lysates in 1x Laemmli sample buffer at 95C for 5-10 min. 
 
2.5: SDS-PAGE and immunoblotting analysis 
Denatured protein samples from whole cell lysates and IP/co-IPs were resolved on 7.5, 10, 
12, or 15% SDS-PAGE gels, then transferred to PVDF membranes (Bio-Rad) by semi-dry 
or wet-tank electroblotting. For immunoblotting, membranes were blocked for 1 h at 21°C 
in 5% non-fat milk powder in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 
mM KH2PO4; pH 7.4) containing 0.15% Triton X-100 (PBST), followed by incubation 
overnight at 4C with primary antibody. Probed membranes were washed with PBST, and 
primary antibodies were detected using 1:10,000 peroxidase-coupled secondary antibodies 
(Jackson ImmunoResearch) and Clarity Western ECL Substrate (Bio-Rad) on a ChemiDoc 
MP system (Bio-Rad). The following primary antibodies were used: 1:1000 ChAT (CTab) 
[440], either 1:1000 actin (Santa Cruz) or 1:10,000 β-actin (Sigma), 1:10,000 GAPDH (Cell 
Signalling), 1:1000 HSC70 (StressMarq), 1:2000 HSP70 (Thermo), 1:2000 HSP90 
(StressMarq), 1:1000 CHIP (Santa Cruz), 1:500 HA (Roche), 1:1000 ubiquitin (Santa 
Cruz), 1:1000 FLAG-M2 (Sigma), and 1:1000 LC3B (Thermo). For anti-CHIP 
immunoblotting from anti-ChAT co-IP samples, 1:1000 VeriBlot IP secondary antibody 
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(Abcam) was used as a substitute for standard secondary antibodies to reduce IgG light-
chain interference of endogenous 35-kDa CHIP detection.  
 
2.6: Purification of recombinant ChAT 
Chemically competent E. coli BL21 (DE3) cells were heat shock transformed at 42°C with 
pProEXHTa expression plasmids encoding N-terminal His6-tagged wild-type, P17A-, 
P19A- or P17A/P19A-ChAT and grown in auto-induction media (1% tryptone, 0.5% yeast 
extract, 50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4, 0.5% glycerol, 0.05% 
glucose, and 0.2% lactose) at 18C on a shaker (225 rpm) for 48 h until OD600 = ~8.0. Cells 
were pelleted by centrifugation at 5,000 g for 20 min at 4C, resuspended in Ni2+-column 
buffer (50 mM Na2HPO4; pH 7.5, 1.0 M KCl, 10% glycerol) supplemented with 50 mM 
imidazole. Purification of His6-tagged ChAT was completed by Ni2+-affinity purification 
with follow-up cation exchange chromatography over either Ni2+-Chelating Sepharose Fast 
Flow or SP-Sepharose Fast Flow (GE Healthcare), respectively, as performed previously 
in our laboratory [480]. Following cation exchange chromatography, protein samples were 
analyzed on Coomassie-stained SDS-PAGE gels and eluent fractions containing purified 
recombinant ChAT were pooled, flash-frozen in liquid nitrogen, and stored at -80C. Final 
protein concentrations of pooled fractions containing purified recombinant ChAT protein 
were determined using a Nanodrop UV spectrometer (Thermo) with Abs0.1% = 0.789 at 280 
nm. Samples of purified recombinant ChAT were denatured in 1x Laemmli sample buffer 
at 95C for 5 min, resolved on 10% SDS-PAGE gels, stained with Imperial Protein Stain 
(Thermo), and imaged using a ChemiDoc MP system. In vitro specific activity of purified 
recombinant ChAT proteins was assessed by radioenzymatic assay [487-488]. 
 
2.7: Circular dichroism (CD) analysis and thermal denaturation 
Purified recombinant wild-type, P17A-, P17A/P19A- and P19A-ChAT were dialyzed 
overnight at 4C against cation exchange buffer without NaN3 (10 mM Na2HPO4; pH 7.0, 
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10% glycerol, 0.5 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP; Sigma)). 
Proteins were diluted to 0.2 mg/ml in cation exchange buffer without NaN3 and CD spectra 
were generated using a Jasco J-810 spectropolarimeter at 4C in a 0.1 cm path length 
cuvette over a wavelength range of 195-260 nm at 0.5 nm intervals. A total of 20 reads 
were averaged per recombinant ChAT protein, and CD spectra were finalized by correcting 
for background buffer spectra and calculating mean residue ellipticity (MRE). Following 
CD, the thermal denaturation midpoint (Tm) was determined for each recombinant ChAT 
protein by measuring the loss of helicity at 222 nm over a 4-95C range at 0.5C intervals. 
Tm was calculated as previously described [489].  
 
2.8: Strain-promoted alkyne-azide cycloaddition (SPAAC) pulse-chase 
SN56 cells grown to ~90% confluence on 100 mm dishes were transfected by 
Lipofectamine 2000 for 6 h at 37C to mediate transient expression of wild-type or 
P17A/P19A-ChAT, then trypsinized and re-plated onto 60 mm dishes and grown overnight. 
SPAAC pulse-chase was initiated by first live-labeling (pulse) cells at 37C for 4 h in 
methionine-free DMEM (Invitrogen) supplemented with 5% dialyzed FBS (Invitrogen) 
and 50 μM Click-iT L-azidohomoalanine (AHA; Invitrogen). Control cells were grown for 
4 h in methionine-containing DMEM with 5% FBS. AHA-labeled cells were then washed 
once with and subsequently incubated in methionine-containing DMEM with 5% FBS for 
2 - 24 h at 37C (chase). For studies of ChAT protein half-life during proteasome inhibition 
cells were treated with 5 µM MG132 throughout both the 4 h pulse and 24 h chase period. 
Cells were collected on ice either immediately following the pulse period (control and 0 h) 
or following the chase periods (2, 4, 10, and 24 h). For fluorescent labeling of AHA-labeled 
proteins from whole cell lysates, collected cells were lysed on ice in 300 µl RIPA buffer 
supplemented with protease/phosphatase inhibitors, 50 µM MG132, 10 mM NEM, and 10 
mM of freshly prepared iodoacetamide. Lysates were centrifuged for 10 min at 21,000 g at 
4C and 50 µl aliquots of whole cell lysate were fluorescently-labelled by incubating with 
10 μM Click-iT TAMRA-DIBO (Invitrogen) for 1 h at 21°C followed by denaturation in 
1x Laemmli sample buffer at 95C for 5 min. For analysis, equal amounts of proteins (e.g. 
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25 µg) from each experimental sample were resolved on 7.5% SDS-PAGE gels and 
fluorescence was detected in-gel using a ChemiDoc MP system at an excitation/emission 
of 555/580 nm. Additionally, for downstream analysis anti-ChAT immunoblotting of 
AHA/TAMRA-labeled protein samples from whole cell lysates was also completed.  
To determine ChAT protein half-life, anti-ChAT IPs were prepared from AHA-
labeled cells by diluting 200 µl of cleared whole cell lysate, as prepared above, with 300 µl 
of supplemented RIPA buffer. Diluted lysates were incubated with 25 µg of anti-ChAT 
CTab primary antibody at 4C for 3 h followed by immunocapture onto 50 µl of protein-G 
Dynabeads for 1 h at 4C. Immunocaptured samples were washed four times with RIPA 
buffer, once with PBS to remove detergents, then subsequently reacted with 10 μM Click-
iT TAMRA-DIBO in 1x PBS for 1 h at 21°C with gentle agitation. Samples were washed 
twice with RIPA buffer to remove excess TAMRA-DIBO and AHA/TAMRA-labeled 
ChAT was eluted into 50 µl of 2x Laemmli sample buffer at 85C for 15 min with 
intermittent mixing. For analysis, equal volumes of immunoprecipitated AHA/TAMRA-
labeled ChAT (e.g. 20 µl) were resolved on 7.5% SDS-PAGE gels and in-gel fluorescence 
was detected as above. Additionally, for downstream analysis anti-ChAT immunoblotting 
of AHA/TAMRA-labeled protein samples from anti-ChAT IPs was also completed.  
To calculate ChAT protein half-life, I assumed that the amount of fluorescent 
AHA/TAMRA-labeled ChAT, P(t), decays exponentially under first order kinetics 
according to the equation, P(t) = Poe
-t, where Po is the fluorescence intensity at t = 0. The 
slope of decay () was calculated by plotting fluorescence intensity of immunoprecipitated 
AHA/TAMRA-labeled ChAT, corrected for the levels of total immunoprecipitated ChAT 
as measured by parallel anti-ChAT immunoblotting, on a semi-logarithmic scale and 
performing linear regression. ChAT protein half-life, T1/2, was calculated according to first 
order kinetics where T1/2 = ln(2)/ [490]. 
Validation of SPAAC pulse-chase was performed using a cycloheximide (CHX)-
chase assay. SN56 cells were transfected and plated as for SPAAC pulse-chase to 
transiently express wild-type or P17A/P19A-ChAT. Cells were treated with either 100 
µg/ml CHX for 2, 4, 6 or 8 h, or with DMSO-control for 8 h. Cells were collected and lysed 
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on ice in supplemented RIPA buffer, lysates were centrifuged for 10 min at 21,000 g at 
4C, and protein samples were prepared for anti-ChAT immunoblotting by denaturing cell 
lysates in 1x Laemmli sample buffer at 95C for 5 min. ChAT immunoreactive bands were 
quantified by densitometry, plotted on semi-logarithmic scale, and analyzed as above by 
linear regression to determine a slope of decay for wild-type and P17A/P19A-ChAT. 
 
2.9: Soluble/insoluble Triton X-100 cellular fractionation and semi-
denaturing detergent agarose gel electrophoresis (SDD-AGE) 
ChAT protein solubility was assessed in SN56 cells, transiently expressing either wild-type 
or mutant ChAT following treatment with 20 µM 2-phenylethynesulfonamide (PES; 
Sigma), a HSC/HSP70 inhibitor, at 37°C for 24 h. Alternatively, ChAT-expressing SN56 
cells were treated with varying concentrations of H2O2 for either 24 h (100 nM – 200 µM) 
or for 1 h (1 µM – 2 mM) alone or were pre-treated with 20 µM PES for 24 h followed by 
co-treatment with 100 µM H2O2 for 1 – 8 h at 37°C. Cells were collected and lysed on ice 
in 0.1% Triton X-100 lysis buffer (50 mM Tris-HCL; pH 8.0, 150 mM NaCl, 0.1% Triton 
X-100) supplemented with protease/phosphatase inhibitors, 50 µM MG132 and 10 mM 
NEM. Lysates were centrifuged for 15 min at 15,000 g at 4C and aliquots of Triton-soluble 
supernatant were prepared for immunoblotting by denaturing in 1x Laemmli sample buffer 
at 95C for 10 min. Triton-insoluble proteins were prepared for immunoblotting by 
washing Triton-insoluble pellets once with ice-cold PBS, then denaturing the pellets in an 
equal volume of 2x Laemmli sample buffer with 5% 2-mercaptoethanol at 85C for 15 min 
prior to separation on SDS-PAGE gels. For analysis of ChAT solubility following co-
expression of either FLAG-CHIP or with mutant FLAG-CHIP-ΔTPR or FLAG-CHIP-ΔU-
box, cells were lysed in 0.5% Triton X-100 co-IP lysis buffer (above) and Triton-
soluble/insoluble protein samples were prepared as above.  
In some cases, following PES treatment Triton-insoluble proteins were further 
analyzed in parallel by semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) 
[491] to determine if PES treatment results in the generation of SDS-resistant ChAT 
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aggregates. Briefly, Triton-insoluble protein samples were loaded onto 1.8% agarose gels 
containing 0.5% SDS and resolved by electrophoresis at 80V for ~2 h in 1x TAE buffer 
(40 mM Tris-HCl; pH 7.6, 20 mM acetic acid, 1 mM EDTA) supplemented with 0.1% 
SDS. Resolved proteins were transferred to PVDF membranes by overnight capillary 
transfer in 1x TBS (50 mM Tris-HCl; pH 7.6, 150 mM NaCl) with 10% methanol at 21°C. 
Membranes were blocked for 1 h at 21°C in 5% non-fat milk powder in PBST then 
immunoblotted for ChAT protein as described above.  
 
2.10: Proximity-dependent biotin identification (BioID) 
HEK293 cells expressing wild-type- or P17A/P19A-ChAT-BirA* fusion proteins were 
live-labeled with 50 µM biotin at 37°C for 24 h to allow proximity-dependent biotinylation 
of cellular proteins. Controls cells were transfected with either empty vector or plasmids 
encoding untagged ChAT or BirA* [483]. Cells were washed three times on ice with PBS 
to remove excess biotin, lysed in supplemented RIPA buffer (above), centrifuged for 10 
min at 21,000 g at 4C, then aliquots of cleared whole cell lysate containing 5 mg protein 
were incubated with 50 µl of MyOne Streptavidin C1 Dynabeads (Invitrogen) at 4°C for 
18 h. Streptavidin pull-down (PD) samples were washed once with 1% SDS lysis buffer 
(50 mM Tris-HCl; pH 8.0, 150 mM NaCl, 1% SDS), 3-4 times with RIPA buffer, then 
biotinylated proteins were eluted into 50 µl of 2x Laemmli sample buffer at 85C for 15 
min. Biotinylated proteins were resolved on SDS-PAGE gels, transferred to PVDF 
membranes, and membranes were blocked overnight at 4°C in PBST with 5% BSA prior 
to incubation with, and subsequent blotting using 1:20,000 Pierce High Sensitivity 
Streptavidin-HRP (Thermo) for 1 h at 21°C. Total protein samples were prepared by 
denaturing whole cell lysates in 1x Laemmli sample buffer at 95C for 10 min prior to 
immunoblotting. For large-scale BioID to identify novel ChAT protein-interactors, 
HEK293 cells expressing either untagged ChAT (control) or ChAT-BirA* fusion proteins 
were live labeled with 50 µM biotin then collected, washed, lysed and centrifuged as above. 
Aliquots of cleared whole cell lysate containing 25 mg protein were incubated with 250 µl 
of MyOne Streptavidin C1 Dynabeads at 4°C for 18 h. Streptavidin PD samples were 
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washed as described above, eluted into 100 µl of 2x Laemmli sample buffer, and resolved 
on 10% SDS-PAGE gels. To visualize biotinylated proteins, the SDS-PAGE gel was 
stained using Pierce Silver Stain for Mass Spectrometry (Thermo).  
 
2.11: Mass spectrometry 
Following large-scale BioID proteins of interest were excised from silver-stained SDS-
PAGE gels using an Ettan Spot Picker (GE Healthcare Life Sciences). In-gel digestion was 
performed at the London Regional Proteomics Center - Functional Proteomics Facility 
(FPF; Western University) using a MassPREP automated digester station (PerkinElmer) 
where gel pieces were first de-stained (50 mM Na2S2O3 and 15 mM K3Fe(CN)6), followed 
by protein reduction (10 mM dithiothreitol), alkylation (55 mM iodoacetamide), and tryptic 
digestion. Digested peptides were extracted in 1% formic acid with 2% acetonitrile, 
lyophilized, then dissolved in 10% acetonitrile containing 0.1% trifluoroacetic acid prior to 
mass spectrometry by either matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS) or by liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS). 
For MALDI-TOF-MS tryptic-digested peptides were mixed 1:1 (v/v) with a 5 
mg/mL –cyano-4–hydroxycinnamic acid MALDI matrix that was prepared in 6 mM 
NH4H2PO4, 50% acetonitrile, and 0.1% trifluoroacetic acid, then submitted to the London 
Regional Proteomics Center - FPF for analysis. Mass spectrum were obtained using a 
TOF/TOF 5800 System (Applied Biosystems, Sciex) equipped with a 349 nm OptiBeam 
On-Axis laser using a laser pulse-rate of 400 Hz. Reflectron positive mode was used and 
was externally calibrated at 50 ppm mass tolerance and internally at 10 ppm. Each mass 
spectrum was collected as a sum of 500 shots. Data acquisition and processing were 
completed using a TOF/TOF Series Explorer and Data Explorer respectively (Applied 
Biosystems, Sciex). The resulting data were analyzed using the online Mascot Server 
(Matrix Science) against the NCBI Human protein database with the following selected as 
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variable modifications; biotin (K), carbamidomethyl (C), NEM (C), oxidation (M). Peptide 
tolerance was set at ± 50 ppm for protein identification. 
 For LC-ESI-MS/MS, tryptic-digested peptides were submitted for protein 
identification by the London Regional Proteomics Center – Biological Mass Spectrometry 
Laboratory (BMSL; Western University). Briefly, digested peptides were injected into and 
analyzed using a LC-ESI-MS/MS system comprised of a nanoAcquity UPLC (Waters) 
followed by an in-line QExactive Hybrid Quadrupole-Orbitrap mass spectrometer 
(Thermo) using a top-12 double-play method. For LC, peptides were trapped onto a 
reverse-phase Acquity Symmetry C18 column, 5 µm, 180 µm x 200 mm (Waters), and 
subsequently were separated/eluted using a H2O-acetonitrile with 0.1% formic acid solvent 
gradient applied to a Acquity Peptide BEH C18 column, 1.7 um, 75 um x 250 mm (Waters). 
Resulting data were analyzed using Peaks 7.5 software (Bioinformatics Solutions Inc.) 
against the NCBI Human protein database allowing for variable carbamidomethylation or 
modification of cysteine residues with NEM with filter criteria set to FDR = 1% and UP = 
1 (unique protein) to show protein identification. 
 
2.12: In situ proximity ligation assay (PLA) 
To evaluate in situ ChAT protein-interactors, SN56 cells were plated on 35 mm glass-
bottom confocal dishes and transiently transfected to express wild-type 69-kDa ChAT. 
Cells were washed with HBSS, formalin-fixed (4% paraformaldehyde in HBSS) for 15 
min, permeabilized with 0.1% Triton X-100, blocked for 1 h in HBSS supplemented with 
3% donkey serum, then finally incubated for 1 h with primary antibodies targeting ChAT 
(1:100; Chemicon, goat primary) together with either endogenous HSC70 (1:100; 
StressMarq, mouse primary), HSP90 (1:200; StressMarq, mouse primary) or CHIP (1:200; 
Santa Cruz, rabbit primary); all steps were performed at 21°C. Controls cells were 
transfected with empty vector or were not incubated with primary antibodies. DuoLink 
PLA technology (Sigma) was utilized to visualize in situ interactions by incubating cells 
with Duolink oligonucleotide-linked secondary antibodies (anti-goat PLUS with either 
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anti-mouse MINUS or anti-rabbit MINUS) for 1 h at 37°C. Cells were washed with Duolink 
In Situ Wash Buffer A, then incubated with 1 U/µL DNA ligase for 30 min followed by 10 
U/µL DNA polymerase for 2 h at 37°C according to manufacturer’s instructions. Finally, 
cells were washed with Duolink In Situ Wash Buffer B and were overlaid with Duolink In 
Situ Mounting Medium with DAPI. Images were acquired using a Leica True Confocal 
Scanner (TCS) 8 SpectroPhotometer (SP8; Leica Microsystems Inc.) confocal laser 
microscope with a 63x-magnification oil-immersion objective (NA = 1.4) and processed 
using ImageJ 1.50b software (NIH). 
 
2.13: Small-interfering RNA (siRNA)  
SN56 cells were incubated for a total of 72 h at 37°C with 25 nM of siRNA targeting either 
mouse Stub1/CHIP (Silencer Select ID: s80537; Thermo) or mouse HSP70 (sc-35605; 
Santa Cruz) following transfection with siLentFect Lipid Reagent (Bio-Rad). As a control, 
cells were either mock transfected with siLentFect alone or transfected with 25 nM of 
scramble-control siRNA (Silencer Select #4390843; Thermo). After 24 h of endogenous 
CHIP/HSP70 knock-down, cells were transfected with Lipofectamine 3000 to transiently 
express either heterologous wild-type or mutant ChAT for an additional 48 h at 37°C. 
Additionally, cells incubated with anti-HSP70 siRNA were treated with 1 µM 17-AAG for 
the final 24 h of HSP70 knock-down at 37°C. Cells were then collected and lysed on ice in 
RIPA buffer containing 0.5% SDS, protease/phosphatase inhibitors, 50 µM MG132 and 10 
mM NEM. Lysates were sonicated, centrifuged for 10 min at 21,000 g at 4C, denatured in 
1x Laemmli sample buffer at 95C for 10 min, then analyzed by immunoblotting. 
 
2.14: Statistical analysis 
For statistical analysis of steady-state proteins levels from immunoblots prepared using 
whole cell lysates, immunoreactive protein levels were measured by densitometry using 
ImageLab 5.0 software (Bio-Rad), normalized to either β-actin or GAPDH protein levels, 
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and graphed as mean ± SEM from individual independent replicate experiments (n). For 
analysis of anti-ChAT co-IP immunoblots, immunoreactive bands for each co-
immunoprecipitated protein (i.e. wild-type and mutant ChAT proteins, HSC70/HSP70, 
HSP90 or FLAG-CHIP) were separately measured by densitometry then internally 
normalized to the total densitometric value for that protein from within their respective 
immunoblots to obtain the relative levels of each co-immunoprecipitated protein. These 
relative levels of HSPs or FLAG-ChAT were then expressed as a function of the relative 
level of co-immunoprecipitated ChAT, and data was graphed as mean ± SEM from n 
number of independent replicate co-IP experiments. Statistical analysis for experiments 
completed within this thesis was performed by Student’s t-test, one-way ANOVA with 
either Tukey’s or Dunnett’s post-hoc test, or by two-way ANOVA with Bonferroni’s post-
hoc test using GraphPad Prism software. Statistical significance was set at p≤0.05. 
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CHAPTER 3: RESULTS 
3.1: ChAT mutations reduce steady-state protein levels and cellular 
enzymatic activity of ChAT 
Multiple missense mutations have been identified in the human 69-kDa ChAT protein that 
have a causative association with development of CMS, with several of these mutations 
reducing both the in vitro enzyme activity of purified recombinant ChAT and the cellular 
steady-state protein levels of mutant ChAT when expressed in COS, BOSC 23, or HEK293 
cells (Figure 1.9) [411, 457-458]. Two such catalytically-deficient mutations, V18M and 
A513T, are positioned distal from the ChAT active site and reduce ChAT protein levels 
and enzymatic activity through unknown mechanism [457].  As these earlier studies were 
performed in non-neural cells, it is currently unknown if these CMS-related mutations also 
reduce ChAT steady-state protein levels in cholinergic cells. Thus, I generated expression 
plasmids encoding for three different catalytically-deficient CMS-related ChAT mutations 
(V18M, A513T, and T490N) that were then transiently expressed in mouse cholinergic 
SN56 neural cells; T490N-ChAT differs from V18M and A513T as this mutation does not 
reduce steady-state ChAT protein levels when expressed in human kidney BOSC 23 cells 
[457]. Following anti-ChAT immunoblotting (Figure 3.1a) I confirmed that the steady-state 
protein levels of both V18M- (p≤0.001) and A513T-ChAT (p≤0.05) are reduced compared 
to wild-type ChAT in cholinergic SN56 cells, whereas the protein levels of T490N-ChAT 
were unaffected as anticipated (Figure 3.1b). As introduced earlier, residue Val18 is located 
within a highly-conserved and surface-exposed N-terminal proline-rich motif at residues 
14PKLPVPP20 that shares homology with the core PxxP-binding motif for SH3-domain-
containg proteins (Figs 1.10 and 1.11) [420, 474]. Therefore, to test whether residues within 
this proline-rich motif beyond residue Val18 may regulate ChAT steady-state protein levels, 
I also generated an expression plasmid encoding for ChAT with proline-to-alanine mutation 
of residues Pro17 together with Pro19 (P17A/P19A). When transiently expressed in SN56 
and analyzed by anti-ChAT immunoblotting, I observed that the steady-state protein levels 
of P17A/P19A-ChAT is also reduced compared to wild-type ChAT (p≤0.001; Figure 3.1).  
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Figure 3.1: CMS-related ChAT mutants demonstrate reduced steady-state protein 
levels. (A) Anti-ChAT immunoblots from SN56 cells transiently expressing wild-type 
(WT), P17A/P19A-, or CMS-related mutant ChAT (V18M-, A513T-, and T490N-ChAT). 
Control cells were transfected with empty pcDNA3.1+ vector. Anti-actin immunoblotting 
was completed as a loading control. (B) Steady-state protein levels of P17A/P19A- 
(***p≤0.001), V18M- (***p≤0.001), or A513T-ChAT (*p≤0.05) are reduced compared to 
wild-type ChAT (one-way ANOVA with Dunnett’s post-hoc test, mean ± SEM, n=5). In 
agreement with previously reported results from human kidney BOSC 23 cells transiently 
expressing mutant T490N-ChAT [457], no significant changes in the steady-state protein 
levels of T490N-ChAT were observed in SN56 cells as compared to wild-type ChAT. 
 
Both the P17A/P19A and CMS-related V18M mutations suggest a critical role for 
the ChAT N-terminus in regulating ChAT protein function. The crystal structure of human 
69-kDa ChAT suggests that residues Met1 to Ser11 are unstructured, while Gly12 through 
Gln30 are structured and surface-exposed [420]. Therefore, to first locate which regions 
within the ChAT N-terminus are functionally critical I generated expression plasmids 
encoding for ChAT with progressive truncation of the N-terminus up to and including 
residue Gln30 (1-5, 1-10, 1-15, 1-20 and 1-30). These N-terminally truncated ChAT 
mutants were then transiently expressed in SN56 cells and cell lysates were analyzed for 
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both steady-state protein levels, by anti-ChAT immunoblotting, and for cellular ChAT 
activity. When compared to wild-type ChAT, I found that truncation of the ChAT N-
terminus up to and including residue Glu10 (1-5 and Δ1-10) had no effect on either ChAT 
steady-state protein levels (Figures 3.2a and 3.2b) or cellular ChAT activity (Figure 3.2c). 
However, deletion of residues including Lys15 and up-to Gln30 (1-15, 1-20 and 1-30) 
dramatically reduced steady-state protein levels of these truncated ChAT mutants in SN56 
cells and abolished their cellular catalytic activity (p≤0.001).  
Residue Lys15, like Val18, is located within the highly-conserved N-terminal proline-
rich motif of ChAT the encompasses residues 14PKLPVPP20. Proline residues impart 
structural rigidity to polypeptides, and proline-rich motifs are often involved in cellular 
signalling processes [474, 492-493]. On this basis, I further investigated the conserved N-
terminal proline-rich motif to find whether mutation of this motif beyond the P17A/P19A 
and CMS-related V18M mutations might also affect ChAT activity and cellular ChAT 
protein levels. Plasmids encoding for ChAT with various N-terminal proline-to-alanine 
mutations (P14A, P17A, P19A, and P20A) were generated and subsequently assessed in 
SN56 cells alongside of P17A/P19A-ChAT. As illustrated in Figures 3.3a and 3.3b, 
mutation of any proline residue within this proline-rich motif reduced ChAT steady-state 
protein levels when compared to wild-type ChAT, with P17A/P19A-ChAT yielding the 
greatest reduction (80%; p≤0.01). Moreover, mutation of these proline residues reduces 
cellular ChAT activity, with P17A/P19A-ChAT being catalytically inactive (p≤0.001; 
Figure 3.3c). Interestingly, though statistical differences in the steady-state protein levels 
between individual proline mutants were not observed, mutation of residue Pro17 alone did 
result in a greater reduction in cellular ChAT activity when compared to mutation of either 
residues Pro14 (p≤0.05) or Pro20 (p≤0.01) alone. Collectively, these results, by disruption, 
removal, or mutation of the ChAT N-terminal proline-rich motif, suggest a critical role for 
this motif on ChAT function. 
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Figure 3.2: N-terminal truncation of ChAT reduces ChAT steady-state proteins levels 
and cellular ChAT activity. (A) Anti-ChAT immunoblots from SN56 cells transiently 
expressing either full-length wild-type (WT) or N-terminally truncated ChAT mutants. 
Control cells were transfected with empty pcDNA3.1+ vector. Anti-actin immunoblotting 
was completed as a loading control. Truncation up-to and including residue Glu10 (1-5 
and Δ1-10) had no effect on either steady-state protein levels (B) or cellular ChAT activity 
(C) when compared to wild-type ChAT. Conversely, truncation of residues including Lys15 
and up-to Gln30 (1-15, 1-20 and 1-30) reduces steady-state protein levels and cellular 
ChAT activity compared to wild-type ChAT (***p≤0.001, one-way ANOVA with 
Dunnett’s post-hoc test, mean ± SEM, n=3). 
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Figure 3.3: Mutation of conserved N-terminal proline-rich motif of ChAT reduces 
ChAT steady-state proteins levels and cellular ChAT activity. (A) Anti-ChAT 
immunoblots from SN56 cells transiently expressing wild-type (WT) or various proline-to-
alanine ChAT mutants. Control cells were transfected with empty pcDNA3.1+ vector. 
Anti-actin immunoblotting was completed as a loading control. (B) Proline-to-alanine 
mutation reduces the steady-state protein levels of proline-mutant ChAT compared to wild-
type ChAT with P17A/P19A-ChAT yielding the greatest reduction (**p≤0.01, one-way 
ANOVA with Tukey’s post-hoc test, mean ± SEM, n=5). (C) Proline-to-alanine mutation 
reduces cellular ChAT activity of proline-mutant ChAT compared to wild-type ChAT with 
P17A/P19A-ChAT yielding the greatest reduction (***p≤0.001). Cellular activity of 
mutant P17A-ChAT is reduced compared to either P14A- (*p≤0.05) or P20A-ChAT 
(**p≤0.01, one-way ANOVA with Tukey’s post-hoc test, mean ± SEM, n=5). 
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3.2: In vitro characterization of recombinant proline-mutant ChAT 
The introduction of proline-to-alanine mutations within the N-terminal proline-rich motif 
of ChAT could potentially alter ChAT protein secondary structure, thereby resulting in 
reduced enzyme activity, gross structural instability, protein misfolding, and increased 
protein degradation. To determine the structural stability of mutant ChAT, I purified 
bacterially-expressed recombinant wild-type and proline-mutant ChAT proteins (Figure 
3.4). I made the important observation that, in contrast to my results in mouse cholinergic 
SN56 cells, expression levels of proline-mutant ChAT proteins (P17A-, P17A/P19A-, and 
P19A-ChAT) in E. coli BL21 cells did not differ from that of wild-type ChAT protein (data 
not shown). Moreover, the proline mutants behaved similarly to wild-type ChAT during 
purification, yielding stable and pure recombinant protein preparations each with an 
approximate molecular mass of 65-kDa in agreement with previously published results 
from our laboratory (Figure 3.4a) [480]. Using these recombinant ChAT proteins, I first 
determined whether proline-mutant ChAT displayed reduced in vitro enzymatic activity 
similar to that observed in cells. One consideration when measuring ChAT activity from 
cell lysates is that both ChAT protein expression and innate enzymatic activity factor into 
these measurements, and therefore loss of cellular ChAT protein, such as that observed for 
proline-mutant ChAT (Figures 3.2 and 3.3), can synergize with catalytic defects. Thus, 
using equal amounts of purified recombinant wild-type and proline-mutant ChAT, I 
measured the in vitro specific activity of recombinant ChAT by radioenzymatic assay 
(Figure 3.4b). As anticipated, proline-to-alanine mutation of residue Pro17 either alone or 
in combination with Pro19 significantly reduced in vitro specific activity of these proline-
mutant ChAT proteins when compared to wild-type ChAT, with P17A/P19A-ChAT 
yielding the greatest reduction (76%; p≤0.05). Surprisingly, unlike in SN56 cells, the in 
vitro specific activity of P19A-ChAT did not differ from that of wild-type ChAT.  
Given the surface-exposed positions of residues Pro17 and Pro19 within the human 
69-kDa ChAT structure [420] it is unlikely that observed differences in in vitro specific 
activity of recombinant P17A- or P17A/P19A-ChAT are due to substantial changes in 
protein secondary structure or stability. To confirm this, I completed circular dichroism 
(CD) analysis on purified recombinant ChAT and, importantly, observed no significant  
62 
 
 
 
Figure 3.4: Purification of bacterially-expressed recombinant wild-type and proline-
mutant ChAT. (A) Representative Imperial Protein-stained SDS-PAGE gel loaded with 
1.0 or 2.0 µg of purified bacterially-expressed recombinant wild-type (WT) and proline-
mutant ChAT. (B) Proline-to-alanine mutation of residue Pro17 either alone or in 
combination with Pro19 (i.e. P17A/P19A) reduces the in vitro specific activity of purified 
recombinant mutant ChAT when compared to wild-type ChAT (***p≤0.001), with 
P17A/P19A-ChAT yielding the greatest reduction compared to either P17A- (*p≤0.05) or 
P19A-ChAT (***p≤0.001). No significant change in in vitro specific activity was observed 
for mutant P19A-ChAT when compared to wild-type ChAT (one-way ANOVA with 
Tukey’s post-hoc test, mean ± SEM, n=8). 
 
differences in the gross protein secondary structure between the different recombinant 
ChAT proteins tested (i.e. wild-type, P17A, P17A/P19A and P19A) (Figure 3.5a). To 
assess the in vitro stability of recombinant wild-type and proline-mutant ChAT I performed 
a thermal denaturation assay by tracking loss of helicity at 222 nm during a thermal melt 
from 4 to 95C (Figure 3.5b). In support of my CD results showing the absence of gross 
structural changes in the recombinant proline-mutant ChAT proteins, the denaturation  
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Figure 3.5: In vitro analysis of recombinant wild-type and proline-mutant ChAT. (A) 
Circular dichroism analysis of purified bacterially-expressed recombinant ChAT reveals 
that both wild-type (WT) and proline-mutant ChAT are well-structured, primarily alpha 
helical, and that there are no overall changes in gross protein secondary structure of proline-
mutant ChAT as compared to that for wild-type ChAT. Mean residue ellipticity (MRE) was 
measured over a wavelength range of 195-260 nm at 0.5 nm intervals. (B) Proline-to-
alanine mutation does not significantly affect the in vitro denaturation midpoint (Tm) of 
recombinant P17A- (50.65 ± 0.081C), P19A- (49.45 ± 0.07C), or P17A/P19A-ChAT 
(50.35 ± 0.07C) as compared to wild-type ChAT (51.15 ± 0.03C). Tm was determined by 
tracking loss of helicity at 222 nm from 4-95°C.  
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midpoint (Tm) of ChAT was not significantly altered by mutations involving the N-terminal 
proline-rich motif as follows; wild-type (51.15 ± 0.03C), P17A-ChAT (50.65 ± 0.081C), 
P17A/P19A-ChAT (50.35 ± 0.07C) and P19A-ChAT (49.45 ± 0.07C).  
 
3.3: Proteasome inhibition increases ChAT steady-state protein levels and 
cellular ChAT enzyme activity  
My studies using purified recombinant ChAT suggest that mutation of the N-terminal 
proline-rich motif can result in loss of enzymatic activity though does not result in gross 
changes in protein secondary structure or thermal stability. Interestingly, in mammalian 
SN56 cells N-terminal mutation of ChAT, including P17A/P19A and CMS-related V18M, 
results in reduced ChAT protein levels (Figures 3.1 – 3.3), though the cellular mechanisms 
responsible for this reduction in mutant ChAT protein levels have not been defined. Loss 
of cellular protein levels can be due to enhanced protein degradation that is mediated 
through either proteasomal or lysosomal proteolysis; it is currently unknown whether 
ChAT is degraded by either of these cellular proteolytic pathways. Thus, I tested whether 
treatment with either the proteasome inhibitor MG132 [26] or the lysosome inhibitor 
chloroquine [117] could alter the steady-state protein levels and/or cellular activity of 
ChAT in SN56 cells transiently expressing either wild-type (Figure 3.6a) or P17A/P19A-
ChAT (Figure 3.6c). Importantly, following analysis of cell lysates by anti-ChAT 
immunoblotting, I observed an increase in the steady-state protein levels for both wild-type 
(p≤0.01; Figure 3.6b) and P17A/P19A-ChAT (p≤0.001; Figure 3.6d) in cells treated with 
5 µM MG132 for 18 h when compared to cells treated with 25 µM chloroquine or to 
DMSO-treated control cells. Additionally, by radioenzymatic assay MG132 treatment was 
found to significantly increased the cellular activity of wild-type ChAT as compared to 
treatment with either chloroquine or DMSO-control (p≤0.00; Figure 3.6e). In contrast, 
treatment with either MG132 or chloroquine failed to increase the cellular activity of 
P17A/P19A-ChAT (Figure 3.6e), suggesting that this mutant enzyme maintains impaired 
cellular catalytic activity despite increased protein levels following MG132 treatment. 
Proteasomal inhibition with MG132 was verified by accumulation of ubiquitinated  
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Figure 3.6: Proteasome inhibition increases ChAT steady-state protein levels and 
cellular ChAT activity. (A) Anti-ChAT immunoblots from SN56 cells transiently 
expressing wild-type (WT) ChAT that were treated for 18 h with 5 µM MG132 or 25 μM 
chloroquine (CQ). Proteasome inhibition by MG132 treatment or lysosome inhibition by 
CQ treatment was validated by immunoblotting for the accumulation of either ubiquitinated 
cellular proteins or for the lysosome-associated protein LC3B-II, respectively. Anti-actin 
immunoblotting was completed as a loading control. (B) Steady-state protein levels of wild-
type ChAT are increased in MG132-treated cells compared to either CQ-treated cells or 
DMSO-treated control cells (**p≤0.01, one-way ANOVA with Tukey’s post-hoc test, 
mean ± SEM, n=3). (C) Anti-ChAT immunoblots from SN56 cells transiently expressing 
mutant P17A/P19A-ChAT that were treated and assessed as in (A). (D) Steady-state protein 
levels of P17A/P19A-ChAT are increased in MG132-treated cells compared to CQ-treated 
cells or DMSO-treated control cells (***p≤0.001, one-way ANOVA with Tukey’s post-
hoc test, mean ± SEM, n=3). (E) Cellular ChAT activity is increased in wild-type ChAT 
expressing cells treated with MG132 as compared to either CQ-treated cells or DMSO-
treated control cells (***p≤0.001, two-way ANOVA with Bonferroni’s post-hoc test, mean ± 
SEM, n=3). Neither MG132 nor CQ treatment increased the cellular activity of mutant 
P17A/P19A-ChAT. 
 
proteins (Figure 3.6a), whereas lysosomal inhibition with chloroquine was verified by 
accumulation of a lysosome-associated isoform of microtubule-associated protein 1A/1B-
light chain 3 (LC3B-II; Figure 3.6c) [494]. 
Together these results suggest that wild-type and mutant P17A/P19A-ChAT may be 
targeted for proteasomal degradation. To next determine whether CMS-related mutant 
ChAT may also be regulated by the proteasome I tested whether proteasomal inhibition 
could increase the steady-state protein levels of CMS-mutant ChAT, and if this may 
correlate with increased cellular ChAT activity. Thus, SN56 cells transiently expressing 
wild-type or CMS-related V18M-, A513T-, or T490N-ChAT were treated for 18 h with 5 
µM MG132 and steady-state protein levels and cellular ChAT activity were measured. As 
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shown in Figures 3.7a and 3.7b, proteasome inhibition significantly increased the steady-
state protein levels of both A513T- (p≤0.05) and T490N-ChAT (p≤0.01) as compared to 
DMSO-treated control cells. Though not statistically significant, I did observe a trend 
towards increased steady-state protein levels of V18M-ChAT with MG132 treatment when 
compared to DMSO-control (p=0.114). Lastly, MG132 treatment also increased the 
cellular activity of both A513T- (p≤0.01) and T490N-ChAT (p≤0.001) as compared to 
DMSO-treated control cells, but, like P17A/P19A-ChAT, had no effect on the cellular 
activity of V18M-ChAT (Figure 3.7c).  
 
3.4: Mutation of the N-terminal proline-rich motif enhances ChAT 
ubiquitination 
My results with MG132 suggest that cellular stability of ChAT protein is regulated through 
proteasome-dependent degradation. Canonically, post-translational ubiquitination of 
cellular proteins by covalent attachment of poly-Ub chains targets proteins for proteasomal 
degradation [44, 60, 93]. Ubiquitination of ChAT protein has not been reported previously, 
and therefore as a preliminary experiment I treated SN56 cells transient expressing either 
wild-type or P17A/P19A with either 5 µM MG132 or 25 µM chloroquine for 18 h. Cells 
were subsequently collected, lysed, and assayed by anti-ChAT immunoblotting for the 
presence of higher molecular mass ChAT proteins that may be representative of 
ubiquitinated forms of ChAT (Figure 3.8). As anticipated, I observed accumulation of 
higher molecular mass ChAT proteins following treatment with 5 µM MG132 that were 
not present in cells treated with either DMSO-control (Figure 3.8a, top panel, anti-ChAT 
long-exposure) or in cells treated with 25 µM chloroquine (Figure 3.8b). Importantly, by 
comparing the levels of higher molecular mass ChAT protein following MG132 treatment, 
relative to total ChAT protein levels, I observed a greater abundance of higher molecular 
mass P17A/P19A-ChAT as compared to that for wild-type ChAT (p≤0.01; Figure 3.8c). 
The presence of higher molecular mass ChAT immunoreactive proteins following 
proteasome inhibition suggests that ChAT may be ubiquitinated in cells. Therefore, I 
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Figure 3.7: Proteasome inhibition partially restores the steady-state protein levels and 
cellular activity of CMS-related ChAT mutants. (A) Anti-ChAT immunoblots from 
SN56 cells transiently expressing wild-type (WT), V18M-, A513T-, or T490N-ChAT that 
were treated with 5 μM MG132 for 18 h. Proteasome inhibition by MG132 treatment was 
validated by immunoblotting for the accumulation of ubiquitinated cellular proteins. Anti-
actin immunoblotting was completed as a loading control. (B) Steady-state protein levels 
of A513T- (*p≤0.05) and T490N-ChAT (**p≤0.01) are increased in MG132-treated cells 
as compared to DMSO-treated control cells. Though not statistically significant, a trend 
towards increased steady-state protein levels of V18M-ChAT with MG132 treatment was 
observed when compared to DMSO-control (p=0.114, two-way ANOVA with Bonferroni’s 
post-hoc test, mean ± SEM, n=4). (C) Cellular ChAT activity of wild-type (***p≤0.001), 
A513T- (**p≤0.01), and T490N-ChAT (***p≤0.001) are increased in MG132-treated cells 
compared to DMSO-treated control cells (two-way ANOVA with Bonferroni’s post-hoc test, 
mean ± SEM, n=4). 
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Figure 3.8: Proteasome inhibition reveals the presence of multiple higher molecular 
mass ChAT proteins. Anti-ChAT immunoblots from SN56 cells transiently expressing 
either wild-type (WT) or P17A/P19A-ChAT that were treated with either (A) 5 µM MG132 
or (B) 25 µM chloroquine (CQ) for 18 h. Control cells were transfected with empty 
pcDNA3.1+ vector. Proteasome inhibition by MG132 treatment or lysosome inhibition by 
CQ treatment was validated by immunoblotting for the accumulation of either ubiquitinated 
cellular proteins or the lysosome-associated protein LC3B-II, respectively. Anti-actin 
immunoblotting was completed as a loading control. Treatment with MG132, but not CQ 
or DMSO-control, resulted in the accumulation of multiple higher molecular mass 
immunoreactive ChAT proteins in cells expressing either wild-type or P17A/P19A-ChAT. 
(C) The levels of higher molecular mass ChAT proteins following MG132 treatment (A), 
relative to total ChAT, is greater in cells expressing P17A/P19A-ChAT compared to wild-
type ChAT (**p≤0.01, Student’s t-test, mean ± SEM, n=4). 
70 
 
co-expressed wild-type or P17A/P19A-ChAT with HA-tagged ubiquitin in SN56 cells and 
completed anti-HA IPs to isolate for ubiquitinated cellular proteins and to test for the 
presence of ChAT protein ubiquitination. Following anti-ChAT immunoblotting from anti-
HA IP samples, I observed that both wild-type and P17A/P19A-ChAT are ubiquitinated, 
and furthermore that treatment of cells with 5 µM MG132 for 18 h increased the recovery 
of ubiquitinated ChAT compared to DMSO-treated control cells (Figure 3.9a). Importantly, 
the abundance of ubiquitinated ChAT, relative to total ChAT protein levels from whole cell 
lysates, is greater for P17A/P19A-ChAT. Treatment of cells with 25 µM chloroquine had 
negligible effect on the recovery of ubiquitinated wild-type or P17A/P19A-ChAT (Figure 
3.9b). To determine whether ubiquitination of CMS-mutant ChAT is also altered, I 
completed anti-HA IPs from SN56 cells transiently co-expressing wild-type or CMS-
mutant ChAT with HA-tagged ubiquitin that were treated with 5 µM MG132 for 18 h. As 
anticipated, by anti-ChAT immunoblotting from anti-HA IP samples I observed increased 
recovery of ubiquitinated wild-type and CMS-mutant ChAT proteins following proteasome 
inhibition by MG132 treatment. Importantly, the abundance of ubiquitinated ChAT, 
relative to total ChAT protein levels from whole cell lysates, was greater for both V18M- 
and A513T-ChAT as compared to wild-type ChAT (Figure 3.9c). In support of Figure 3.1, 
the ubiquitination of T490N-ChAT appears to be unchanged from that of wild-type ChAT.  
To validate my results regarding enhanced ubiquitination of P17A/P19A-ChAT, I 
performed anti-ChAT IPs from SN56 cells transiently co-expressing wild-type or 
P17A/P19A-ChAT with HA-tagged ubiquitin that were treated for 18 h with either 5µM 
MG132, 25 µM chloroquine, or with 2.5 µM lactacystin, another proteasome inhibitor [23, 
25] (Figure 3.10a). Following anti-HA immunoblotting from anti-ChAT IP samples, I 
observed increased recovery of ubiquitinated ChAT following proteasome inhibition by 
treatment with either MG132 or lactacystin compared to DMSO-treated control cells. The 
abundance of ubiquitinated ChAT, relative to total ChAT protein levels from whole cell 
lysates, was greater for P17A/P19A-ChAT when compared to wild-type ChAT. Treatment 
with chloroquine had no effect on recovery of ubiquitinated ChAT by anti-ChAT IP.  
These initial experiments investigating ChAT ubiquitination were performed in 
cells transiently overexpressing HA-tagged ubiquitin, and therefore I next wanted to 
71 
 
 
72 
 
Figure 3.9: ChAT ubiquitination is increased upon mutation of the N-terminal 
proline-rich motif and in cases of CMS-related mutations. (A) Representative anti-
ChAT and anti-HA immunoblots demonstrating that treatment of SN56 cells with 5 μM 
MG132 for 18 h increases recovery of ubiquitinated wild-type (WT) and P17A/P19A-
ChAT by anti-HA IP from cells co-expressing HA-tagged ubiquitin (HA-Ub) as compared 
to DMSO-treated control cells. The abundance of ubiquitinated ChAT, relative to total 
ChAT protein levels from whole cell lysates, is greater with P17A/P19A-ChAT as analyzed 
by anti-ChAT immunoblotting. Control cells were transfected to transiently express ChAT 
without HA-Ub or were transfected with empty pcDNA3.1+ vector. Proteasome inhibition 
by MG132 treatment was validated by anti-HA immunoblotting for the accumulation of 
ubiquitinated cellular proteins from whole cell lysates. Anti-actin immunoblotting was 
completed as a loading control (n=5). (B) Treatment of SN56 cells with 25 μM chloroquine 
(CQ) for 18 h had negligible effect on recovery of ubiquitinated wild-type or P17A/P19A-
ChAT by anti-HA IPs from cells co-expressing HA-Ub as compared to DMSO-treated 
control cells. Lysosome inhibition by CQ treatment was validated by immunoblotting for 
the accumulation of the lysosome-associated protein LC3B-II (n=3). (C) Treatment of 
SN56 cells with 5 μM MG132 for 18 h enhances recovery of ubiquitinated wild-type and 
CMS-mutant ChAT by anti-HA IPs from cells co-expressing HA-tagged ubiquitin as 
compared to DMSO-treated control cells. The abundance of ubiquitinated ChAT, relative 
to total ChAT protein levels, is greater with mutant P17A/P19A-, V18M-, and A513T-
ChAT compared to wild-type ChAT as evaluated by anti-ChAT immunoblotting (n=5). 
 
confirm that ChAT is ubiquitinated in cells under conditions of endogenously-expressed 
ubiquitin. Thus, I completed anti-ChAT IPs from SN56 cells transiently expressing only 
either wild-type or P17A/P19A-ChAT and that were treated for 18 h with either 5 µM 
MG132 or 25 µM chloroquine (Figure 3.10b). Following anti-ubiquitin immunoblotting 
from anti-ChAT IP samples, I observed that both wild-type and mutant P17A/P19A-ChAT 
are ubiquitinated in SN56 cells with endogenous ubiquitin. In addition, recovery of 
ubiquitinated ChAT was again increased following proteasome inhibition by MG132, and  
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Figure 3.10: Anti-ChAT IP reveals enhanced ubiquitination of mutant P17A/P19A-
ChAT. (A) Representative anti-ChAT and anti-HA immunoblots demonstrating that 
proteasome inhibition by treatment of SN56 cells with 5 μM MG132 or 2.5 μM lactacystin 
(Lac) for 18 h increases recovery of ubiquitinated wild-type (WT) and P17A/P19A-ChAT 
following anti-ChAT IPs from cells co-expressing HA-tagged ubiquitin (HA-Ub) as 
compared to DMSO-treated control cells. Distinct bands in anti-HA immunoblots 
corresponding to different molecular mass species of ubiquitinated ChAT are indicated by 
red arrows. The abundance of ubiquitinated ChAT, relative to total ChAT protein levels 
from whole cell lysates, is greater with P17A/P19A-ChAT compared to wild-type ChAT. 
Treatment with 25 μM CQ for 18 h had no effect on recovery of ubiquitinated ChAT. 
Proteasome inhibition by MG132 treatment or lysosome inhibition by CQ treatment was 
validated by immunoblotting from whole cell lysates for the accumulation of either 
ubiquitinated cellular proteins (i.e. HA-Ub) or for the lysosome-associated protein LC3B-
II, respectively. Anti-actin immunoblotting was completed as a loading control (n=5). (B) 
Ubiquitination of P17A/P19A-ChAT with endogenous ubiquitin is enhanced compared to 
wild-type ChAT in SN56 cells transfected to transiently express only either wild-type or 
P17A/P19A-ChAT. Ubiquitinated ChAT was analyzed by anti-ubiquitin immunoblotting 
from anti-ChAT IPs samples. Proteasome inhibition by 5 µM MG132 treatment for 18 h 
increases recovery of ubiquitinated ChAT compared to DMSO-control, whereas treatment 
with 25 μM CQ for 18 h had no effect on recovery of ubiquitinated ChAT. Distinct bands 
in anti-ubiquitin immunoblots corresponding to different molecular mass species of 
ubiquitinated ChAT are indicated by red arrows. Control cells were transfected with empty 
pcDNA3.1+ vector (n=4).  
 
furthermore that the abundance of ubiquitinated ChAT, relative to total ChAT protein levels 
from whole cell lysates, is greater for P17A/P19A-ChAT when compared to wild-type 
ChAT. Of importance, these results with endogenously-expressed ubiquitin reflect my 
earlier results using transient co-expression of ChAT with HA-tagged ubiquitin.  
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3.5: ChAT protein can be targeted for proteasomal degradation by both 
K48-dependent and K48-independent polyubiquitination  
My results with the proteasome inhibitors MG132 and lactacystin and either HA-tagged or 
endogenously-expressed ubiquitin suggest that ChAT protein stability is regulated by the 
ubiquitin-proteasome system. As illustrated in Figure 1.4, proteins targeted for proteasome-
dependent degradation are modified by E3 ubiquitin ligases through covalent attachment 
of monomeric ubiquitin onto lysine residues that then serves as a primer for construction 
of K48-linked poly-Ub chains by addition of free ubiquitin onto residue Lys48 of substrate-
bound ubiquitin. Subsequently, K48-linked poly-Ub chains are directly recognized by the 
26S-proteasome, resulting in proteolysis of these polyubiquitinated proteins [44, 60, 93]. 
In addition to Lys48, ubiquitin contains six other lysine residues (K6, 11, 27, 29, 33 and 63) 
that can be used for formation of poly-Ub chains that differ from K48-linked chains [44, 
50]. These alternative poly-Ub chains can have non-proteolytic roles, with K63-linked 
chains best known to regulate endosomal substrate trafficking, receptor endocytosis, kinase 
activation and DNA repair [44, 51].  
My initial work investigating ChAT ubiquitination was performed under conditions 
of proteasome inhibition by treatment of cells with either MG132 or lactacystin, and thus I 
wanted to further characterize ChAT ubiquitination in SN56 cells having active and 
functional proteasomes. To this end, SN56 cells transiently expressing either wild-type 
(Figure 3.11a) or P17A/P19A-ChAT (Figure 3.11b) were co-transfected to express HA-
tagged wild-type ubiquitin or different HA-tagged ubiquitin mutants that either cannot form 
poly-Ub chains (K0), that can only form K48-linked chains (K48), or that can only form 
non-K48-linked poly-Ub chains (i.e. K11, K48R, or K63) and anti-HA IPs were completed 
to isolate ubiquitinated cellular proteins. Following anti-ChAT immunoblotting from anti-
HA IP samples, I observed that recovery of polyubiquitinated wild-type and P17A/P19A-
ChAT was reduced in SN56 cells that co-express K48-ubiqutin as compared to wild-type-
ubiquitin. Alternatively, prevention of K48-linked polyubiquitination of ChAT by co-
expression of either K0-, K11- (only K11-linked chains), or K48R-ubiquitin increased 
recovery of polyubiquitinated wild-type and P17A/P19A-ChAT in anti-HA IPs. Co- 
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Figure 3.11: Wild-type and P17A/P19A-ChAT can be targeted for proteasomal 
degradation by both K48-dependent and K48-independent polyubiquitination. 
Recovery of ubiquitinated wild-type (WT) ChAT (A) (n=3) and P17A/P19A-ChAT (B) 
(n=3) is reduced in SN56 cells co-expressing HA-tagged mutant ubiquitin (Ub)-K48 (only 
K48-linked polyubiquitin chains) compared to wild-type HA-Ub as assessed by anti-ChAT 
immunoblotting following anti-HA IPs. Conversely, recovery of wild-type and mutant 
P17A/P19A-ChAT is increased in cells with co-expression of HA-tagged Ub-K0 (no 
polyubiquitin linkages) or either Ub-K11 or Ub-K48R that are unable to form K48-linked 
polyubiquitin chains. Control cells were transfected with empty pcDNA3.1+ vector. Anti-
actin immunoblotting from whole cell lysates was completed as a loading control. (C) 
Treatment with 5 μM MG132 for 18 h increases recovery of both K48-linked and non-K48-
linked (K48R) polyubiquitinated wild-type ChAT and P17A/P19A-ChAT in SN56 cells 
co-expressing either HA-Ub-K48 or HA-Ub-K48R compared to DMSO-treated control 
cells. Cellular ChAT ubiquitination was assessed by anti-ChAT immunoblotting following 
anti-HA IPs. Proteasome inhibition by MG132 treatment was validated by anti-HA 
immunoblotting (i.e. HA-Ub) for the accumulation of ubiquitinated cellular proteins from 
whole cell lysates (n=4). 
 
-expression with K63-ubiquitin (only K63-linked chains) had no effect on the recovery of 
polyubiquitinated wild-type or P17A/P19A-ChAT as compared to co-expression with wild-
type-ubiquitin. Closer examination of ubiquitinated P17A/P19A-ChAT from anti-HA IP 
samples (Figure 3.11b, top panel, anti-ChAT immunoblot) revealed an additional higher 
molecular mass ubiquitinated ChAT species in samples co-expressing K0, K11 or K48R-
ubiquitin when compared to cells co-expressing wild-type ubiquitin. This additional 
ubiquitinated ChAT species suggests that increased P17A/P19A-ChAT ubiquitination may 
be due to multi-ubiquitination of additional and/or alternative lysine residues within mutant 
ChAT that may differ from those utilized for the basal ubiquitination of wild-type ChAT. 
These results suggest that ChAT protein degradation by the proteasome is regulated 
through K48-linked polyubiquitination. To confirm this, we treated cells for 18 h with 5 
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µM MG132 that were transiently co-expressing either wild-type or P17A/P19A-ChAT with 
HA-tagged wild-type, K48-, or K48R-ubiquitin (Figure 3.11c). As anticipated, proteasome 
inhibition increased the recovery of K48-linked polyubiquitinated ChAT. Interestingly, 
MG132 treatment also enhanced the recovery of non-K48-linked polyubiquitinated ChAT 
when ChAT was co-expressed with K48R-ubiquitin. The abundance of both K48-linked 
and non-K48-linked polyubiquitinated ChAT, relative to total ChAT protein levels from 
whole cell lysates, appears greater for P17A/P19A-ChAT compared to wild-type ChAT. 
 
3.6: ChAT protein half-life is reduced upon mutation of the N-terminal 
proline-rich motif and can be increased by proteasome inhibition 
My assessment of ChAT ubiquitination suggests that enhanced ubiquitination, and resultant 
enhanced proteasome-dependent degradation, may be responsible for the observed 
reduction in the steady-state protein levels of P17A/P19A-ChAT. To confirm that the rate 
of degradation of P17A/P19A-ChAT is increased, I investigated whether the protein half-
life of P17A/P19A-ChAT is reduced in SN56 cells when proteasomes are functional. To 
measure protein half-life, I developed a novel fluorescent strain-promoted alkyne-azide 
cycloaddition (SPAAC) pulse-chase procedure that utilizes non-radioactive labeling and 
detection reagents (Figure 3.12). This protocol is an adaptation on classical 35S-methionine 
pulse-chase labeling and is based on metal-free “click” chemistry whereby azide-labeled 
compounds react specifically and efficiently with strained cyclooctynes, by 1,3-dipolar 
cycloaddition, to form stable 1,2,3-triazole conjugates without the need of a metal catalyst 
[495-496]. While SPAAC reactions have been used previously both in vitro and in vivo to 
measure global changes in protein synthesis [497-500], my study is the first to apply the 
use of SPAAC reactions to measure half-life of a specific cellular protein. Briefly, in my 
protocol proteins are live-labeled (pulsed) with L-azidohomoalanine (AHA), a 
biorthogonal methionine analog that contains a reactive azide moiety, under methionine-
free conditions and then chased with excess methionine. AHA-labeled proteins are then 
detected by reaction with 4-dibenzocyclooctynol (DIBO), a strained cyclooctyne, that 
79 
 
 
 
 
Figure 3.12: Schematic overview of biorthogonal strain-promoted alkyne-azide 
cycloaddition (SPAAC) pulse-chase for fluorescent determination of protein half-life. 
(1) Briefly, proteins are live-labeled (pulsed) with L-azidohomoalanine (AHA), a 
biorthogonal methionine analog that contains a reactive azide moiety, under methionine-
free conditions and then (2) chased with medium containing methionine for desired times 
(e.g. up-to 24 hours). (3) Cell are then collected, lysed, and (4) immunoprecipitation for a 
protein-of-interest (e.g. ChAT) is completed. (5) AHA-labeled proteins are reacted with the 
strained cyclooctyne 4-dibenzocyclooctynol (DIBO) that is modified with a fluorescent 
tetramethylrhodamine (TAMRA) probe to form stable fluorescent triazole conjugates. (6) 
AHA/TAMRA-labeled proteins are resolved on SDS-PAGE gels, and (7a) TAMRA 
fluorescence is detected in-gel at an excitation/emission of 555/580 nm. In addition, (7b) 
AHA/TAMRA-labeled proteins can be transferred to PVDF membranes and standard 
immunoblotting can be completed for downstream analysis. 
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is modified with a fluorescent tetramethylrhodamine (TAMRA) probe. Importantly, 
treatment of HEK293 cells with AHA has been shown to be non-toxic, resulting in highly-
specific labeling of newly-synthesized proteins that does not affect ubiquitination or protein 
degradation of these AHA-labeled proteins [498]. 
Using this pulse-chase protocol in SN56 cells transiently expressing either wild-type 
or P17A/P19A-ChAT, I detected the global progressive loss of fluorescent AHA/TAMRA-
labeled proteins from whole cell lysates during the 0-24 h chase period in the absence of 
changes in total protein levels as measured in parallel by anti-actin immunoblotting (Figure 
3.13a). Additionally, following anti-ChAT IP from ChAT-expressing SN56 cells live-
labeled with AHA, I also observed progressive loss of fluorescent AHA/TAMRA-labeled 
ChAT during the 0-24 h chase period. Importantly, the decline in protein levels of 
immunoprecipitated AHA/TAMRA-labeled P17A/P19A-ChAT is more rapid than that of 
wild-type ChAT. By quantifying the fluorescence intensities of AHA/TAMRA-labeled 
ChAT, I determined that the protein half-life of P17A/P19A-ChAT (2.2 h) is significantly 
reduced by ~10-fold compared to wild-type ChAT (19.7 h; F(1,41)=110.043, p≤0.0001; 
Figure 3.13b). A 24 h time point was not included for the quantification of P17A/P19A-
ChAT half-life as the fluorescence intensity was indistinguishable from background. 
To validate the results of my novel SPAAC pulse-chase assay, I performed a 
cycloheximide (CHX)-chase assay on SN56 cells transiently expressing either wild-type or 
P17A/P19A-ChAT. CHX is a potent, though toxic, inhibitor of protein biosynthesis 
commonly used for the molecular determination of protein half-life [501]. Thus, by anti-
ChAT immunoblotting from ChAT-expressing SN56 cells that were treated with 100 µg/ml 
CHX for 2 – 8 h (Figure 3.14a) I determined that the cellular half-life of P17A/P19A-ChAT 
(4 h) is again ~10-fold shorter than that of wild-type ChAT (45 h; F(1,46)=36.802, 
p≤0.0001; Figure 3.14b). Although the absolute half-life values determined for wild-type 
ChAT and P17A/P19A-ChAT by these two methods differ, importantly they both revealed 
that the protein half-life of P17A/P19A-ChAT is ~10% that of wild-type ChAT.  
My earlier results show that proteasome inhibition by MG132 treatment resulted in 
increased steady-state protein levels of both wild-type and P17A/P19A-ChAT (Figure 3.6). 
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Figure 3.13: SPAAC pulse-chase reveals that ChAT protein half-life is reduced upon 
mutation of the N-terminal proline-rich motif. (A) Fluorescent detection of 
immunoprecipitated (IP) AHA/TAMRA-labeled wild-type (WT) and P17A/P19A-ChAT 
following SPAAC pulse-chase (Figure 3.12) from transiently transfected SN56 cells. 
Control cells were incubated without AHA (i.e. unlabeled). Fluorescent AHA/TAMRA-
labeled proteins from either whole cell lysates or anti-ChAT IPs were detected in resolved 
SDS-PAGE gels at an Ex/Em of 555/580 nm. Anti-ChAT and anti-actin immunoblotting 
was completed on AHA/TAMRA-labeled samples for downstream data analysis and as 
loading controls. (B) Protein half-life of P17A/P17A-ChAT (2.2 h) is reduced compared to 
wild-type ChAT (19.7 h). ChAT fluorescence intensities from (A) were plotted on a semi-
logarithmic scale and linear regression was completed. The slopes of decay for wild-type 
and P17A/P19A-ChAT were significantly different: F(1,41)=110.043, p≤0.0001, n=5. 
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Figure 3.14: Validation of SPAAC pulse-chase by cycloheximide (CHX)-chase assay. 
(A) SN56 cells, transiently expressing either wild-type (WT) or P17A/P19A-ChAT, were 
treated with 100 μg/ml CHX for indicated time points (hours) and anti-ChAT 
immunoblotting was completed. Anti-actin immunoblotting was completed as a loading 
control. (B) Protein half-life of P17A/P17A-ChAT (4 h) is reduced as compared to wild-
type ChAT (45 h). Steady-state ChAT protein levels from (A) were plotted on a semi-
logarithmic scale and linear regression completed. The slopes of decay for wild-type and 
P17A/P19A-ChAT were significantly different: F(1,46) = 36.802, p≤0.0001, n=5. 
 
Therefore, I tested next whether proteasome inhibition would correlate with an increase in 
ChAT protein half-life. To determine ChAT protein half-life during proteasome inhibition, 
I performed SPAAC pulse-chase on SN56 cells transiently expressing either wild-type 
(Figure 3.15a) or P17A/P19A-ChAT (Figure 3.15b) that were treated with 5 µM MG132 
throughout both the 4 h pulse and 24 h chase periods. Following anti-ChAT IP from AHA-
labeled SN56 cells and quantification of fluorescence intensities of immunoprecipitated 
AHA/TAMRA-label ChAT, I observed that proteasome inhibition by MG132 treatment 
prevented the decay of wild-type ChAT protein as compared to DMSO-treated control cells 
(half-life = 22.5 h; Figure 3.15c). Additionally, the protein half-life of P17A/P19A-ChAT 
was also increased during MG132 treatment (16.8 h) as compared to  
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Figure 3.15: Proteasome inhibition increase ChAT protein half-life. Fluorescent 
detection of immunoprecipitated (IP) AHA/TAMRA-labeled wild-type (WT; A) or 
P17A/P19A-ChAT (B) following SPAAC pulse-chase from transiently transfected SN56 
cells that were treated with either DMSO-control or 5 µM MG132 throughout both the 4 h 
AHA-labeling and the 24 h chase periods. Control cells were incubated without AHA (i.e. 
unlabeled). Fluorescent AHA/TAMRA-labeled proteins were detected in resolved SDS-
PAGE gels at an Ex/Em of 555/580 nm. Anti-ChAT and anti-actin immunoblotting was 
completed on AHA/TAMRA-labeled samples for downstream data analysis and as loading 
controls. (C) Proteasome inhibition by MG132 treatment increased the protein half-life of 
wild-type ChAT (no protein decay) as compared to DMSO-treated control cells (22.5 h). 
Wild-type ChAT fluorescence intensities from (A) were plotted on a semi-logarithmic scale 
and linear regression was completed. The slopes of decay for DMSO- and MG132-treated 
cells were significantly different from each other: F(1,46) = 4.79241, p≤0.05, n=5. (D) 
Proteasome inhibition by MG132 treatment increased the protein half-life of mutant 
P17A/P19A-ChAT (16.6 h) as compared to DMSO-control (2.2 h). ChAT fluorescence 
intensities from (B) were plotted on a semi-logarithmic scale and linear regression was 
completed. The slopes of decay for DMSO and MG132-treated cells were significantly 
different from each other: F(1,41)=18.9864, p≤0.0001, n=5. 
 
DMSO-control (2.2 h; Figure 3.15d). No 24 h time point was included for protein half-life 
quantification from DMSO-treated control cells expressing P17A/P19A-ChAT as the 
fluorescence intensity was indistinguishable from background. 
 
3.7: Identification of the heat shock proteins HSP70 and HSP90 as 
putative ChAT protein interactors 
To summarize my findings thus far, I initially sought to identify a functional role of the N-
terminal proline-rich motif of ChAT and have shown that both cellular ChAT protein levels 
and enzyme activity are dramatically reduced following alteration of this motif, particularly 
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for the P17A/P19A and CMS-related V18M mutations. Furthermore, I also demonstrated 
for the first time that cellular degradation of ChAT protein is modulated through the 
ubiquitin-proteasome system, and that ubiquitination of mutant ChAT is enhanced. The 
mechanism/s responsible for basal ChAT ubiquitination or enhanced ubiquitination of 
catalytically-deficient ChAT have not been elucidated (Figure 3.16) [502].  
Regulation of protein stability through the ubiquitin-proteasome system involves a 
complex network of protein chaperones, E3 ubiquitin ligases, and other cellular proteostatic 
factors. Therefore, to identify putative protein-interactors that may regulate ChAT protein 
stability I utilized the BioID proteomics approach [483] to screen for direct and proximal 
ChAT-interacting proteins. Briefly, in the BioID protocol cells expressing fusions proteins 
consisting of a protein-of-interest (e.g. ChAT) fused to the 35-kDa HA-tagged promiscuous 
biotin ligase BirA-R118G-HA (BirA*) are treated with exogenous biotin to allow for 
proximity-dependent biotinylation of proximal and directly-interacting proteins. Cells are 
then lysed, streptavidin pull-downs (PDs) are completed, and biotinylated proteins can be 
analyzed by SDS-PAGE and identified by mass spectrometry (Figure 3.17a). To optimize 
this protocol for my studies I chose to compare wild-type ChAT to P17A/P19A-ChAT as 
this mutation had the greatest impact on ChAT ubiquitination and degradation following 
modification of the proline-rich motif [502]. Thus, HEK293 cells transiently expressing 
either wild-type- or P17A/P19A-ChAT-BirA* fusion proteins were treated with either 
vehicle-control (water) or 50 µM biotin for 24 h to allow proximity-dependent biotinylation 
of ChAT-interacting proteins. Subsequent analysis of protein samples from whole cell 
lysates by anti-ChAT and anti-HA immunoblotting revealed expression of ChAT-BirA* 
fusion proteins with an apparent molecular mass of ~100 kDa as compared to untagged 
ChAT proteins at ~70 kDa (Figure 3.17b, top panels). The steady-state protein levels of 
P17A/P19A-ChAT-BirA* was less than that of wild-type-ChAT-BirA* in agreement with 
my previous results demonstrating enhanced ubiquitination and degradation of mutant 
P17A/P19A-ChAT (Figures 3.10 and 3.13) [502]. Furthermore, the BioID-dependent 
biotinylation of cellular proteins was analyzed by blotting of protein samples obtained from 
streptavidin PDs with HRP-conjugated streptavidin (Strep-HRP). As anticipated, I detected 
biotinylation of multiple cellular proteins in samples from biotin-treated HEK293 cells  
86 
 
 
 
 
Figure 3.16: Model for the regulation of ChAT protein stability by the ubiquitin-
proteasome system. ChAT synthesizes the neurotransmitter acetylcholine using acetyl-
CoA (AcCoA) and choline as substrates in cholinergic neurons. Steady-state protein levels 
of wild-type (WT) ChAT are regulated by ubiquitination (Ub) and subsequent degradation 
by the 26S-proteasome. Ubiquitination and proteasomal degradation of ChAT is enhanced 
upon mutation of the N-terminal proline-rich motif of ChAT (i.e. P17A/P19A) as well as 
for the CMS-related V18M- and A513T-ChAT mutants. These mutations also reduce the 
cellular catalytic activity of mutant ChAT, thereby resulting in a synergistic impairment in 
cellular acetylcholine production (red hashed arrow). 
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Figure 3.17: Proximity-dependent biotin identification (BioID) for the determination 
of novel ChAT protein-protein interactions. (A) Overview of BioID protocol. Briefly, a 
protein of interest (e.g. ChAT), fused to the promiscuous biotin ligase BirA-R118G-HA 
(BirA*), is expressed in mammalian cells (e.g. HEK293 cells). Upon the addition of 
exogenous biotin to live-cell growth media, proteins that are either proximal-to or directly 
bound-to BirA* fusion protein will be live-labeled with biotin. Cells are then lysed, and 
biotinylated proteins are subsequently purified by streptavidin pull-down, resolved on 
SDS-PAGE gels, and identified by mass spectrometry. (B) Optimization of BioID in 
HEK293 cells transiently expressing wild-type (WT) or P17A/P19A-ChAT fused to HA-
tagged BirA*. Control cells were transfected with empty pcDNA3.1+ vector or plasmids 
encoding either untagged ChAT or unfused BirA*. Cells were treated for 24 h with 50 µM 
biotin to induce proximity-dependent biotinylation of ChAT-interacting cellular proteins 
or with vehicle-control (water). Protein samples were prepared from both whole cell lysates 
and from streptavidin pull-downs (PD: Strep), resolved on SDS-PAGE gels, and transferred 
to PVDF membranes. Biotinylated cellular proteins were detected by blotting with HRP-
conjugated streptavidin (Strep-HRP). ChAT-BirA* fusion proteins were detected by anti-
ChAT and anti-HA immunoblotting. Anti-actin immunoblotting from whole cell lysates 
was completed as a loading control (n=2). 
 
that expressed ChAT-BirA* fusion proteins, but not in control cells grown in the absence 
of biotin (vehicle) or in cells expressing untagged ChAT (Figure 3.17b). Importantly, the 
abundance of several of these biotinylated proteins was different in cells expressing 
P17A/P19A-ChAT-BirA* as compared to wild-type-ChAT-BirA*; an ~70 kDa protein was 
notably enriched in cells expressing P17A/P19A-ChAT-BirA*.  
My initial BioID experiments suggest that multiple proteins interact with and may 
differentially regulate P17A/P19A-ChAT as compared to wild-type ChAT. My primary 
goal for using BioID was to identify putative ChAT protein-interactors that may be 
responsible for the enhanced degradation of mutant ChAT observed earlier, and thus 
biotinylated proteins enriched in cells expressing P17A/P19A-ChAT-BirA* were of prime 
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interest to identify. Therefore, I completed a large-scale BioID experiment in HEK293 cells 
expressing either wild-type-ChAT-BirA* or P17A/P19A-ChAT-BirA* and, following 
streptavidin PDs, biotinylated proteins were visualized on a silver stained SDS-PAGE gel 
(Figure 3.18). Two proteins of interest that were enriched in cells expressing P17A/P19A-
ChAT-BirA* with apparent molecular masses of ~70 kDa and ~90 kDa were excised from 
the gel, along with an intense band at ~100 kDa correlating with the estimated molecular 
mass of the putative P17A/P19A-ChAT-BirA* fusion protein. In-gel protein samples were 
digested with trypsin and identified by either matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF-MS) and/or by liquid chromatography-
electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). Initial identification 
by MALDI-TOF-MS revealed the ~70 kDa protein as the heat shock protein HSP70 and, 
as anticipated, the ~100 kDa protein as ChAT-BirA* (Figure 3.18). By comparing the 
peptides masses generated by MALDI-TOF-MS to the NCBI protein database I obtained a 
30% sequence coverage for human HSP70 (20 peptides; Figure 3.19). The ~100 kDa 
protein analyzed from cells expressing P17A/P19A-ChAT-BirA* was confirmed as ChAT-
BirA* with a sequence coverage for human 69-kDa ChAT and bacterial BirA of 31% (20 
peptides) and 42% (16 peptides) respectively (Figure 3.20). My data did not contain 
peptides with masses that matched tryptic peptides that would cover the mutated residues 
in the P17A/P19A-ChAT sequence. Identification of the BioID-enriched ~90 kDa protein 
could not be achieved by MALDI-TOF-MS due to low sample yield, though subsequently 
by using the more sensitive LC-ESI-MS/MS approach I was able to identify this protein as 
HSP90 with a 16% sequence coverage (10 peptides; Figure 3.21).  Furthermore, by using 
LC-ESI-MS/MS I obtained a greater sequence coverage for HSP70 of 34% (25 peptides; 
Figure 3.22). Importantly, tryptic peptides with masses indicating the addition of biotin 
were detected for both HSP70 and ChAT-BirA* by MALDI-TOF-MS; these peptides 
contained lysine residue that could be sites for biotinylation by BirA*.  
To verify these proteins identified by MALDI and LC-ESI-MS/MS following 
BioID, I performed anti-HSP70 and anti-HSP90 immunoblotting on biotinylated protein 
samples obtained by streptavidin PDs from biotin-treated HEK293 cells expressing either 
wild-type-ChAT-BirA* or P17A/P19A-ChAT-BirA* (Figure 3.23). Importantly, as 
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Figure 3.18: Identification of the heat shock proteins HSP70 and HSP90 as novel 
ChAT protein-interactions by BioID. Streptavidin pull-down samples prepared from 
biotin-treated HEK293 cells expressing either wild-type (WT)-ChAT-BirA* or 
P17A/P19A-ChAT-BirA* fusion proteins that were resolved and visualized on a silver-
stained SDS-PAGE gels. Two biotinylated proteins (~70 kDa and ~90 kDa) that were 
enriched in samples expressing P17A/P19A-ChAT-BirA* were identified by MALDI-
TOF-MS or LC-ESI-MS/MS as HSP70 and HSP90, respectively. An ~100 kDa protein 
correlating with the estimated molecular mass of the P17A/P19A-ChAT-BirA* fusion 
protein was confirmed by MALDI-TOF-MS as ChAT-BirA*. Biotin-treated control cells 
were transfected to express untagged wild-type ChAT (n=1). 
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Figure 3.19: MALDI-TOF-MS data for HSP70 following BioID. (A) Peptide coverage 
map of human heat shock 70 kDa protein 1B (HSP70; NCBIprot database, RefSeq: 
NP_005337.2) obtained by MALDI-TOF-MS from P17A/P19A-ChAT-BirA* BioID 
samples (Figure 3.18). A total sequence coverage of 30% was obtained. (B) Peptide list of 
20 unique peptides with indicated amino acid modifications and relevant MALDI-TOF-
MA data for HSP70. One peptide (bordered) was identified with a mass-shift correlating 
with biotinylation of residue Lys507 of human HSP70.  
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Figure 3.20: MALDI-TOF-MS data for ChAT-BirA* fusion protein following BioID. 
(A) Peptide coverage map of human 69-kDa choline acetyltransferase (ChAT; NCBIprot 
database; GenBank: AAI30618.1) obtained by MALDI-TOF-MS from P17A/P19A-
ChAT-BirA* BioID samples (Figure 3.18). A total sequence coverage of 33% was obtained 
for human 69-kDa ChAT. (C) Peptide coverage map of bacterial BirA (NCBIprot database; 
GenBank: AEP13897.1) obtained by MALDI-TOF-MS from P17A/P19A-ChAT-BirA* 
BioID samples.  A total sequence coverage of 42% was obtained for bacterial BirA. Peptide 
lists of either 23 (B; ChAT) or 16 (D; BirA) unique peptides with indicated modifications 
and relevant MALDI-TOF-MA data. One ChAT peptide (B; bordered) was identified with 
a mass-shift correlating with biotinylation of residue Lys4 of human ChAT.  
 
anticipated I observed PD of endogenous HSP70 and HSP90 from biotin-treated cells 
expressing P17A/P19A-ChAT-BirA*; streptavidin PD of these HSPs was not consistently 
observed from cells expressing wild-type-ChAT-BirA* (2 of 4 trials). As controls, neither 
HSP70 nor HSP90 were visualized in immunoblots prepared from streptavidin PDs from 
biotin-treated control cells that expressed untagged ChAT. In addition, anti-ChAT and anti-
HA immunoblots revealed recovery of ChAT-BirA*, but not untagged ChAT, following 
streptavidin PD, suggesting that ChAT-BirA* can undergo self-biotinylation. This has been 
reported in other BioID studies for BirA*-tagged proteins [483] and confirms my MALDI-
TOF-MS analysis of biotinylated P17A/P19A-ChAT-BirA* (Figure 3.20). 
 
3.8: Co-immunoprecipitation of ChAT with HSPs is altered by mutation 
of N-terminal proline-rich motif of ChAT  
HSPs, such as HSP70 and HSP90, are well-characterized molecular chaperones capable of 
performing protein triage decisions by either promoting the folding and stabilization of 
cellular proteins or by targeting terminally misfolded proteins for degradation [118, 135]. 
As such, these HSPs may represent molecular chaperones involved in the stabilization of 
ChAT and/or that may promote degradation of mutant or misfolded ChAT. Therefore, to 
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Figure 3.21: LC-ESI-MS/MS data for HSP90 following BioID. (A) Peptide coverage 
map of human heat shock protein HSP 90-beta isoform c (HSP90; NCBInr_new database, 
RefSeq: NP_001258901.1) obtained by LC-ESI-MS/MS from P17A/P19A-ChAT-BirA* 
BioID samples (Figure 3.18). A total sequence coverage of 16% with 10 unique peptides 
with indicated modifications was obtained. (B) LC-ESI-MS/MS peptide list for human 
HSP90 with relevant MS data following ChAT-BirA* BioID. 
 
to verify these putative BioID interactions between ChAT and endogenous HSP70 and 
HSP90, I performed co-IP assays from HEK293 cells expressing either untagged wild-type 
or P17A/P19A-ChAT (Figure 3.24a). Interestingly, I was able to observe both HSP70 and 
HSP90 in anti-ChAT co-IP samples from cells expressing either wild-type or P17A/P19A-
ChAT. Furthermore, in addition to HSP70 and HSP90, I also found that endogenous 
HSC70, a constitutively-expressed HSP that has analogous chaperone function and shares 
similar substrate proteins to that of HSP70 [194], can co-IP with ChAT (Figure 3.24a). 
Importantly, by comparing the levels of ChAT protein to that of HSPs in anti-ChAT co-IP  
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Figure 3.22: LC-ESI-MS/MS data for HSP70 following BioID. (A) Peptide coverage 
map of human heat shock 70 kDa protein 1B (HSP70; NCBInr_new database, RefSeq: 
NP_005337.2) obtained by LC-ESI-MS/MS from P17A/P19A-ChAT-BirA* BioID 
samples (Figure 3.18). A total sequence coverage of 34% with 25 unique peptides with 
indicated modifications was obtained. (B) LC-ESI-MS/MS peptide list for human HSP70 
with relevant MS data following ChAT-BirA* BioID. 
 
96 
 
 
 
Figure 3.23: Immunoblot verification of putative ChAT interacting proteins following 
BioID. Confirmation of endogenous HSP70 and HSP90 as putative ChAT-interacting 
proteins by immunoblotting of protein samples following streptavidin pull-down (PD: 
Strep). HEK293 cells, transiently expressing HA-tagged wild-type (WT)-ChAT-BirA* or 
P17A/P19A-ChAT-BirA*, were treated for 24 h with 50 µM of exogenous biotin. Biotin-
treated control cells were transfected with empty vector or with vectors encoding for 
untagged ChAT proteins. Biotinylated cellular proteins from whole cell lysates were 
detected with HRP-conjugated streptavidin (Strep-HRP). ChAT-BirA* fusion proteins 
were detected by anti-ChAT and anti-HA immunoblotting. Anti-actin immunoblotting 
from whole cell lysates was completed as a loading control (n=4). 
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Figure 3.24: Co-immunoprecipitation of ChAT with HSC/HSP70 and HSP90 from 
HEK293 cells. (A) Immunoblots showing co-immunoprecipitation (co-IP) of ChAT with 
endogenous HSC70, HSP70, and HSP90 following anti-ChAT co-IP from HEK293 cells 
transiently expressing either wild-type (WT) or P17A/P19A-ChAT. Control cells were 
transfected with empty pcDNA3.1+ vector. Anti-actin immunoblotting from whole cell 
lysates was completed as a loading control. Co-IP of P17A/P19A-ChAT with HSP70 (B), 
HSP90 (C), and HSC70 (D) is greater than that of wild-type ChAT (***p≤0.001, Student’s 
t-test, mean ± SEM, n=4).   
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samples, I found enhanced association of mutant P17A/P19A-ChAT with endogenous 
HSP70 (p≤0.001; Figure 3.24b), HSP90 (p≤0.001; Figure 3.24c) and HSC70 (p≤0.001; 
Figure 3.24d) relative to wild-type ChAT. 
 My initial BioID and co-IP experiments were performed in HEK293 cells as these 
cells are easily transfected to transiently express heterologous proteins. As my earlier 
experiments assessing ChAT ubiquitination and degradation were carried out with mouse 
cholinergic SN56 cells, I next confirmed my novel results by performing anti-ChAT co-IPs 
from SN56 neural cells expressing either wild-type or P17A/P19A-ChAT. Furthermore, to 
assess whether enhanced association of ChAT with HSC/HSP70 and HSP90 would also be 
seen in selected CMS-related ChAT mutant proteins, I also evaluated anti-ChAT co-IPs 
from SN56 cells expressing either V18M- or A513T-ChAT. These two catalytically-
deficient CMS-related mutations were selected as they were shown earlier in my study to 
enhance the ubiquitination and degradation of these ChAT mutant proteins [Figures 3.1, 
3.7, and 3.9]. Importantly, I detected both endogenous HSC70 and HSP90 in anti-ChAT 
co-IP samples from SN56 cells expressing either wild-type or mutant ChAT proteins 
(Figure 3.25a). Unlike HEK293 cells, I did not observe constitutive expression of HSP70 
in whole cell lysates from SN56 cells. By comparing the relative levels of ChAT proteins 
to that of endogenous HSC70 in anti-ChAT co-IP samples, I found enhanced association 
of both P17A/P19A- (p≤0.001) and V18M-ChAT (p≤0.05), but not A513T-ChAT, with 
HSC70 as compared to wild-type ChAT (Figure 3.25b). Interestingly, there were no 
significant differences in association of mutant ChAT with HSP90, but there was a trend 
towards enhanced association of HSP90 with P17A/P17A-ChAT (p=0.09; Figure 3.25c). 
Lastly, to confirm whether endogenous HSC70 and HSP90 interact with ChAT in 
situ, I performed a proximity ligation assay (PLA) in SN56 cells transiently expressing 
wild-type ChAT. As predicted, I observed in situ interaction of wild-type ChAT with 
endogenous HSC70 and HSP90 in cells (Figure 3.26). Confocal images show that the 
ChAT-HSP PLA complexes are predominantly cytoplasmic in agreement with the 
previously reported subcellular distribution of human 69-kDa ChAT [414]. As controls, 
PLA complexes were not observed in SN56 cells that were transfected with empty vector  
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Figure 3.25: Co-immunoprecipitation of ChAT with HSC70 and HSP90 from mouse 
cholinergic SN56 cells. (A) Immunoblots showing co-immunoprecipitation (co-IP) of 
ChAT with endogenous HSC70 and HSP90 following anti-ChAT co-IP from mouse 
cholinergic SN56 cells expressing wild-type (WT), P17A/P19A-ChAT, or the CMS-related 
mutants V18M- or A513T-ChAT. Control cells were transfected with empty pcDNA3.1+ 
vector. Anti-actin immunoblotting from whole cell lysates was completed as a loading 
control. (B) Co-IP of P17A/P19A-ChAT (***p≤0.001) and V18M-ChAT (*p≤0.05), but 
not A531T-ChAT, with HSC70 is greater than that of wild-type ChAT (mean ± SEM, n=5). 
(C) While there was a trend toward increased HSP90 interaction with P17A/P19A-ChAT 
(p=0.09), no significant differences were observed for HSP90 interaction with mutant 
ChAT as compared to wild-type ChAT in SN56 cells (mean ± SEM, n=5). Statistical 
analysis for (B) and (C) was performed by one-way ANOVA with Dunnett’s post-hoc test. 
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Figure 3.26: In situ interaction of ChAT with endogenous HSC70 and HSP90. 
Detection of in situ ChAT-HSP interactions with HSC70 and HSP90 by proximity ligation 
assay (PLA) in SN56 cells transiently expressing heterologous wild-type (WT) ChAT. 
Formalin-fixed cells were first co-labeling with goat anti-ChAT together with either mouse 
anti-HSC70 or mouse anti-HSP90 primary antibodies, then incubated with oligonucleotide-
linked secondary antibodies. Following DNA ligation and DNA amplification using the 
Duolink In Situ Orange Kit (Sigma), in situ ChAT-HSP interactions were imaged by 
confocal microscopy at an excitation/emission of 554/576 nm. Positive in situ ChAT-HSP 
interactions where visualized and are presented as fluorescent red dots while nuclei were 
stained with DAPI (blue). Control cells were either transfected with empty pcDNA3.1+ 
vector or had primary antibodies omitted from the assay (No 1o antibodies). Images are 
representative of 3 independent experiments; scale bars are 10 µm. 
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and incubated with primary antibodies, or when primary antibodies recognizing ChAT, 
HSC70, or HSP90 were omitted from the assay. 
 
3.9: Inhibition of HSC/HSP70-substrate protein interactions promotes 
accumulation of high molecular mass Triton-insoluble ChAT aggregates 
Functionally, HSPs aid in the stabilization of cellular proteins by interacting with exposed 
peptide sequences rich in hydrophobic amino acids, thereby preventing unintended protein 
aggregation and promoting protein folding and solubility [118, 135, 202, 503]. Therefore, 
to test whether HSC/HSP70 may regulate the folding of ChAT protein, I treated SN56 cells, 
transiently expressing wild-type or mutant ChAT, with the HSC/HSP70 inhibitor 2-
phenylethynesulfonamide (PES), a small-molecule that interferes with HSC/HSP70-
substrate interactions leading to substrate insolubilization and the subsequent accumulation 
of misfolded and aggregation-prone proteins [216-217]. Cells were treated with 20 µM PES 
for 24 h, then levels of Triton-soluble and insoluble ChAT protein were assessed by 
immunoblotting to determine levels of misfolded and/or aggregated ChAT (Figure 3.27a). 
Importantly, I found that PES treatment of cells did not alter the Triton-soluble levels of 
either wild-type or mutant ChAT proteins (Figure 3.27b), but levels of Triton-insoluble 
wild-type (p≤0.01), P17A/P19A- (p≤0.001), V18M- (p≤0.01) and A513T-ChAT proteins 
(p≤0.001) were significantly increased compared to DMSO-treated control cells (Figure 
3.27c). Moreover, immunoblots of Triton-insoluble samples from PES-treated cells 
revealed accumulation of high molecular mass ChAT-immunoreactive proteins and the 
presence of insoluble ChAT that was retained in the loading pockets of the stacking layer 
of SDS-PAGE gels (Figure 3.27a, top panel, anti-ChAT long-exposure). The accumulation 
of high molecular mass Triton-insoluble ChAT was greater for mutant ChAT than for wild-
type ChAT, with levels of Triton-insoluble P17A/P19A-ChAT having been the greatest. 
Interestingly, high molecular mass Triton-insoluble P17A/P19A-ChAT was also observed 
in DMSO-treated cells, though at a lower abundance than following PES treatment. 
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Figure 3.27: Inhibition of HSC/HSP70-substrate protein interaction promotes 
accumulation of high molecular mass Triton-insoluble ChAT aggregates. (A) Anti-
ChAT immunoblots from SN56 cells expressing wild-type (WT) or mutant ChAT that were 
treated for 24 h with either 20 μM PES, a HSC/HSP70 inhibitor, or DMSO-vehicle. Cells 
were lysed in buffer containing 0.1% Triton X-100 and fractionated into soluble and 
insoluble proteins. Triton X-100 insoluble proteins were solubilized prior to SDS-PAGE 
by denaturing in 2x Laemmli sample buffer with 5% 2-mercaptoethanol. PES treatment 
resulted in production of high molecular mass Triton-insoluble ChAT-immunoreactive 
proteins that accumulated in the loading pockets of the SDS-PAGE gels (top panel, anti-
ChAT long-exposure). The abundance of insoluble ChAT in the loading pockets appears 
to be greater for mutant ChAT as compared to wild-type ChAT, with levels of Triton-
insoluble P17A/P19A-ChAT appearing the greatest. Anti-actin immunoblotting from both 
Triton-soluble and -insoluble samples was completed as a loading control. (B) Treatment 
with 20 μM PES had no effect on the total levels of Triton-soluble ChAT protein. (C) PES 
treatment significantly increased the levels of Triton-insoluble wild-type (**p≤0.01), 
P17A/P19A- (***p≤0.001), V18M- (**p≤0.01) and A513T-ChAT (***p≤0.001) proteins 
compared to vehicle-control (two-way ANOVA with Bonferroni’s post-hoc test, mean ± 
SEM, n=6). (D) Triton-insoluble protein samples from (A) were analyzed by semi-
denaturing detergent agarose gel electrophoresis (SDD-AGE) revealing the presence of 
insoluble SDS-resistant ChAT aggregates in PES-treated cells. The abundance of these 
SDS-resistant ChAT aggregates is greater for mutant ChAT compared to wild-type ChAT, 
with P17A/P19A-ChAT being the greatest (n=6). 
 
To assess whether high molecular mass Triton-insoluble ChAT observed following 
PES treatment may consist of detergent-resistant ChAT aggregates, I performed semi-
denaturing detergent agarose gel electrophoresis (SDD-AGE) [491, 504] on Triton-
insoluble protein samples assessed in Figure 3.27a. Using anti-ChAT immunoblotting, I 
observed accumulation of high molecular mass SDS-resistant ChAT protein aggregates 
from lysates of PES-treated cells, but not generally from DMSO-treated control cells 
(Figure 3.27d). The abundance of these insoluble SDS-resistant ChAT aggregates was 
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greater for mutant ChAT as compared to wild-type ChAT, with P17A/P19A-ChAT having 
been the greatest. Moreover, insoluble SDS-resistant aggregates of P17A/P17A-ChAT 
were found in DMSO-treated cells, suggesting that this mutation may promote ChAT 
insolubility and aggregation under basal conditions.  
 
3.10: Inhibition of HSC/HSP70 or HSP90 ATPase activity reduces ChAT 
steady-state protein levels  
In addition to interaction with substrate proteins the protein-chaperoning function of 
HSC/HSP70 requires activity of its N-terminal ATPase domain, and inhibition of this 
domain by the small-molecule VER-155008 has been shown to promote the degradation of 
HSC/HSP70 clients [213-214]. Thus, to determine if HSC/HSP70 activity is required for 
ChAT protein stability, SN56 cells expressing either wild-type (Figure 3.28a), P17A/P19A- 
(Figure 3.28b), V18M- (Figure 3.28c) or A513T-ChAT (Figure 3.28d) were treated with 
varying concentrations (5-50 µM) of VER-155008 for 24 h. When analyzed by anti-ChAT 
immunoblotting, I observed dose-related reductions in the steady-state protein levels for 
both wild-type and mutant ChAT in VER-155008 treated cells. Interestingly, mutant ChAT 
appears more sensitive than wild-type ChAT to HSC/HSP70 inhibition. Specifically, a 
significant decrease in wild-type ChAT steady-state protein level was observed when cells 
were treated with at least 20 µM VER-155008 (p≤0.05; Figure 3.28e), while lower 
concentrations of VER-155008 were sufficient to significantly reduce protein levels of 
P17A/P19A- (5 µM; p≤0.001; Figure 3.28f), V18M- (5 µM; p≤0.001; Figure 3.28g), or 
A513T-ChAT (10 µM; p≤0.001; Figure 3.28h), as compared to DMSO-treated control 
cells. Furthermore, treatment of ChAT-expressing cells with 50 µM VER-155008 reduced 
ChAT steady-state proteins levels, compared to DMSO-treated control cells, as follows: 
wild-type ChAT (38.6 ± 4.97%), P17A/P19A-ChAT (61.0 ± 4.17%), V18M-ChAT (75.7 
± 2.82%) and A513T-ChAT (53.6 ± 2.69%).  
Like HSC/HSP70, HSP90 has an N-terminal ATP-binding domain with ATPase 
activity that is required for HSP90 chaperoning function, and pharmacological inhibition 
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Figure 3.28: Inhibition of HSC/HSP70 ATPase activity reduces ChAT steady-state 
protein levels in a dose-related manner. Anti-ChAT immunoblots from SN56 cells 
expressing wild-type (WT; A), P17A/P19A- (B), V18M- (C) or A513T-ChAT (D) that 
were treated for 24 h with 5-50 µM VER-155008, an inhibitor of HSC/HSP70 activity. 
Control cells were treated with DMSO-vehicle. Anti-actin immunoblotting was completed 
as a loading control. Steady-state protein levels of wild-type (E), P17A/P19A- (F), V18M- 
(G) and A513T-ChAT (H) are reduced following treatment with VER-155008 as compared 
to DMSO-control (**p≤0.01, ***p≤0.001, one-way ANOVA with Dunnett’s post-hoc test, 
mean ± SEM, n=4). Mutant ChAT appears more sensitive to HSC/HSP70 inhibition where 
treatment with 50 µM VER-155008 reduced ChAT steady-state proteins levels, compared 
to vehicle-control, as follows; wild-type ChAT (38.63% ± 4.97), P17A/P19A-ChAT 
(61.04% ± 4.17), V18M-ChAT (75.71% ± 2.82), and A513T-ChAT (53.60% ± 2.69). 
 
of this domain by the small molecule 17-allylamino-17-demethoxygeldanamycin (17-
AAG) has been shown to promote proteasomal degradation of HSP90 clients [286-287]. 
Therefore, to determine whether HSP90 activity may also promote ChAT protein 
stabilization, I treated ChAT-expressing SN56 cells with 0.5-2 µM 17-AAG for 24 h 
(Figure 3.29). Analysis by anti-ChAT immunoblotting showed that treatment of cells with 
concentrations of 17-AAG up to 2 µM had no effect on the steady-state levels of wild-type 
ChAT protein (Figures 3.29a and 3.29e). Importantly though, treatment with 0.5-2 µM 17-
AAG did significantly reduce the steady-state levels of mutant P17A/P19A- (p≤0.001; 
Figures 3.29b and 3.29f), V18M- (p≤0.001; Figures 3.29c and 3.29g), and A513T-ChAT 
proteins (p≤0.001; Figures 3.29d and 3.29h) as compared to DMSO-treated control cells. 
Overall, these data using the HSP inhibitors VER-155008 and 17-AAG suggest that 
while the ATPase activity of HSC/HSP70 is necessary for both wild-type and mutant ChAT 
protein stability, the ATPase activity of HSP90 may be uniquely critical for stabilization of 
mutant ChAT, but not of wild-type ChAT protein. Interestingly, previous studies have 
shown that treatment of cells with 17-AAG can lead to the expression of stress-inducible 
HSP70 [287, 505-506]. Therefore, to assess whether 17-AAG-induced HSP70 may have a  
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Figure 3.29: Inhibition of HSP90 by 17-AAG specifically reduces steady-state protein 
levels of mutant ChAT. Anti-ChAT immunoblots from SN56 cells expressing wild-type 
(WT; A), P17A/P19A- (B), V18M- (C), or A513T-ChAT (D) that were treated for 24 h 
with 0.5-2 µM with 17-AAG, an inhibitor of HSP90 activity. Control cells were treated 
with DMSO-vehicle. Anti-GAPDH immunoblotting was completed as a loading control.  
(E) Treatment of cells with 17-AAG at concentrations up to 2 µM has no effect on the 
steady-state levels of wild-type ChAT protein. By comparison, steady-state protein levels 
of P17A/P19A- (F), V18M- (G), and A513T-ChAT (H) are reduced following treatment 
of cells with 17-AAG as compared to DMSO-control (***p≤0.001, one-way ANOVA with 
Dunnett’s post-hoc test, mean ± SEM, n=4). 
 
protective role towards ChAT protein stability during HSP90 inhibition I performed 
siRNA-mediated knock-down of HSP70 in SN56 cells, transiently expressing wild-type or 
mutant ChAT, that were treated with 1 µM 17-AAG for 24 h (Figure 3.30). In support of 
Figure 3.29, treatment with 17-AAG once again reduced the proteins levels of mutant 
P17A/P19A-, V18M-, and A513T-ChAT but had no effect on the steady-state protein levels 
of wild-type ChAT as compared to DMSO-treated control cells. While I found that 17-
AAG treatment did induce HSP70 protein expression in SN56 cells, siRNA knock-down 
of HSP70 had no additional effect on the loss of steady-state protein levels of mutant ChAT 
following 17-AAG treatment and, furthermore, failed to sensitize wild-type ChAT to 17-
AAG-induced loss of ChAT protein.   
 
3.11: Proteasome inhibition prevents loss of ChAT protein following 
HSC/HSP70 and HSP90 inhibition 
My earlier results suggest that ChAT protein degradation is regulated by the proteasome 
(Figures 3.6, 3.7, 3.15). Therefore, to test whether the loss of ChAT protein following 
inhibition of either HSC/HSP70 or HSP90 was due to proteasome-dependent degradation 
of ChAT, I co-treated ChAT-expressing SN56 cells with either VER-155008 or 17-AAG  
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Figure 3.30: siRNA-mediated knock-down of HSP70 fails to sensitize wild-type ChAT 
to 17-AAG-induced loss of ChAT protein. Anti-ChAT immunoblots from SN56 cells 
transiently expressing either wild-type (WT) or mutant ChAT that were co-transfected with 
25 nM of either anti-HSP70 siRNA or scramble-control siRNA for 72 h. In addition, cells 
were treated for the final 24 h of siRNA incubation with either 1 µM 17-AAG or with 
DMSO-vehicle control. 17-AAG-induced expression of and subsequent siRNA knock-
down of HSP70 was assessed by anti-HSP70 immunoblotting. Anti-actin immunoblotting 
was completed as a loading control (n=3). 
 
along with the proteasome inhibitor MG132. Importantly, I observed that treatment of cells 
expressing either wild-type and mutant ChAT with 40 µM VER-155008 for 24 h reduced 
ChAT steady-state protein levels, and that co-treatment of cells with 5 µM MG132 for 18 
h attenuated this effect (Figure 3.31a). In addition, treatment of ChAT-expressing cells with 
1 µM 17-AAG alone for 24 h reduced the steady-state protein levels of mutant ChAT only,  
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Figure 3.31: Proteasome inhibition by MG132 treatment prevents loss of ChAT 
protein following inhibition of HSC/HSP70 or HSP90 activity. Anti-ChAT 
immunoblots from SN56 cells transiently expressing wild-type (WT) or mutant ChAT that 
were co-treated with either 40 µM VER-155008 (A) or 1 µM 17-AAG (B) for 24 h and 
with 5 µM MG132 for the final 18 h of HSP inhibition (n=4). Lysosomal inhibition by co-
treatment of ChAT-expressing cells with 50 µM chloroquine (CQ) for 18 h did not prevent 
the effects of 24 h treatment with either VER-155008 (C) or 17-AAG (D) on ChAT steady-
state protein levels (n=3). Control cells were treated with DMSO-vehicle or alone with 
either VER-155008 or 17-AAG. Proteasome inhibition by MG132 treatment or lysosome 
inhibition by CQ treatment was validated by immunoblotting for the accumulation of either 
ubiquitinated cellular proteins or for the lysosome-associated protein LC3B-II, 
respectively. Anti-actin immunoblotting was completed as a loading control. 
111 
 
while co-treatment with 5 µM MG132 for 18 h also prevented this effect (Figure 3.31b). 
As anticipated, and in support of my earlier findings, co-treatment of ChAT-expressing 
SN56 cells for 18 h with 50 µM chloroquine to inhibit lysosomal proteolysis did not prevent 
the effects of either 40 µM VER-155008 (Figure 3.31c) or 1 µM 17-AAG (Figure 3.31d) 
on the steady-state levels of either wild-type or mutant ChAT protein.  
 
3.12: Inhibition of HSC/HSP70 and HSP90 activity enhances ChAT 
ubiquitination and reduces ChAT enzymatic activity  
In addition to protein folding, HSPs perform essential protein quality control functions by 
triaging stress-damaged or terminally misfolded proteins for degradation through the 
ubiquitin-proteasome system [118, 135]. Therefore, to determine if inhibition of either 
HSC/HSP70 or HSP90 may promote degradation of ChAT through enhanced ChAT 
ubiquitination, I treated ChAT-expressing SN56 cells with either 40 µM VER-155008 for 
24 h or 1 µM 17-AAG for either 8 or 24 h, along with 20 µM MG132 during the final 6 h 
of HSP inhibition to prevent the degradation of ubiquitinated ChAT. By anti-ubiquitin 
immunoblotting from anti-ChAT IPs, I observed that treatment of cells with VER-155008 
resulted in enhanced ubiquitination of both wild-type and mutant ChAT as compared to 
DMSO-treated control cells (Figure 3.32a). Furthermore, ubiquitination of mutant ChAT, 
in particular P17A/P19A-ChAT, was greater than that of wild-type ChAT following VER-
155008 treatment when compared to DMSO-treated control cells. Surprisingly, while 
treatment of cells with 17-AAG for 24 h had no effect on the ubiquitination of either wild-
type or mutant ChAT proteins, treatment for 8 h did enhance ChAT ubiquitination, with 
this effect being greater for mutant than for wild-type ChAT, particularly for P17A/P19A-
ChAT, when compared to DMSO-control (Figure 3.32b). 
Canonically, ubiquitination targets proteins for proteasomal and/or lysosomal 
degradation, but it can also regulate subcellular trafficking, receptor endocytosis, and 
enzymatic activity of various proteins [44]. Therefore, to determine if HSP inhibition may 
also affect ChAT enzymatic activity, I treated SN56 cells transiently expressing  
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Figure 3.32: Inhibition of HSC/HSP70 and HSP90 activity enhances ChAT 
ubiquitination. (A) Representative anti-ChAT and anti-ubiquitin immunoblots from SN56 
cells expressing wild-type (WT) or mutant ChAT that were treated for 24 h with 40 μM 
VER-155008. To inhibit degradation of ubiquitinated ChAT cells were co-treated for the 
final 6 h of VER-155008 treatment with 20 μM MG132. ChAT ubiquitination was then 
assessed by anti-ubiquitin immunoblotting following anti-ChAT immunoprecipitation (IP). 
Inhibition of HSC/HSP70 by VER-155008 treatment enhanced ChAT ubiquitination, 
where levels of ubiquitinated mutant ChAT, particularly P17A/P19A-ChAT, are greater 
than that of wild-type ChAT. Control cells were transfected with empty pcDNA3.1+ vector 
and/or were treated with DMSO-vehicle. Proteasome inhibition by MG132 treatment was 
validated by immunoblotting from whole cell lysates for the accumulation of ubiquitinated 
cellular proteins. Anti-actin immunoblotting from whole cell lysates was completed as a 
loading control (n=3). (B) Immunoblots following anti-ChAT IP from ChAT-expressing 
SN56 cells that were co-treated for either 8 or 24 h with 1 μM 17-AAG and for the final 6 
h with 20 μM MG132. Inhibition of HSP90 by treatment with 1 μM 17-AAG for 8 h, but 
not for 24 h, enhanced ubiquitination of wild-type and mutant ChAT; the ubiquitination of 
ChAT appears to be greater for mutant ChAT than for wild-type ChAT following 17-AAG 
treatment, with levels of ubiquitinated P17A/P19A-ChAT being the greatest (n=3). 
 
heterologous wild-type ChAT with either 40 µM VER-155008 or 1 µM 17-AAG alone or 
in combination for 24 h, then analyzed cellular ChAT activity by radioenzymatic assay. 
Interestingly, I found that the cellular activity of wild-type ChAT is reduced following 24 
h treatment of cells with either 40 μM VER-155008, 1 µM 17-AAG, or a combination of 
the two as compared to DMSO-treated control cells (p≤0.01; Figure 3.33). While treatment 
with VER-155008 alone trended towards a greater reduction in cellular ChAT activity 
when compared to 17-AAG alone (p=0.058), co-treatment of cells with VER-155008 and 
17-AAG did lead to a greater reduction in wild-type ChAT activity as compared to 17-
AAG alone (p≤0.01). Importantly, these data show that while inhibition of HSP90 by 17-
AAG treatment had no effect on the steady-state protein levels of wild-type ChAT (Figures  
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Figure 3.33: Inhibition of HSC/HSP70 and HSP90 activity reduces cellular enzymatic 
activity of wild-type ChAT. Cellular enzymatic activity of heterologously-expressed wild-
type ChAT is reduced following treatment of SN56 cells for 24 h with either 40 μM VER-
155008 or 1 µM 17-AAG alone or a combination of the two as compared to DMSO-control 
treated cells (**p≤0.01). While treatment with VER-155008 trended towards a greater 
reduction in cellular ChAT activity compared to 17-AAG (p=0.058), co-treatment with 
these inhibitors did result in a greater reduction in ChAT activity as compared to 17-AAG 
alone (**p≤0.01, one-way ANOVA with Tukey’s post-hoc test, mean ± SEM, n=3). 
 
3.29 and 3.31), this treatment did significantly reduce the cellular enzymatic activity of 
wild-type ChAT like that observed with HSC/HSP70 inhibition by VER-155008 treatment, 
suggesting that the folding activity of both HSC/HSP70 and HSP90 are necessary in order 
to generate fully-functional and active ChAT enzyme.  
115 
 
3.13: ChAT interacts with the HSP-associated E3 ubiquitin ligase CHIP  
The E3 ubiquitin ligase CHIP/Stub1 ubiquitinates proteins in an HSP-dependent manner 
through direct interaction with either HSC/HSP70 or HSP90 and their bound substrate 
proteins [76-78]. My results demonstrating enhanced ubiquitination and proteasomal 
degradation of ChAT protein following HSC/HSP70 and HSP90 inhibition suggest that 
ubiquitination of ChAT may be regulated by CHIP. Therefore, to first determine if ChAT 
may interact with CHIP, I performed anti-ChAT co-IPs from SN56 cells co-expressing 
either wild-type or mutant ChAT with FLAG-tagged CHIP (Figure 3.34a). As anticipated, 
FLAG-CHIP was detected in anti-ChAT co-IP samples from both wild-type and mutant 
ChAT-expressing cells by anti-FLAG immunoblotting. By comparing the levels of 
immunoprecipitated FLAG-CHIP to that of ChAT protein, I observed enhanced co-IP of 
FLAG-CHIP with mutant P17A/P19A- (p≤0.001), V18M- (p≤0.001) and A513T-ChAT 
(p≤0.05) as compared to wild-type ChAT (Figure 3.34b). Subsequently, association of 
wild-type and mutant ChAT with endogenous CHIP was confirmed by anti-ChAT co-IP 
from ChAT-expressing SN56 cells with follow-up anti-CHIP immunoblotting (Figure 
3.34c). Lastly, to assess whether ChAT can interact with CHIP in situ I also performed 
PLA assays to visualize and confirm, by confocal microscopy, the presence of in situ 
interactions between wild-type ChAT and endogenous CHIP in SN56 cells (Figure 3.35). 
As predicted, I observed predominantly cytoplasmic in situ interaction of wild-type ChAT 
with endogenous CHIP in cells. As controls, I did not observe in situ interactions in control 
cells that were either transfected with either empty vector or when primary antibodies 
towards ChAT and CHIP were omitted from the assay.  
 
3.14: CHIP co-expression promotes proteasomal degradation and 
insolubilization of ChAT 
Interaction of ChAT with CHIP may promote the ubiquitination and proteasome-dependent 
degradation of ChAT. Therefore, to determine if ChAT is a substrate for CHIP, I first tested 
if co-expression of FLAG-CHIP promotes loss of ChAT protein in SN56 cells transiently 
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Figure 3.34: Co-immunoprecipitation of ChAT with HSP-associated E3 ubiquitin 
ligase C-terminus of HSC70-interaction protein (CHIP). (A) Immunoblots showing co-
immunoprecipitation (co-IP) of ChAT with FLAG-CHIP from SN56 cells co-expressing 
either wild-type (WT) or mutant ChAT with FLAG-tagged CHIP. Control cells were 
transfected with empty pcDNA3.1+ vector or to express FLAG-CHIP alone. Anti-FLAG 
and anti-actin immunoblotting from whole cell lysates was completed as loading controls. 
(B) Co-IP of ChAT with FLAG-CHIP is enhanced for P17A/P19A- (***p≤0.001), V18M- 
(***p≤0.001), and A513T-ChAT (*p≤0.05) as compared to wild-type ChAT (one-way 
ANOVA with Dunnett’s post-hoc test, mean ± SEM, n=5). (C) Co-IP of heterologously-
expressed wild-type and mutant ChAT with endogenous CHIP following anti-ChAT co-IP 
from SN56 cells. Control cells were transfected with empty vector (n=3). 
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Figure 3.35: In situ interaction of ChAT with endogenous CHIP. Detection of in situ 
ChAT-CHIP interactions by proximity ligation assay (PLA) in SN56 cells transiently 
expressing heterologous wild-type ChAT. Formalin-fixed cells were first co-labeling with 
goat anti-ChAT together with rabbit anti-CHIP primary antibodies, then incubated with 
oligonucleotide-linked secondary antibodies. Following DNA ligation and DNA 
amplification using the Duolink In Situ Orange Kit (Sigma), in situ ChAT-CHIP 
interactions were imaged by confocal microscopy at an excitation/emission of 554/576 nm. 
Positive in situ ChAT-CHIP interactions were visualized and presented as fluorescent red 
dots while nuclei were stained with DAPI (blue). Control cells were either transfected with 
empty pcDNA3.1+ vector or primary antibodies omitted from the assay (No 1°). Images 
are representative of 4 independent experiments; scale bars are 10 µm. 
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expressing wild-type or mutant ChAT. By anti-ChAT immunoblotting (Figure 3.36a) I 
observed that co-expression of FLAG-CHIP significantly reduced the steady-state protein 
levels of wild-type (p≤0.001), P17A/P19A- (p≤0.05), V18M- (p≤0.001), and A513T-ChAT 
(p≤0.001) as compared to cells co-transfected with equal amounts (µg) of empty vector 
(Figure 3.36b). To assess whether the effects of FLAG-CHIP co-expression on reduced 
ChAT protein levels were proteasome dependent, SN56 cells, transiently co-expressing 
wild-type ChAT with FLAG-CHIP, were treated for 18 h with either 5 µM MG132 or 50 
µM chloroquine alone or with these two inhibitors together in combination. Following anti-
ChAT immunoblotting I found that proteasome inhibition by treatment with either MG132 
alone or together with chloroquine partially ameliorated the FLAG-CHIP-induced loss of 
wild-type ChAT protein (Figure 3.36c). As anticipated, treatment with chloroquine alone 
failed to prevent the loss of wild-type ChAT protein in cells co-expressing FLAG-CHIP.  
CHIP has two distinct functional protein domains, a C-terminal U-box domain that 
contains E3 ubiquitin ligase activity and three N-terminal TPR domains that allow for and 
facilitate interaction of CHIP with HSPs and their substrates (Figure 3.37a) [73, 76, 276, 
315]. To determine if the E3 ligase activity of CHIP is required to promote CHIP-associated 
loss of ChAT protein, and furthermore whether the TPR domains of CHIP are required for 
ChAT-CHIP interaction, SN56 cells were transiently transfected to co-express wild-type 
ChAT with either full-length wild-type FLAG-CHIP or mutant FLAG-CHIP missing either 
the N-terminal TPR domains (ΔTPR) or the C-terminal U-box domain (ΔU-box). Cells 
were collected, lysed in buffer containing 0.5% Triton X-100, and lysates were used for 
completion of both anti-ChAT co-IPs and for the immunoblot assessment of Triton-soluble 
and -insoluble ChAT proteins (Figure 3.37b). By anti-FLAG immunoblotting from anti-
ChAT co-IP samples I observed that wild-type ChAT can co-IP with both full-length 
FLAG-CHIP or FLAG-CHIP-ΔU-box but was unable to co-IP with FLAG-CHIP-ΔTPR. 
Surprisingly, co-expression of either full-length FLAG-CHIP or FLAG-CHIP-ΔU-box 
reduced the Triton-soluble levels of ChAT protein and led to a reciprocal increase in the 
Triton-insoluble levels of ChAT. These effects on ChAT solubility were not observed when 
ChAT was co-expressed with FLAG-CHIP-ΔTPR, suggesting that the TRP 
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Figure 3.36: CHIP co-expression promotes proteasomal degradation of ChAT. (A) 
Anti-ChAT immunoblots from SN56 cells co-expressing wild-type (WT) or mutant ChAT 
with FLAG-tagged CHIP. Anti-FLAG and anti-actin immunoblotting was completed as 
loading controls. (B) The steady-state proteins levels of wild-type (***p≤0.001), 
P17A/P19A- (*p≤0.05), V18M- (***p≤0.001), and A513T-ChAT (*p≤0.05) are reduced 
following co-expression of FLAG-CHIP as compared to control cells co-transfected with 
empty pcDNA 3.1+ vector (two-way ANOVA with Bonferroni’s post-hoc test, mean ± 
SEM, n=4). (C) Proteasome inhibition partially attenuates loss of ChAT protein following 
co-expression of FLAG-CHIP. Immunoblots from SN56 cells co-expressing wild-type 
ChAT with FLAG-tagged CHIP that were treated with either 5 µM MG132 or 50 µM 
chloroquine (CQ) alone or in combination for 18 h. Control cells were treated with DMSO-
vehicle and/or transfected with either empty pcDNA 3.1+ vector or to express wild-type 
ChAT alone. Proteasome inhibition by MG132 treatment was validated by immunoblotting 
for the accumulation of ubiquitinated cellular proteins (n=6). 
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Figure 3.37: The TPR domains of CHIP are critical for ChAT-CHIP protein 
interaction and promote CHIP-mediated ChAT insolubilization. (A) Schematic 
overview of the functional protein domains of the E3 ubiquitin ligase CHIP/Stub1. CHIP 
contains three N-terminal tetracopeptide repeat (TPR) domains that facilitate interaction of 
CHIP with HSPs and their substrates. Additionally, a C-terminal U-box domain imparts E3 
ligase activity to CHIP. (B) The TPR domains, but not the U-box domain, of CHIP are 
necessary for ChAT-CHIP protein interaction. Additionally, co-expression of either full-
length FLAG-CHIP or FLAG-CHIP-ΔU-box increased Triton-insoluble levels of wild-type 
(WT) ChAT protein while ChAT co-expression with FLAG-CHIP-ΔTPR had no effect on 
ChAT solubility. Shown are representative anti-ChAT and anti-FLAG immunoblots 
following anti-ChAT co-immunoprecipitation (co-IP) from SN56 cells transiently co-
expressing wild-type ChAT with either full-length FLAG-tagged CHIP or with mutant 
FLAG-CHIP missing either its TPR domains (ΔTPR) or U-box domain (ΔU-box). Control 
cells were transfected with empty pcDNA3.1+ vector or to express either wild-type ChAT 
or full-length FLAG-CHIP alone. Cells were lysed in 0.5% Triton X-100, fractionated into 
Triton-soluble and -insoluble fractions, and anti-ChAT co-IPs were completed from the 
soluble fractions. Triton X-100 insoluble proteins were solubilized prior to SDS-PAGE by 
denaturing in 2x Laemmli sample buffer. Anti-actin immunoblotting from Triton-soluble 
and -insoluble proteins samples was completed as loading controls (n=5). 
 
domains of CHIP are critical for not only ChAT-CHIP association, but also for the effects 
of CHIP co-expression on ChAT protein solubility and degradation.   
These initial studies investigating the role of CHIP on the regulation of ChAT 
protein degradation and stability were completed in cells co-expressing ChAT with 
heterologous FLAG-tagged CHIP. Though I was able to show that ChAT can co-IP and 
interact in situ with endogenous CHIP (Figures 3.34c and 3.35), it is unknown whether 
ChAT may be a substrate for degradation by endogenous CHIP. Thus, to determine if 
endogenous CHIP regulates ChAT protein stability I monitored ChAT steady-state protein 
levels from SN56 cells, transiently expressing wild-type or mutant ChAT, that were co-
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transfected with siRNA targeting endogenous mouse CHIP (Figure 3.38). Surprisingly, as 
assessed by anti-ChAT and anti-CHIP immunoblotting, while I was able to achieve a 
greater-than 95% CHIP knock-down in cells, siRNA-mediated knock-down of endogenous 
CHIP had no effect on the steady-state levels of either wild-type or mutant ChAT protein. 
 
3.15: Oxidative stress by exposure of cells to H2O2 enhances ChAT 
ubiquitination  
In summary of my results investigating the regulation of ChAT by HSPs, I have shown that 
ChAT interacts with and is a substrate for HSC/HSP70 and HSP90, where inhibition of 
HSC/HSP70 protein interactions results in accumulation of insoluble ChAT protein, and 
inhibition of HSC/HSP70 and HSP90 activity led to reduced cellular ChAT activity, along 
with enhanced ChAT ubiquitination and proteasome-dependent loss of ChAT protein. 
Furthermore, the effects of HSP inhibition appear greater for mutant ChAT (P17A/P19A-, 
V18M-, and A513T-ChAT) than for wild-type ChAT (Figure 3.39).  
HSPs, such as HSC/HSP70 and HSP90, have been best characterized for their role 
in promoting the folding and stabilization of nascent proteins, as well as in refolding of 
misfolding-prone and aggregated proteins during proteotoxic stress such as hyperthermia 
[118, 135, 154, 371]. Oxidation of cellular proteins and subsequent formation of aberrant 
stress-induced disulfide bonds during oxidative stress can induce protein misfolding with 
severe functional consequences [361, 364-365]. Interestingly, ChAT has a higher-than-
average cysteine content of 3.2% compared to 1.6% for intracellular mammalian proteins 
[367] which, like the cysteine-rich E3 ubiquitin ligase Parkin, may sensitize ChAT to 
oxidative damage [370]. Importantly, work performed in our laboratory by Shawn Albers, 
M.Sc., has demonstrated that treatment of ChAT-expressing SN56 cells with 50 µM – 2 
mM of H2O2, a potent inducer of cellular oxidative stress, results in the dose- and redox-
dependent accumulation of higher molecular mass wild-type ChAT proteins that can be 
observed by anti-ChAT immunoblotting specifically in non-reducing conditions (Figure 
3.40a). Additionally, Shawn Albers has shown that treatment of ChAT-expressing SN56 
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Figure 3.38: siRNA knock-down of endogenous CHIP has no effect on the steady-state 
protein levels of wild-type or mutant ChAT. Anti-ChAT immunoblots from ChAT-
expressing SN56 cells that were transfected with 25 nM of either anti-CHIP siRNA or 
scramble-control siRNA for 72 h. Cells were co-transfected to express wild-type (WT) or 
mutant ChAT for the final 48 h of siRNA incubation. Control cells were mock-transfected 
with siLentFect transfection reagent. Knock-down of CHIP was assessed by anti-CHIP 
immunoblotting. Anti-actin immunoblotting was completed as a loading control (n=4). 
 
cells for up-to 4 h with 1 mM H2O2 reduced the cellular activity of wild-type ChAT when 
compared to vehicle-treated control cells (p<0.001; Figure 3.40b) [507]. Lastly, Nunes-
Tavares and colleagues [439] have demonstrated that cellular ChAT activity is reduced 
following exposure of neural cells to Aβ oligomers, a hallmark of AD and stimulator of 
cellular oxidative stress [429, 508-509].  
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Figure 3.39: Model for the regulation of ChAT protein stability by the heat-shock 
family of molecular chaperones. Under physiological conditions ChAT protein folding is 
promoted by the molecular chaperoning-function of the heat shock proteins HSC/HSP70 
and HSP90, resulting in stable and active ChAT enzyme. Though, if ChAT protein folding 
becomes compromised, potentially in case of ChAT mutations (e.g. P17A/P19A, V18M, 
and A513T) or following HSP inhibition (e.g. PES, VER-155008, and 17-AAG), misfolded 
and/or insoluble ChAT is targeted for proteasomal degradation via enhanced ubiquitination 
by a yet-to-be identified chaperone-associated E3 ubiquitin ligase. It is currently unknown 
whether cellular stresses, such as oxidative stress, can induce ChAT dysfunction through 
enhanced misfolding and subsequent degradation of ChAT, and/or if HSPs may assist in 
the stabilization of ChAT protein during cellular stress. 
 
The aforementioned studies suggest that ChAT protein function, and potentially 
protein stability, may be altered during cellular exposure to oxidative stress. Additional 
studies have demonstrated that the ubiquitination, and subsequent proteasomal degradation, 
of various cellular proteins is altered during oxidative stress [510-512]. Importantly, as 
presented earlier in this thesis, I have demonstrated that ChAT protein stability is regulated 
by the ubiquitin-proteasome system, though it is unknown whether ChAT ubiquitination is 
altered during oxidative stress. Therefore, ChAT ubiquitination was monitored in SN56 
cells, transiently co-expressing wild-type ChAT with HA-tagged ubiquitin, that were  
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Figure 3.40: H2O2 treatment promotes the generation of redox-dependent higher 
molecular mass ChAT proteins and decreases cellular ChAT activity. (A) Anti-Myc 
immunoblots from SN56 cells, transiently expressing Myc-tagged 69-kDa wild-type 
ChAT, that were treated for 1 hour with 1 mM H2O2. Control cells were transfected with 
empty pcDNA3.1+ vector or were treated with vehicle-control (0 µM; water). Treatment 
of ChAT-expressing cells with H2O2 generated higher molecular mass ChAT proteins that 
were observed on anti-Myc immunoblots only under non-reducing conditions. Anti-actin 
immunoblotting was completed as a loading control (n=3). (B) Cellular ChAT activity is 
reduced in SN56 cells following treatment with 1 mM H2O2 for 240 min as compared to 
vehicle-treated cells (***p≤0.001, one-way ANOVA with Dunnett’s post-hoc test, mean ± 
SEM, n=4). Experiments were completed previously by Shawn Albers, M.Sc. [507]. 
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treated for 30 – 60 min with 1 mM H2O2 to induce cellular oxidative stress. To prevent 
degradation of ubiquitinated ChAT cells were co-treated for 18 h with 5 µM MG132 prior-
to and during treatment with H2O2. Following anti-HA IP and anti-ChAT immunoblotting 
I observed that ChAT ubiquitination is enhanced following treatment of cells with 1 mM 
H2O2 for either 30 or 60 min as compared to DMSO-treated control cells (Figure 3.41). No 
differences in the abundance of ubiquitinated ChAT were detected when comparing the 30 
min H2O2-treated cells to the 60 min-treated cells.  
 
3.16: Oxidative stress by H2O2 treatment promotes the insolubilization of 
ChAT protein 
These preliminary ubiquitination experiments following H2O2 treatment suggest that ChAT 
protein stability may be negatively affected by oxidative damage. Furthermore, work by 
Shawn Albers showing the appearance of higher molecular mass ChAT proteins under non-
reducing conditions following H2O2 exposure suggests that ChAT may be susceptible to 
oxidative misfolding that is dependent on cysteine oxidation and formation of aberrant 
disulfide bonds. Therefore, to first assess whether ChAT solubility, and potentially ChAT 
protein folding, is altered during oxidative stress I treated SN56 cells transiently expressing 
wild-type ChAT with varying concentrations of H2O2 for either 24 h (100 nM – 200 µM) 
or for 1 h (1 µM – 2 mM). Cells were lysed with buffer containing 0.1% Triton X-100 and 
Triton-soluble and -insoluble ChAT proteins were fractionated. Following anti-ChAT 
immunoblotting I observed that treatment of ChAT-expressing cells for 24 h with 100 nM 
– 200 µM H2O2 had no significant effect on the overall solubility of ChAT protein (Figure 
3.42a). Interestingly, though no changes in Triton-soluble levels of ChAT were detected, 
enhanced levels of Triton-insoluble ChAT were observed following 1 h treatment of cells 
specifically with 0.5-2 mM H2O2 compared to vehicle-treated control cells (Figure 3.42b).  
HSPs, such as HSC/HSP70 and HSP90, have been shown to bind to and chaperone 
oxidized proteins to maintain and/or restore protein function during oxidative conditions 
[371]. My earlier studies using the HSC/HSP70 inhibitor PES suggest that the folding and 
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Figure 3.41: Oxidative stress by H2O2 treatment enhances ChAT ubiquitination. 
Representative anti-ChAT and anti-HA immunoblots from SN56 cells transiently co-
expressing wild-type ChAT with HA-tagged ubiquitin (HA-Ub) that were treated with 1 
mM H2O2 for either 30 or 60 min. Levels of ubiquitinated ChAT protein were assessed by 
anti-ChAT immunoblotting from anti-HA IP samples. Cells were treated with 5 µM 
MG132 for 18 h prior-to and during H2O2 treatment to prevent proteasomal degradation of 
ubiquitinated proteins. Control cells were either transfected with empty pcDNA3.1+ vector 
or to express wild-type ChAT or HA-Ub alone, or were treated with vehicle-control (water). 
Proteasome inhibition by MG132 treatment was validated by anti-HA immunoblotting 
from whole cell lysates for the accumulation of ubiquitinated cellular proteins. Anti-actin 
immunoblotting from whole cell lysates was completed as a loading control (n=3). 
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Figure 3.42: Oxidative stress by H2O2 treatment promotes ChAT insolubilization. 
Anti-ChAT immunoblots from SN56 cells transiently expressing wild-type ChAT that were 
treated with either 0.1 – 200 µM H2O2 for 24 h (A) or with 1 µM – 2 mM H2O2 for 1h (B). 
Control cells were treated with water-vehicle. Cells were lysed in 0.1% Triton X-100 and 
Triton-soluble and -insoluble proteins were fractionated. Triton X-100 insoluble proteins 
were solubilized prior to SDS-PAGE by denaturing in 2x Laemmli sample buffer with 5% 
2-mercaptoethanol. No differences in ChAT protein solubility was detected following 24 h 
of 0.1 – 200 µM H2O2 treatment (A; n=3). While no changes in the Triton-soluble levels of 
ChAT were detected following 1h H2O2 treatment, levels of Triton-insoluble ChAT protein 
were increased in cells specifically treated for 1 h with 0.5 – 2 mM H2O2 (B; n=3). Anti-
actin immunoblotting was completed as loading controls. 
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solubility of ChAT protein may be promoted by interaction of ChAT with HSC/HSP70 
(Figure 3.27). Therefore, to determine whether HSC/HSP70 may play a protective role 
during acute oxidative stress by preventing oxidative insolubilization of ChAT, I co-treated 
wild-type ChAT-expressing SN56 cells with 1-8 h of 100 µM H2O2 that had been pre-
treated for 24 h with 20 µM PES. Following anti-ChAT immunoblotting, I again observed 
that treatment of cells with 20 µM PES increased the levels of higher molecular mass 
Triton-insoluble ChAT protein as compared to DMSO-treated control cells (Figure 3.43). 
Furthermore, PES treatment again led to the accumulation of Triton-insoluble ChAT 
aggregates retained in the loading pockets of the stacking layer of SDS-PAGE gels. 
Importantly, I observed that pre-treatment of cells with 20 µM PES sensitized ChAT to 
H2O2-induced insolubilization such that treatment of ChAT-expressing cells for 4 or 6 h 
with 100 µM H2O2 resulted in an enhanced accumulation of higher molecular mass Triton-
insoluble ChAT proteins as compared to PES or H2O2 treatment alone. Lastly, greater levels 
of Triton-insoluble ChAT aggregates were observed in the loading pockets of SDS-PAGE 
gels when cells treated with H2O2 for 4 or 6 h were first pre-treated with 20 µM PES.  
 
3.17: Co-immunoprecipitation of ChAT with HSC70 is altered following 
exposure of cells to H2O2 
Protein misfolding stresses, such as oxidative stress, can promote the formation of aberrant 
disulfide-bonds and exposure of hydrophobic regions within various cellular proteins, 
increasing the affinity of HSPs for these misfolded proteins [246, 365, 371]. My ChAT 
solubility experiments with H2O2 and PES treatment suggest that ChAT protein folding 
may be negatively impacted following exposure to acute elevated levels of oxidative stress 
(i.e. 1 mM H2O2), though under more moderate oxidative conditions (i.e. 100 µM H2O2) 
that interaction of ChAT with HSC/HSP70 may protect ChAT from oxidative misfolding. 
Therefore, I next assessed by co-IP assay whether interaction of ChAT with either HSC70 
or HSP90 is enhanced in ChAT-expressing SN56 cells treated for 1 - 8 h with 100 µM 
H2O2 or for 1 h with 1 mM H2O2. Following anti-HSC70 and anti-HSP90 immunoblotting 
from anti-ChAT co-IP samples, I observed that co-IP of wild-type ChAT with endogenous 
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Figure 3.43: HSC/HSP70 inhibition by PES treatment sensitizes ChAT to H2O2-
induced insolubilization. Anti-ChAT immunoblots from SN56 cells transiently 
expressing wild-type ChAT that were pre-treated for 24 h with 20 µM PES then co-treated 
for an additional 1-8 h with 100 µM H2O2. Control cells were treated with DMSO- or water-
vehicle (Veh) for PES or H2O2 treatment respectively. Cells were lysed in 0.1% Triton X-
100 and Triton-soluble and -insoluble proteins were fractionated. Triton X-100 insoluble 
proteins were solubilized prior to SDS-PAGE by denaturing in 2x Laemmli sample buffer 
with 5% 2-mercaptoethanol. Co-treatment of cells with PES and H2O2 had no effect on the 
total levels of Triton-soluble ChAT protein. However, co-treatment with PES and 4-6 h of 
H2O2 resulted in greater accumulation of higher molecular mass Triton-insoluble ChAT 
proteins as compared to cells treated with PES or H2O2 alone. Deposition of Triton-
insoluble ChAT aggregates could be observed in the loading pockets of the SDS-PAGE 
gels following co-treatment of cells with PES and 4-6 h H2O2 (top panel, anti-ChAT long-
exposure). Anti-actin immunoblotting was completed as loading controls (n=3). 
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HSC70 is enhanced following acute exposure of cells to 100 µM H2O2 for either 1 or 2 h 
as compared to vehicle-treated control cells (Figure 3.44). Interestingly, exposure of ChAT-
expressing cells with 1 mM H2O2 for 1 h or to 100 µM H2O2 for extended periods of time 
(4 – 8 h) had no effect on ChAT-HSC70 co-IP. Lastly, co-IP of ChAT with endogenous 
HSP90 appears to be unaffected by treatment with either 100 µM or 1 mM H2O2.  
 
3.18: Inhibition of the co-chaperone Cdc48/p97/VCP prevents the 
degradation of ubiquitinated ChAT   
Previously in our laboratory we have shown that the co-chaperone Cdc48/p97/Valosin-
containing protein (VCP) can stably interact with ChAT in IMR32 neural cells exposed to 
oxidative Aβ [440, 508]. Interestingly, VCP has also been documented to modulate HSP 
substrates through interaction with HSC/HSP70 [513] and HSP90 [514], and additionally 
can regulate the subcellular trafficking and degradation of ubiquitinated proteins [98, 441-
442]. It is currently unknown if VCP may regulate ChAT ubiquitination and degradation 
under basal conditions, and therefore to examine if ChAT protein stability is regulated by 
VCP I treated SN56 cells, transiently expressing either wild-type or mutant ChAT, for 18 
h with 5-10 µM Eeyarestatin I (Eer1), a small-molecule inhibitor of VCP [515-516]. 
Following anti-ChAT immunoblotting, I observed accumulation of high molecular mass 
wild-type and mutant ChAT-immunoreactive proteins following cell treatment with 10 µM 
Eer1, but not in control cells treated with DMSO-vehicle (Figure 3.45a). The abundance of 
high molecular mass ChAT was greater for mutant than for wild-type ChAT, with levels of 
P17A/P19A-ChAT being the greatest. Additionally, Eer1 treatment led to accumulation of 
insoluble high molecular mass ChAT proteins for both wild-type and mutant ChAT that 
were retained in the loading pockets of the stacking layer of SDS-PAGE gels. 
 VCP can promote the proteasome-dependent degradation of ubiquitinated proteins 
from both the ER and the cytoplasm [441-442], and furthermore inhibition of VCP by Eer1 
treatment has been shown to prevent the degradation of ubiquitinated VCP substrates [515-
516].  Thus, to determine if the higher molecular mass ChAT proteins observed following 
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Figure 3.44: Co-IP of ChAT with endogenous HSC70 is enhanced following exposure 
of cells to H2O2. Immunoblots showing co-immunoprecipitation (co-IP) of ChAT with 
endogenous HSC70 and HSP90 from SN56 cells transiently expressing wild-type ChAT 
that were treated with 100 µM H2O2 for 1-8 h or with 1 mM H2O2 for 1 h. Controls cells 
were either treated with water-vehicle (Veh) or were transfected with empty pcDNA3.1+ 
vector. As assessed by anti-HSC70 and anti-HSP90 immunoblotting, co-IP of wild-type 
ChAT with endogenous HSC70 is enhanced in cells treated with 100 µM H2O2 for 1-2 h, 
whereas co-IP of ChAT with endogenous HSP90 is unaffected by H2O2 treatment. Anti-
actin immunoblotting from whole cell lysates was completed as a loading control (n=4). 
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Figure 3.45: Inhibition of the co-chaperone Cdc48/p97/Valosin-containing protein 
(VCP) prevents degradation of ubiquitinated ChAT. (A) Anti-ChAT immunoblots from 
SN56 cells transiently expressing either wild-type (WT) or mutant ChAT that were treated 
for 18 h with 5-10 μM Eeyarestatin I (Eer1), a VCP inhibitor, or with DMSO-vehicle 
control. Inhibition of VCP with 10 µM Eer1 resulted in the generation of high molecular 
mass ChAT-immunoreactive proteins and the presence of insoluble ChAT retained in the 
loading pockets of SDS-PAGE gels (top panel, anti-ChAT long-exposure). Accumulation 
of high molecular mass ChAT appears greater for mutant ChAT compared to wild-type 
ChAT, with levels of P17A/P19A-ChAT being the greatest. Anti-actin immunoblotting was 
completed as a loading control (n=3). (B) Inhibition of VCP attenuates the degradation of 
ubiquitinated ChAT. ChAT ubiquitination was analyzed by anti-ubiquitin immunoblotting 
following anti-ChAT IP from ChAT-expressing SN56 cells that were treated for 18 h with 
10 μM Eer1. Control cells were transfected with empty pcDNA31+ vector and/or treated 
with DMSO-vehicle. Proteasome function was maintained to allow for the degradation of 
ubiquitinated ChAT in DMSO-treated control conditions. The abundance of ubiquitinated 
ChAT following VCP inhibition appears to be greater for mutant ChAT, with levels of 
ubiquitinated P17A/P19A-ChAT being the greatest. Anti-actin and anti-ubiquitin 
immunoblotting from whole cell lysates were completed as loading controls (n=3).  
 
VCP inhibition are ubiquitinated forms of ChAT, and therefore whether ubiquitinated 
ChAT may be degraded in a VCP-dependent manner, I completed anti-ChAT IPs from 
ChAT-expressing SN56 cells that were treated with 10 µM Eer1 for 18 h. Importantly, to 
maintain proteasome function and thus to allow for the degradation of ChAT in cells treated 
with DMSO-control I omitted the addition of MG132. By anti-ubiquitin immunoblotting 
of anti-ChAT IP samples, I confirmed that VCP inhibition prevented the degradation of 
ubiquitinated wild-type and mutant ChAT when compared to DMSO-treated control cells 
(Figure 3.45b). The abundance of ubiquitinated ChAT following VCP inhibition was 
greater for mutant ChAT when compared to wild-type ChAT, with levels of ubiquitinated 
P17A/P19A-ChAT being the greatest. Lastly, higher molecular mass ubiquitinated ChAT 
was observed in the loading pockets of SDS-PAGE gels following Eer1 treatment.  
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CHAPTER 4: DISCUSSION 
4.1: Significant Findings 
Maintenance of ChAT protein stability and activity are essential for cholinergic neural 
function, and thus are critical for the regulation of both central and autonomic neural 
processes as well as somatic neuromuscular functions. Unfortunately, little is known 
regarding the cellular factors that either stabilize ChAT protein or, conversely, that promote 
the degradation of ChAT. Alterations in ChAT protein stability and enzymatic activity have 
been documented and correlated with the pathogenesis of the neuromuscular disease CMS. 
Previous studies from other laboratories have identified and characterized multiple CMS-
related ChAT mutations that result in reduced in vitro ChAT activity as well as reduced 
steady-state protein levels when expressed in mammalian cells [411, 457-458]. One of 
these CMS-related mutations, V18M, is positioned distal to the ChAT active site and is 
located within a highly-conserved and surface-exposed proline-rich motif at residues 
14PKLPVPP20 that shares homology with PxxP SH3-binding motifs [420, 457-458, 474]. 
The cellular mechanisms underlying the dysfunction of mutant V18M-ChAT protein are 
still unknown, though mutation of residue Val18 could potentially result in disruption of the 
ChAT N-terminal proline-rich motif; it is currently unknown whether this proline-rich 
motif regulates ChAT function. Thus, the goal of my thesis was to first investigate a 
functional role of the ChAT N-terminus on human 69-kDa ChAT protein, with a focus on 
the highly-conserved proline-rich motif that surrounds the CMS-related residue Val18. 
Second, and in conjunction with my first aim, I sought to determine cellular mechanisms 
that regulate the basal stabilization and/or degradation of wild-type ChAT protein and/or 
that regulate mutant ChAT protein stability.  
In summary, this thesis details the characterization and establishment of a role for 
the conserved N-terminal proline-rich motif in regulating the protein stability and activity 
of human 69-kDa ChAT. To begin, I found that disruption of the ChAT proline-rich motif 
by either N-terminal truncation or proline-to-alanine mutation, or in relation to the CMS-
related V18M mutation, reduces both the steady-state protein levels and cellular activity of 
mutant ChAT when transiently expressed in mouse cholinergic SN56 cells. Interestingly, 
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proline-to-alanine mutation of residues Pro17 and Pro19 together (P17A/P19A) rendered the 
mutant enzyme inactive in cellular lysates and yielded the greatest loss of ChAT protein in 
cells similar to that observed for N-terminal truncations that involved partial or complete 
removal of the ChAT proline-rich motif. The in vitro catalytic activity of purified 
bacterially-expressed recombinant P17A/P19A-ChAT is impaired, though this does not 
appear to be due to substantial changes in either gross protein secondary structure or in 
vitro thermal stability of mutant ChAT. Importantly, I demonstrated for the first time that 
ChAT is ubiquitinated in cells and that the ubiquitination of mutant P17A/P19A- and 
V18M-ChAT is enhanced, resulting in increased proteasome-dependent degradation and 
loss of mutant ChAT protein in SN56 cells. The cellular loss of P17A/P19A-ChAT protein 
correlated with a reduction in ChAT protein half-life as measured using a novel fluorescent-
biorthogonal pulse-chase protocol. Proteasome inhibition prevented the degradation of 
ubiquitinated wild-type and mutant ChAT, increasing the steady-state protein levels and 
protein half-life of ChAT. Lastly, I observed that ChAT can undergo K48-dependent and 
K48-independent polyubiquitination and proteasomal degradation. These data have been 
peer reviewed and published in the Journal of Neurochemistry [502].  
Of significance, these initial studies demonstrated that ChAT protein stability is 
regulated by the ubiquitin-proteasome system, and that ubiquitination of catalytically-
deficient mutant ChAT is enhanced, thus identifying a mechanism that may be responsible 
for the cellular loss of CMS-related ChAT mutant protein. The molecular mechanisms that 
regulate basal ChAT ubiquitination and/or that promote enhanced ubiquitination of mutant 
ChAT remained unknown following the aforementioned experiments, and thus I sought to 
identify novel cellular mechanisms that regulate ChAT protein stability. By BioID, co-
immunoprecipitation, and in situ PLA, I identified the heat shock proteins HSC/HSP70 and 
HSP90 as novel ChAT protein-interactors in mammalian cells. Both of these molecular 
chaperones are well-known for their role in promoting the folding and stabilization of 
cellular proteins. Thus, by pharmacological means I found that inhibition of HSC/HSP70-
substrate interactions by treatment of SN56 cells with the HSC/HSP70 inhibitor PES 
resulted in the accumulation of Triton-insoluble and SDS-resistant wild-type and mutant 
ChAT protein aggregates. Furthermore, inhibition of HSC/HSP70 and HSP90 activity by 
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treatment of cells with VER-155008 or 17-AAG, respectively, led to reduced cellular 
ChAT activity, enhanced ChAT ubiquitination, and increased proteasome-dependent loss 
of ChAT protein. Importantly, the effects of HSP inhibition were greater for mutant ChAT 
(P17A/P19A-, V18M-, and A513T-ChAT) as compared to wild-type ChAT. HSPs can 
alternatively promote the ubiquitination and degradation of misfolded proteins through 
cooperative interaction with the E3 ubiquitin ligase CHIP/Stub1, and while I show that 
ChAT interacts with CHIP by both co-IP assays and in situ PLA, siRNA-mediated knock-
down of CHIP had no effect on either wild-type or mutant ChAT protein levels. However, 
inhibition of the ER- and HSP-associated co-chaperone Cdc48/p97/VCP prevented the 
degradation of ubiquitinated ChAT. Together, these results identify novel mechanisms for 
the functional regulation of both wild-type and CMS-related mutant ChAT by pro-
stabilizing HSPs and the pro-degradative co-chaperone p97/VCP which may have broader 
implications for ChAT function during cellular stress and disease. These data have been 
peer reviewed and published in Frontiers in Molecular Neuroscience [517] 
An important function of HSPs is to chaperone cellular proteins when cells are 
exposed to acute proteotoxic stresses, such as hyperthermia and oxidative stress, thereby 
maintaining protein stability, solubility, and function. Earlier studies in our laboratory by 
Shawn Albers, M.Sc., showed that cellular ChAT activity is decreased in cells exposed to 
oxidative stress by H2O2 treatment, and furthermore that ChAT forms redox-dependent 
higher molecular mass oligomers following H2O2 treatment [507]. In my work, I found that 
the solubility of ChAT protein is decreased, and that ChAT ubiquitination is enhanced in 
cells treated with H2O2. Furthermore, inhibition of HSC/HSP70-substrate interactions by 
PES treatment further sensitized ChAT to H2O2-induced insolubilization and formation of 
higher molecular mass ChAT protein aggregates. Lastly, as assessed by co-IP assays, the 
association of ChAT with HSC70, but not HSP90, is enhanced following H2O2-treatment, 
suggesting that HSC70 may help to prevent oxidative dysfunction of ChAT by chaperoning 
ChAT protein and preventing ChAT misfolding during exposure to oxidative stress. These 
initial experiments investigating the effects of oxidative stress on ChAT protein stability, 
solubility, and function will help to inform and provide rationale for future work within the 
Rylett Laboratory as will be discussed later in this thesis. 
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Taken altogether, my results detail within this thesis support a model (Figure 4.1) 
where the heat shock proteins HSC/HSP70 and HSP90 promote the folding, stabilization, 
and catalytic activity of human 69-kDa ChAT in a cooperative manner, thereby ultimately 
regulating ACh synthesis and cholinergic neural function. Furthermore, the basal turnover 
of ChAT protein is regulated by the ubiquitin-proteasome system where the co-chaperone 
p97/VCP promotes the degradation of ubiquitinated ChAT. I propose that ChAT mutations 
that impair ChAT enzymatic activity, such as P17A/P19A and CMS-related V18M, do so 
by interfering with the correct/complete conformational folding of ChAT in cells, thus 
leading to ChAT destabilization and the generation of misfolded mutant ChAT protein. 
Additionally, under cellular conditions that can promote protein misfolding, such as during 
exposure to oxidative stress or when HSP functions are inhibited, ChAT protein folding 
becomes compromised, resulting in the formation of misfolded and insoluble ChAT protein 
aggregates. Subsequently, misfolded and dysfunctional ChAT protein is targeted for 
cellular clearance via enhanced ubiquitination and proteasome-dependent degradation, 
potentially through chaperone-mediated mechanisms. The identity of the E3 ubiquitin 
ligase responsible for ChAT ubiquitination under either basal conditions or that promotes 
enhanced ubiquitination of mutant and/or misfolded ChAT remains to be elucidated. 
 
4.2: General Discussion 
Canonically, HSPs such as HSC/HSP70 and HSP90 have been characterized for their role 
in the folding and stabilization of nascent proteins, as well as refolding of aggregation- and 
misfolding-prone proteins during proteotoxic stress [118, 135, 154-155]. In the present 
studies I show that inhibition of HSC/HSP70 led to the insolubilization, destabilization, 
and degradation of both wild-type and mutant ChAT, and while I found that inhibition of 
HSP90 reduced cellular ChAT activity, this had no effect on the steady-state protein levels 
of wild-type ChAT. In the currently accepted model (Figure 1.6) multiple HSPs can act 
together to chaperone cellular proteins in a cooperative and processive manner, with initial 
recognition and folding of non-native nascent proteins completed by a HSP40-HSC/HSP70 
complex, followed by transfer of semi-folded HSP substrates to HSP90 by HSP70-HSP90  
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Figure 4.1: Model for the dynamic regulation of ChAT protein stability and function 
by molecular chaperones and the ubiquitin-proteasome system. (1) The heat shock 
proteins HSC/HSP70 and HSP90 act in a cooperative and processive manner to promote 
the folding, stabilization, and catalytic activity of human 69-kDa ChAT protein. (2) Under 
basal conditions the co-chaperone Cdc48/p97/Valosin-conaining protein (VCP) regulates 
the turnover of ChAT protein where inhibition of VCP by Eeyarestatin I (Eer1) treatment 
prevents the proteasomal degradation of ubiquitinated ChAT. (3) ChAT protein folding can 
become compromised following exposure of cells to either oxidative stress (i.e. H2O2) or 
to HSP inhibition (i.e. PES/VER-155008 and 17-AAG), as well as in cases where mutation 
of ChAT impairs ChAT enzymatic activity, such as with P17A/P19A and CMS-related 
V18M, leading to the generation of misfolded ChAT protein. (4) Misfolded ChAT is then 
targeted for cellular clearance through enhanced ubiquitination and proteasome-dependent 
degradation, potentially through chaperone-mediated mechanisms. The E3 ubiquitin ligase 
responsible for ChAT ubiquitination under either basal conditions or that promotes the 
enhanced ubiquitination of mutant and/or misfolded ChAT remains to be elucidated. 
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organizing protein (Hop) and subsequent final folding by HSP90 [178-180].  Thus, HSP90 
works downstream of HSC/HSP70 to interact with semi- or pre-folded proteins where 
formation of stable HSP90-substrate interactions is promoted by availability of labile 
solvent-accessible hydrophobic domains, such as those found in ligand-binding domains 
and enzyme active sites [234-236, 238, 246, 503]. As such, HSP90 plays an essential role 
in the structural maturation and conformational activation of various cellular kinases and 
enzymes involved in a wide array of cell signaling pathways, such as endothelial nitric 
oxide synthase (eNOS) [518], the cell cycle-associated tyrosine kinase Wee1 [519], steroid 
hormone receptors [244, 520], and the receptor tyrosine kinase ErbB2 [245, 503]. This 
contrasts with HSC/HSP70 that interacts with a diverse and extensive range of nascent non-
native proteins (20% of all nascent proteins) that minimally contain solvent-exposed 
regions enriched with 4-7 hydrophobic residues [167-168, 187, 202]. Thus, I propose that 
ChAT protein folding, stability, and cellular activity is regulated in a similar processive 
manner by HSC/HSP70 and HSP90 respectively. It is important to note that inhibition of 
the ATPase activity of either HSC/HSP70 or HSP90 resulted in the loss of cellular ChAT 
activity, suggesting that cooperation of these HSPs is essential for the formation of 
natively-folded and active ChAT enzyme, and thus that these HSPs may be critical to 
cholinergic neural function. Interestingly though, inhibition of HSC/HSP70 and/or HSP90 
did not fully abolish ChAT enzymatic activity, nor did it result in complete loss of ChAT 
protein in cells suggesting that these HSPs may work in collaboration with other cellular 
molecular chaperones to promote ChAT protein folding, stability, and function.  
 Multiple co-chaperones regulate the function of HSPs, including HSP40, Hop, and 
CHIP. Previous studies from our laboratory have shown that the co-chaperone 
Cdc48/p97/VCP can interact with ChAT in IMR-32 neural cells exposed to Aβ [440]. VCP 
is a member of the AAA-ATPase family that has diverse cellular functions, including the 
ability to interact with and modulate HSC/HSP70 and HSP90 substrates [513-514], as well 
as to interact with ubiquitinated proteins to regulate their subcellular trafficking and 
degradation [97, 441-442]. Importantly, in the present studies I not only demonstrate for 
the first time that ChAT is ubiquitinated in cells and that the degradation of ubiquitinated 
ChAT is proteasome dependent, but also show that pharmacological inhibition of VCP led 
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to the accumulation of ubiquitinated ChAT and prevented its degradation in cells with 
functional proteasomes. Related to its proteolytic functions, studies have demonstrated a 
role for VCP in the handling and degradation of protein aggregates [521], as well as in the 
degradation of ubiquitinated proteins by the autophagy-lysosomal system [443-444]. While 
the autophagy-lysosomal system is one possible mechanism involved in the VCP-mediated 
degradation of ubiquitinated ChAT, my studies show that ChAT protein degradation is 
largely unaffected by pharmacological inhibition of the lysosome and, conversely, is 
regulated chiefly by the proteasome as assessed using the proteasome inhibitors MG132 
and lactacystin. Interestingly, VCP is best known for its role in promoting the proteasome-
dependent degradation of ERAD substrates [441-442], where VCP is critical for the ER-
to-cytoplasm transfer of proteins ubiquitinated in the ER, thereby directly mediating 
degradation of ERAD substrates by the cytosolic 26S-proteasome [522]. Furthermore, VCP 
can directly influence the ubiquitination of ERAD substrates by interacting with the ER-
associated E3 ubiquitin ligases gp78/AMFR and Hrd1/SYVN1 [522-524] that act 
downstream of 78-kDa glucose-regulated protein (GRP-78), an ER-associated HSP known 
to promote protein folding and stability of nascent proteins in a fashion similar to that of 
HSC/HSP70 [525]. Therefore, an alternative possibility by which VCP regulates the 
degradation of ubiquitinated ChAT may involve ERAD-associated mechanisms in addition 
to those related to cytosolic HSPs, and thus I hypothesize that ChAT may be regulated by 
various cytosolic and/or ER-associated chaperones that act cooperatively to promote ChAT 
protein function. Importantly, while my data suggest that the proteasomal degradation of 
ubiquitinated ChAT is promoted by VCP, it is unclear whether this pro-degradative 
function of VCP is primarily HSP- or ER-associated. Lastly, though the E3 ubiquitin 
ligase/s responsible for the ubiquitination of ChAT protein have yet to be identified, my 
results establish the possibility that ChAT ubiquitination may be regulated by the E3 
ubiquitin ligases gp78 and/or Hrd1; this requires further investigation.  
Many neurological disorders, including AD, Parkinson’s, and Huntington’s disease 
exhibit dysfunction of HSPs, accumulation of misfolded and aggregate-prone proteins, and 
build-up of oxidative stress [10, 526]. Protein oxidation and subsequent formation of 
aberrant stress-induced disulfide bonds during cellular exposure to oxidative stress can 
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result in gross misfolding of cellular proteins with severe functional consequences [361, 
365]. As an example, the cysteine-rich (7.5%) E3 ubiquitin ligase Parkin has been shown 
to misfold, inactivate, and aggregate following exposure to H2O2 [368-370]. Of 
significance to my studies, human 69-kDa ChAT also has a higher-than-average cysteine 
content of 3.2% compared to 1.6% for intracellular mammalian proteins [367] which may 
sensitize ChAT to oxidative damage. In support, previous studies from both our laboratory 
and by others [439, 507] have demonstrated that cellular ChAT activity is reduced 
following exposure of neural cells to oligomeric Aβ1-42, a molecular hallmark of AD and 
stimulator of cellular oxidative stress [429, 508]. Additionally, our laboratory has shown 
that Aβ1-42 treatment results in stable interaction of ChAT with VCP [440] and, together 
with my results establishing a novel role for VCP in the degradation of ubiquitinated ChAT, 
suggest that ChAT ubiquitination and subsequent protein stability may be altered during 
cellular stress. Importantly, work in this thesis shows that acute exposure of ChAT-
expressing cells to H2O2-induced oxidative stress results in enhanced insolubilization and 
ubiquitination of ChAT protein. One well-known function for HSPs, such as HSC/HSP70 
and HSP90, is to maintain proteostasis during acute exposure to cellular stress [118, 135, 
154-155], and as such during oxidative conditions these HSPs have been shown to 
chaperone oxidized proteins in order to maintain and/or restore protein function [371]. My 
results using pharmacological inhibitors of HSC/HSP70 and HSP90 suggest that these 
HSPs regulate basal ChAT protein stability in non-stressed cells, and therefore it is likely 
that they may also chaperone ChAT during oxidative stress. In support, by co-IP assay I 
found that interaction of ChAT with HSC/HSP70 appears enhanced in H2O2-treated cells, 
and furthermore that HSC/HSP70 inhibition promoted the H2O2-induced insolubilization 
of ChAT protein. It is currently unknown whether exposure to oxidative Aβ results in 
alterations in ChAT ubiquitination or solubility, or whether ChAT protein stability is 
altered following exposure to other cellular stresses, such as hyperthermia, or during human 
protein misfolding diseases such as AD. 
In addition to their role as cellular protein chaperones that promote protein folding 
and stabilization, HSC/HSP70 and HSP90 are also well-known for their ability to triage 
mutated, misfolded, and aggregated proteins for degradation through coordination with the 
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cytosolic U-box-containing and HSP-associated E3 ubiquitin ligase CHIP/Stub1 [76-78, 
184]. In fact, HSP-mediated protein degradation often requires the formation of pro-
degradative trimeric complexes between substrate-bound HSC/HSP70 or HSP90 and the 
N-terminal TPR domains of CHIP [76, 78, 293]. As such, CHIP has been shown to regulate 
a diverse range of cellular functions through CHIP-mediated ubiquitination of HSC/HSP70 
and HSP90 substrate proteins, including but not limited to the glucocorticoid receptor [184, 
294], hypoxia-inducible factor 1-alpha (HIF-1α) [295], and the receptor tyrosine kinase 
ErbB2 [230, 285]. In my present studies, I demonstrate that inhibition of HSC/HSP70 and 
HSP90 enhances the ubiquitination of ChAT protein, and subsequently show that ChAT 
interacts in situ with endogenous CHIP in SN56 cells. Furthermore, though overexpression 
of CHIP promoted the proteasomal degradation of ChAT, siRNA-mediated knock-down of 
CHIP failed to stabilize and prevent the degradation of ChAT protein. While unexpected, 
one plausible reason for this observation is that other HSP-associated E3 ubiquitin ligases 
may regulate ChAT ubiquitination as previous studies have demonstrated functional 
redundancy for CHIP-mediated degradation of HSP clients in CHIP-/- mouse fibroblasts 
[527]. As such, the E3 ubiquitin ligase Parkin has been shown to associate with both HSPs 
and CHIP to co-regulate the chaperone-mediated degradation of HSP clients such as 
neuronal nitric oxide synthase (nNOS) and various polyglutamine-expanded proteins [527-
528]. In addition, other cytosolic E3 ubiquitin ligases can also regulate the ubiquitination 
of nascent and misfolded HSP clients, including E6-associated protein (E6-AP) and the N-
end rule E3 ligase Ubr1 [529-530]. Interestingly, in my studies I found that the HSP-
binding TPR domains of CHIP, but not the catalytic U-box domain, are required for both 
the interaction of CHIP with ChAT as well as for the loss of ChAT protein following CHIP 
overexpression. Importantly, CHIP has been previously shown to compete with other pro-
folding TPR-containing co-chaperones, such as HOP, for binding to the C-terminal EEVD-
motif of HSC/HSP70 and HSP90 thus promoting the destabilization of HSP substrates 
[276, 318]. Thus, I hypothesize that alternative HSP-related E3 ubiquitin ligases, such as 
Parkin or E6-AP, may regulate the ubiquitination of ChAT protein, potentially in 
cooperation with CHIP, whereas CHIP overexpression likely promotes ChAT protein 
degradation by interfering with the pro-folding functions of HSPs that stabilize ChAT.  
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To my knowledge, work in this thesis demonstrates for the first time the 
ubiquitination of human 69-kDa ChAT protein in mammalian cells. Subsequent 
characterization of ChAT ubiquitination revealed that ubiquitinated ChAT is degraded in a 
proteasome-dependent manner, and furthermore that proteasome inhibition by MG132 
treatment prevents degradation of both K48-linked and non-K48-linked polyubiquitinated 
ChAT. Canonically, cellular proteins targeted for proteasomal degradation are done so 
through covalent modification with poly-Ub chains containing at least four K48-linked 
ubiquitin molecules [44, 54, 93]. However, studies investigating either the APC, a RING-
domain E3 ubiquitin ligase involved in cell cycle regulation, or the ERAD-associated co-
chaperone p97/VCP have identified K11-linked poly-Ub chains as an alternative signal for 
proteasomal degradation [94-95, 97-98]. These studies, together with my results, suggest 
that ChAT degradation may be regulated by K48- and/or K11-linked polyubiquitination. 
Interestingly, in cells with functional proteasomes where ChAT ubiquitination was limited 
to modification with proteolytic K11-linked poly-Ub chains I observed impaired 
degradation of polyubiquitinated ChAT. Therefore, I hypothesize that K48-mediated 
proteasomal degradation represents the dominant mechanism for degradation of ChAT 
protein in cells, with K11-mediated degradation potentially representing either a low 
abundance or compensatory mechanism for ChAT protein degradation when K48-mediated 
degradation is prevented or impaired. Furthermore, given that VCP can interact with K11-
linked polyubiquitinated proteins [98], and that interaction of ChAT with VCP in enhanced 
in neural cells exposed to Aβ1-42 [440], ubiquitination of ChAT with alternative K11-linked 
poly-Ub chains may represent a unique modification of ChAT during cellular stress, though 
this requires future confirmation. 
The initial goal of my thesis was to determine a functional role for the highly-
conserved N-terminal proline-rich motif of human 69-kDa ChAT at residues 14PKLPVPP20. 
Subsequently, my studies have demonstrated that this motif is essential for the catalytic 
activity of ChAT both in vitro and in cells, as well as for the cellular stability of ChAT 
protein. Briefly, I show that the ubiquitination and proteasomal degradation of mutant 
P17A/P19A-ChAT is enhanced compared to wild-type human 69-kDa ChAT, correlating 
with a loss in cellular steady-state protein levels and a reduction in the protein half-life of 
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P17A/P19A-ChAT. In studies performed by others, disease-related ChAT mutations have 
been identified in CMS patients that reduce both in vitro enzymatic activity and cellular 
steady-state protein levels of ChAT when expressed in mammalian cells [411, 457-458], 
though the mechanisms underlying the loss of CMS-mutant ChAT protein in cells remains 
unknown. One of these catalytically-deficient CMS-related mutations, V18M, is located 
within the N-terminal proline-rich motif of ChAT and was found previously to reduce both 
the in vitro catalytic efficiency and the steady-state protein levels of the mutant enzyme 
[457-458]. Importantly, my results show that the ubiquitination and proteasomal 
degradation of mutant V18M-ChAT is increased when compared to wild-type ChAT, 
paralleling my observations made for catalytically-inactive P17A/P19A-ChAT. Moreover, 
I observed increased ubiquitination of an additional non-active site and catalytically-
deficient CMS-related mutant, A513T-ChAT, that has been previously shown to also 
display reduced steady-state ChAT protein levels in cells [457]. Given these data, ChAT 
mutations positioned either within or outside of the N-terminal proline-rich motif that 
reduce ChAT catalytic activity may also promote enhanced ubiquitination and proteasomal 
degradation of mutant ChAT, thereby synergistically enhancing the catalytic defects of 
these mutants in vivo. Thus, I propose that enhanced ubiquitination and subsequent 
proteolytic degradation may be a common feature among various CMS-related mutant 
ChAT proteins, suggesting that prevention of proteasomal degradation may enhance the 
cellular activity of some CMS-related ChAT mutants. In support of this, I have shown that 
proteasome inhibition increases the steady-state protein levels and cellular enzymatic 
activity of both wild-type and the CMS-related ChAT mutants A513T- and T490N-ChAT. 
Conversely, while proteasome inhibition did increase the steady-state protein levels of 
mutant P17A/P19A- and CMS-related V18M-ChAT, these mutants remained catalytically 
impaired in cells. Thus, these results suggest that inhibition of ChAT ubiquitination and/or 
proteasomal degradation may represent a novel avenue for the in vivo stabilization and 
synergistic enhancement of the enzymatic activity of certain CMS-related ChAT mutants.  
While my results show that mutation of the N-terminal proline-rich motif enhances 
ChAT ubiquitination and degradation in cells, the cellular mechanisms responsible for 
these effects remain to be elucidated. Interestingly, the N-terminal proline-rich motif of 
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ChAT shares structural and sequence homology with the core “PxxP” SH3 binding motif 
[420, 474-477]. Interactions between SH3 motif- and SH3 domain-containing proteins have 
been shown to regulate the subcellular trafficking, activity, and stability of multiple cellular 
proteins, most often by modulating changes in protein phosphorylation through SH3 
domain-containing adaptor proteins, such as Grb2 and Nck, and various cellular protein 
tyrosine kinases [476-479]. Prior to work completed in this thesis, only a handful of protein-
protein interaction involving human ChAT had been identified, of which include the protein 
kinases PKC and CaMKII and the co-chaperone p97/VCP [438]. Importantly, work in our 
laboratory has shown that hierarchical phosphorylation of ChAT by either PKC or CaMKII 
alters the cellular activity of ChAT, indicating that ChAT enzymatic function is influenced 
by dynamic phosphorylation [410, 426-427, 440]. Furthermore, studies by others have 
demonstrated that phosphorylation can influence the ubiquitination and degradation of 
multiples members involved within the EGFR/MAPK signalling network through various 
phospho-binding E3 ubiquitin ligases, such as members of the Cbl family [531-533]. It is 
currently unknown whether ChAT engages in SH3-dependent protein-protein interactions 
mediated through its N-terminal proline-rich motif. Furthermore, it is unknown if ChAT 
mutations, specifically those found within the N-terminal proline rich motif (i.e. V18M), 
alter the phosphorylation of ChAT, and whether this may correlate with loss of cellular 
activity and protein stability of mutant ChAT. 
As discussed above, in this thesis I found that the ubiquitination and degradation of 
specific CMS-related ChAT mutants (i.e. V18M- and A513T-ChAT), as well as mutant 
P17A/P19A-ChAT, is enhanced in cells. All three of these mutations are positioned distal 
to the ChAT active site [420, 457], and while the mechanisms responsible for the loss of 
mutant ChAT protein in mammalian cells are not yet fully clear, one possibility is that these 
mutations may produce local labile changes to the ChAT protein secondary structure that 
are then responsible for both the catalytic impairment of ChAT and that target these ChAT 
mutants for chaperone-mediated degradation. Importantly, using purified bacterially-
expressed recombinant ChAT proteins I found that mutation of the ChAT N-terminal 
proline-rich motif does not produce substantial changes to the overall gross protein 
secondary structure or the in vitro thermal stability of purified recombinant ChAT as 
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measured by circular dichroism analysis. As such, it is not obvious how these mutations 
destabilize ChAT protein in vivo, and thus by BioID I sought to identify ChAT protein-
interactors responsible for the stabilization and/or enhanced degradation of mutant ChAT 
in mammalian cells. Though I did not detect any SH3-mediated ChAT protein-protein 
interactions by BioID, I did identify the heat shock proteins HSC/HSP70 and HSP90 as 
novel ChAT protein-chaperones and observed by co-IP assay enhanced interaction of 
mutant ChAT with these HSPs as compared to that seen for wild-type ChAT. Furthermore, 
I show that various ChAT mutants (i.e. P17A/P19A, V18M, and A513T) have increased 
sensitivity to pharmacological inhibition of both HSC/HSP70 and HSP90 where, 
importantly, HSP90 inhibition resulted in the proteasomal loss of mutant but not of wild-
type ChAT. In general, HSPs aid in the stabilization of their substrates through a process 
of kinetic partitioning, whereby they interact with exposed hydrophobic domains within 
cellular proteins that is thought to prevent client protein misfolding and aggregation [6, 
167-168, 503]. In support of this, I found that inhibition of HSC/HSP70-substrate 
interactions by PES treatment resulted in loss of ChAT protein solubility and the generation 
of Triton-insoluble and SDS-resistant ChAT aggregates, with the abundance of these PES-
induced insoluble ChAT proteins being greatest for mutant ChAT. Interestingly, Triton-
insoluble aggregates of mutant P17A/P19A-ChAT protein was observed in cells with 
functional HSPs, suggesting that the folding of this mutant ChAT protein may be 
compromised under basal conditions, resulting in the production of catalytically-impaired 
ChAT that may be susceptible to misfolding and inactivation. While my results suggest that 
HSC/HSP70 and HSP90 are critical for the stabilization of mutant ChAT, these HSPs are 
also known to promote the degradation of misfolded proteins through the ubiquitin-
proteasome system [6, 76-78, 118]. Importantly, I observed enhanced ubiquitination of both 
wild-type and mutant ChAT following HSP inhibition, suggesting that impairment of HSP-
mediated folding of ChAT protein may promote the ubiquitination and degradation of 
misfolded ChAT. Therefore, taken together my data suggest that mutations, such as CMS-
related V18M and A513T, may compromise ChAT protein folding and the conformational 
activation of ChAT in vivo, leading to enhanced chaperone-mediated ChAT degradation 
and/or enhanced dependence of mutant ChAT proteins on HSPs to maintain mutant ChAT 
stability and function. It is important to note that my HSP observations related to mutant 
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ChAT are significant as protein misfolding and enhanced functional dependence on 
molecular chaperones is frequently observed for mutated and disease-relevant proteins 
[125, 534]. Thus, my observations may represent a general HSP-related mechanism for the 
regulation of ChAT protein stability that may apply to not only various CMS-related ChAT 
mutants beyond those studied presently, but also to the maintenance of ChAT function 
during cellular stress and disease, such as that observed in this thesis for ChAT-expressing 
cells exposed to oxidative stress by H2O2 treatment. 
An important outcome of my studies was the development of a novel approach to the 
study of cellular protein half-life. The biochemical determination of protein half-life can 
provide insight into the stability, regulation, and function of cellular proteins. Two differing 
methods are commonly used to determine protein half-life; ribosomal inhibition by CHX 
treatment, a potent yet cytotoxic inhibitor of protein synthesis [501], or pulse-chase 
experiments that utilize radioactive 35S-methionine live-labeling [535-537]. While 35S-
methionine labeling is held as the gold standard for pulse-chase analysis, metabolic 
radiolabeling has been found to induce cellular damage and reduce cell survival, suggesting 
that care is needed when interpreting results gathered by this approach [538-539]. In 
response to these concerns, I have developed an alternative and novel protocol for the 
biorthogonal determination of protein half-life by fluorescent labeling of nascent proteins 
using “click chemistry” [502]. My protocol is a direct adaptation on 35S-methionine pulse-
chase labeling whereby newly synthesized nascent proteins are first live-labeled in culture 
with the biorthogonal amino acid L-azidohomoalanine (AHA), a non-radioactive and azide-
containing methionine analog, that are then reacted with fluorescently-tagged strained 
cyclooctynes to form stable fluorescent triazole conjugates using metal-free SPAAC 
reactions [495-496]. Importantly, using this novel protocol I not only determined the 
protein half-life of human 69-kDa ChAT, but have also shown that ChAT protein half-life 
is reduced following mutation of ChAT N-terminal proline-rich motif (i.e. P17A/P19A) or 
that it is increased following cellular proteasome inhibition by MG132 treatment. While 
SPAAC reactions have been used previously both in vitro and in vivo to measure global 
changes in protein synthesis [497-500], to my knowledge my studies are the first to use 
SPAAC reactions to measure the protein half-life of a specific cellular protein of interest. 
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My protocol has several advantages over the more standardized CHX or 35S-methionine 
pulse-chase assays, foremost being that AHA live-labeling of HEK293 cells has been 
previously shown to be highly specific for newly-synthesized proteins and, importantly, is 
non-toxic to cells [498]. Second, AHA-labeled proteins can be used for both fluorescent 
and immunoblotting analysis from the same sample preparation, thereby eliminating the 
need to prepare both labelled and non-labelled protein samples when performing similar 
35S-methionine pulse-chase experiments. Lastly, an additional advantage of my protocol is 
the ever-growing selection of commercially available biorthogonal amino acids and 
complementary fluorescent or chemiluminescent probes that can be used in copper-free 
SPAAC reactions. This advantage allows for increased flexibility when designing pulse-
chase experiments and increases the compatibility of my protocol with commonly-used 
laboratory equipment and procedures without the reliance on radioactive 35S-methionine or 
cytotoxic CHX. Overall, I propose that my SPAAC pulse-chase protocol represents a novel, 
non-toxic, and non-radioactive alternative/replacement to classical CHX or 35S-methionine 
pulse-chase methods, and furthermore is an important example of the utility for click 
chemistry in the safe and effective alteration of existing and well-practiced methods. 
 
4.3: Study Limitations and Alternative Approaches 
The major limitation for any study is the choice of biological model/s and the associated 
techniques used to assess study objectives. For my studies, to determine the effects of 
ChAT mutations on the regulation of ChAT protein stability and function I used transiently 
transfected cells lines due to their availability, ease of use, and speed by which I was able 
assess my initial experimental aims centered around mutated forms of human ChAT 
protein. Given that ChAT is a defining cholinergic protein, the use of cholinergic neural 
cells in my studies was imperative to minimalize the acquisition of misleading results 
associated with studying neural proteins in non-neural cells. In addition, as transient 
transfection was to be my primary means to express wild-type and mutant ChAT protein in 
cells, transfection efficiency and the ability to express heterologous proteins were major 
considerations for an appropriate cell line for my study. Many well-documented neural cell 
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lines exist, including human neuroblastoma SH-SY5Y cells [540-541], a cell line that has 
been extensively used for the study of cholinergic molecular mechanisms related to 
neurogenerative diseases [542-544]. Though useful for the study of either endogenous 
neural proteins or for the generation of stable cell lines, SH-SY5Y cells are notoriously 
difficult to transfect, transiently express heterologous proteins at low levels relative to other 
mammalian cell lines, and often experience transfection-related cytotoxicity. Therefore, to 
circumvent these limitations, for the majority of my studies I used mouse cholinergic SN56 
cells [485, 545], a neural cell line that has been used by other groups to study both 
cholinergic and ChAT function in cell culture [546-550]. Ultimately, my choice for using 
mouse SN56 cells was four-fold, being that these cells are easy to transfect by multiple 
methods (e.g. calcium phosphate and Lipofectamine), express relatively higher levels of 
heterologous protein, are resistant to transfection-induced cytotoxicity, and in culture 
require minimal serum (2 – 5%) and grow quickly with a doubling-time of ~24 hours. 
Importantly, SN56 cells also have an undifferentiated cholinergic phenotype [485, 547], 
whereas SH-SY5Y cells require differentiation to attain this phenotype [544, 551]. These 
attributes together make SN56 cells an excellent and effective option for the molecular 
study of cholinergic processes in cell culture that require transection-based methods.  
 Though SN56 cells proved useful throughout my thesis, there were limitations to 
my study of human ChAT protein function in these cells. First, my studies were completed 
in undifferentiated SN56 cells, and while these cells do have a basal cholinergic phenotype, 
differentiation using retinoic acid and dibutyryl-cAMP has been shown to enhance the 
cholinergic properties of SN56 cells, correlating with enhanced endogenous ChAT activity 
and ACh content, reduced cell division, and neurite outgrowth [485, 547]. It is currently 
unknown what impact differentiation would have had on my results, though I hypothesize 
that any effects may have been negligible as the mechanisms found to regulate ChAT 
protein stability in this thesis, i.e. the ubiquitin-proteasome system and HSPs, are known to 
be well-conserved between many different tissue types. A second limitation to my use of 
SN56 cells is that I studied a human protein in mouse cells. While this is common when 
studying disease-related human proteins in mouse models [552-553], this limitation is often 
avoidable in cell culture studies due to the variety of available human cell lines. As 
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discussed above, mouse SN56 cells are an excellent option for cholinergic studies requiring 
transfection, and while the mouse proteome does differ from that found in human cells, a 
high degree of compositional and function proteomic similarity has been observed between 
cells from these two species [554-555]. Interestingly, in my studies I observed results that 
differed in some respects when analyzing anti-ChAT co-IPs completed from either human 
kidney HEK293 or mouse SN56 cells. Specifically, unique to HEK293 cells I observed co-
IP of ChAT with stress-inducible HSP70 and saw enhanced interaction of P17A/P19A-
ChAT with HSP90; co-IP of ChAT with HSC70 and HSP90 was observed in both HEK293 
and SN56 cells. Of note, HEK293 cells have elevated constitutive expression of HSP70 
due to the E1A-mediated immortalization of these cells [556-557], whereas in SN56 cells 
the stress-induced expression of HSP70 was limited to cells exposed to either hyperthermia 
(data not shown) or to the HSP90 inhibitor 17-AAG (Figure 3.30). Therefore, observational 
differences made between these two cell lines are likely multifactorial (i.e. species/tissue 
type and HSP expression) and may be unique to HEK293 cells. It is unknown if my results 
would have also differed if assessed in human cholinergic cells, such as SH-SY5Y cells.  
As is common for cell-based studies, transient transfections were used throughout my 
experiments as I required straightforward, routine, effective, and consistent heterologous 
expression of multiple proteins of interest including engineered and CMS-related ChAT 
mutants. A limitation of this approach is the typical overexpression of heterologous protein 
observed when using expression vectors, such as pcDNA3.1, that contain strong 
constitutive promoters [558]. As it is often unknown whether overexpressed heterologous 
proteins behave like or are regulated in a similar fashion to their endogenous counterparts, 
studies that can wholly or partially investigate endogenous proteins have an advantage by 
limiting the potential for unintended effects due to protein overexpression. Importantly, 
though my studies relied on heterologous expression of wild-type or mutant ChAT, my 
experiments focused on ChAT function as it was related to various endogenous proteins, 
including ubiquitin, HSC/HSP70, HSP90, CHIP, and p97/VCP. It is currently unknown 
whether endogenous ChAT protein is regulated likewise to that observed in my studies. 
One alternative to transient heterologous protein expression is the generation of cells stably 
expressing a heterologous protein of interest [559], though this carries risks associated with 
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random genome integration of plasmid cDNA and unintended cellular consequences due 
to long-term constitutive protein overexpression. To address these issues, modern 
techniques have been developed that allow for guided genomic integration of inducible 
cDNA (e.g. Flp-In T-Rex System; Thermo) or for genomic editing of endogenous proteins 
using CRISPR-Cas9 technology [560-561], though transient transfection remains the most 
standard and simplest approach for the expression of heterologous proteins in cell lines. 
The most significant limitation of my study was the extensive use of immortalized cell 
lines to study ChAT protein stability, and while the use of cell lines remains a standard 
approach for the molecular study of protein function, care must be taken when interpreting 
results generated from such studies. Specifically, most immortalized cell lines are derived 
from genetically unstable tumorigenic cells, including SN56 cells [485, 545, 562-563], and 
thus a major concern is that these cell likely harbour tumour-promoting proteomic changes 
that could have an unforeseen or deleterious impact on experimental results. While this is 
a well-known limitation, the availability and accessibility of immortalized cell lines has 
made them an effective molecular tool, particularly for exploratory studies such as mine. 
Alternatively, the use of non-tumorigenic primary cells or induced pluripotent stem cells 
(IPSCs) has gained popularity due to the development of effective transfection techniques 
for primary cells [564], as well as the creation of protocols for the growth, differentiation, 
and use of IPSCs. While proposed to be a more physiologically-relevant tool for the study 
of biological processes, the use of primary cells or IPSCs remains today both costly and 
challenging, particularly due to difficulties in the isolation, culturing, and transfection of 
these cells. Though these constraints may reduce the experimental flexibility of these cells 
as compared to immortalized cell lines, I propose that it will be important to assess whether 
select results from my thesis are reproducible in either primary neurons or IPSCs.  
In addition to these study-wide limitations, experiment-specific limitations also need to 
be addressed. First, to characterizing ChAT ubiquitination in SN56 cells I overexpressed 
various ubiquitin mutants over-top of an endogenous ubiquitin background (Figure 3.11). 
Unexpectedly, I observed enhanced recovery of ubiquitinated ChAT in MG132-treated 
cells expressing heterologous K48R-ubiquitin that is unable to form proteolytic K48-linked 
poly-Ub chains (Figure 3.11c). While this result may suggest that ChAT can be targeted 
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for proteasomal degradation by non-classical polyubiquitin chains, such as K11-linked 
poly-Ub chains, it is more likely that under these experimental conditions small quantities 
of ChAT protein could be degraded through ubiquitination with endogenous K48-linked 
poly-Ub chains. To address this limitation in future experiments, ChAT polyubiquitination 
can be further characterized following anti-ChAT IPs using linkage-specific anti-ubiquitin 
antibodies (e.g. K11, K48, and K63 linkages) in substitution of total-ubiquitin antibodies 
that were used earlier in my studies (Figure 3.10).  
A second experimental limitation is that my BioID experiments were completed in 
human HEK293 cells, and not in cholinergic SN56 cells, primarily due to the superior 
transfectability and transient expression of heterologous proteins typically seen in HEK293 
cells. In support of my use of HEK293 cells, I found in initial optimization experiments 
that the transient expression of multiple ChAT-BirA* fusion proteins was the greatest in 
HEK293 cells as compared to either SN56 or SH-SY5Y cells, and that this correlated with 
a greater abundance in the total amount of biotinylated cellular proteins that could be used 
downstream for BioID (Appendix A). Additionally, another limitation of my BioID studies 
is that my large-scale BioID experiment with follow-up mass spectrometry was completed 
once without repetition (n=1), though this did result in the identification of HSP70 and 
HSP90 as potential ChAT-interacting proteins (Figures 3.18 – 3.22). It is important to note 
that while my large-scale BioID experiment was completed only once, biotinylated proteins 
correlating with the molecular mass of HSP70 were observed in repeated optimization 
experiments on streptavidin-HRP blots (Figure 3.17; n=2), and furthermore that HSP70 and 
HSP90 were directly confirmed by immunoblotting from streptavidin PDs from follow-up 
small-scale BioID experiments (Figure 3.23; n=4). While there are limitations to my use of 
HEK293 cells for BioID, the goal of these experiments was ultimately to identify potential 
ChAT-interacting proteins that could then later be confirmed by alternative methods, such 
as by co-IP and in situ PLA assays, in cholinergic cells. As such, and importantly, my BioID 
results were largely confirmed and expanded upon by follow-up studies in cholinergic 
SN56 cells, though I propose that any future BioID experiments investigating ChAT 
protein-interactions should be completed in cholinergic cells where feasible. 
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Following BioID I used in situ PLA assays to test and confirm the presence of ChAT 
protein-interactions with HSC70 and HSP90 in SN56 cells. One limitation to my approach 
of these experiments was that cells were not co-stained with a second alternative anti-ChAT 
antibody that could be used to verify that PLA-positive cells were expressing heterologous 
human ChAT protein. The stringent nature of the in situ PLA technique is based on the 
observation that, to generate a positive PLA reaction, two antibody-labeled proteins must 
be no more than 40 nm apart from each other [565-567], and therefore it is unlikely to 
generate PLA signals unless the tested proteins in questions are in direct contact. 
Importantly, as no positive PLA signals was generated in control cells transfected with 
empty vector that were incubated with anti-ChAT and either anti-HSP or anti-CHIP 
antibodies (Figures 3.26 and 3.35), I propose that this limitation does not significantly 
impact my results. However, in future PLA experiments involving heterologous expression 
of human ChAT protein it will be important that this limitation be addressed.  
Lastly, a fourth experimental limitation to my studies is the use of small molecule 
inhibitors for the study of HSC/HSP70, HSP90, and p97/VCP function. While this is a 
common approach to the study of molecular pathways, and provided that the inhibitors used 
within my studies, including PES and VER-155008 (HSC/HSP70), 17-AAG (HSP90), and 
Eer1 (VCP), have all been previously shown to be selective for and efficacious against their 
intended targets [213, 217, 516, 568], off-target effects of these small molecules must 
always be considered. The most common alternatives to small molecule inhibitors typically 
involve reducing (knock-down) or eliminating (knockout) the endogenous expression of a 
protein of interest. While knockout studies that do not require the generation of transgenic 
animals are becoming more common and accessible due to the advent of CRISP-Cas9 
technology [560-561], RNAi-mediated knock-down remains the standard approach for 
cell-based studies that offers a high degree of experimental flexibility for the study of 
endogenous proteins in cells. Unfortunately, in preliminary experiments I found that 
siRNA-mediated knock-down of HSC/HSP70 reduced the cellular viability of SN56 cells 
by 70-90% as compared to cells transfected with scramble-control siRNA when assessed 
by alamar blue assay (Appendix B). Furthermore, while I was able to obtain an ~50% 
knock-down of HSP90 in SN56 cells, this is most likely insufficient to prevent the cellular 
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chaperoning functions of HSP90 due to the high endogenous levels of HSP90 (1-2% of all 
cellular protein) [162, 227]. In relation to VCP inhibition, other studies have previously 
shown comparable results between Eer1 treatment and siRNA-mediated knock-down of 
VCP [515-516]. Though knock-down studies have been used to investigate the function of 
many cellular proteins, one advantage of pharmacological inhibition is the possibility to 
target different functional domains within a protein of interest. In my studies, this advantage 
was most evident when using the HSC/HSP70 inhibitors PES (substrate binding) and VER-
155008 (ATPase activity) that produced differing though complementary results towards 
ChAT protein solubility and stability in SN56 cells. Taken together, I propose that the use 
of small molecule inhibitors within this thesis was a safe and effective approach to studying 
the cellular mechanisms that regulate ChAT protein function. 
 
4.4: Future Directions 
Future work related to my studies can be separated into two categories involving either 
short-term follow-up experiments or more long-term projects. To begin, in the short-term 
it will be important to follow-up on select observations from my thesis given the 
experimental limitations to my studies as discussed above. Subsequently, I propose that an 
immediate follow-up study should be to test whether my core observations from SN56 cells 
are reproducible in alternative cholinergic cells, such as differentiated human SH-SY5Y 
cells and/or primary mouse neuron cultures. Importantly, these cell models can be used to 
confirm that (a) P17A/P19A- and CMS-mutant ChAT are targeted for proteasome-
dependent degradation through enhanced ubiquitination, (b) that wild-type and mutant 
ChAT interact with HSC/HSP70 and HSP90, (c) that HSP inhibition promotes the 
insolubilization, ubiquitination, and degradation of ChAT protein, and (d) that the 
solubility and ubiquitination of ChAT is altered following exposure to cellular oxidative 
stress. Most if not all these follow-up experiments in alternative cholinergic cells will need 
to be performed using heterologous-expressed wild-type and/or mutant ChAT protein, and 
while this poses a potential setback due to transfection difficulties, recent studies have 
detailed new and enhanced transfection techniques designed for difficult-to-transfect cell 
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lines (i.e. SH-SY5Y cells) and primary neuron cultures [564, 569-570]. Furthermore, 
alongside of these conformational studies using either human cholinergic cells lines or 
primary neuron cultures it may be useful to also assess whether (a) endogenous ChAT is 
targeted for proteasomal degradation, and (b) if HSP inhibition promotes degradation 
and/or reduces the enzymatic activity of endogenous ChAT in cells. Unfortunately, as 
tested previously in our laboratory, the relative protein expression of endogenous 69-kDa 
ChAT in cholinergic cells is very low when compared to cells transiently transfected to 
express heterologous ChAT (data not shown), making the molecular study of endogenous 
ChAT protein very challenging. As such, these follow-up experiments investigating 
endogenous ChAT are a possibility, though are not a priority. 
In addition to these alternative cell model studies, the direct follow-up of specific 
experiments from this thesis in SN56 cells would be to useful to further build on my studies 
and expand our understanding of the mechanisms that regulate ChAT protein stability. 
These include, for example, (a) the use of chain-specific anti-ubiquitin antibodies to 
characterize ChAT polyubiquitination, (b) to assess whether inhibition of HSC/HSP70 by 
PES treatment results in enhanced ChAT ubiquitination in addition to reducing the 
solubility of ChAT protein as observed above (Figures 3.27 and 3.43), (c) to test if VCP 
inhibition using Eer1 also promotes ChAT insolubilization, and (d) to investigate if ChAT 
interacts with VCP under non-stressed conditions using co-IP and/or in situ PLA assays. In 
addition, further experimentation related to my novel SPAAC pulse-chase protocol is 
needed to build on and provide more evidence for the applicability, flexibility, and accuracy 
of this novel technique as compared to more standard CHX or 35S-methionine pulse-chase 
assays. To this end it will be important to perform SPAAC pulse-chase in alternative cell 
lines, potentially including primary cells, using either heterologous or endogenous proteins 
that have either an unknown (e.g. 82-kDa ChAT) or well-defined protein half-life (e.g. p53) 
[571-572].  Additionally, given the wide-array of commercially available click chemistry 
reagents, these follow-up SPAAC pulse-chase experiments could use alternative probes, 
such as various DIBO-conjugated Alexa Fluors, or Biotin-DIBO (Thermo) that would 
enable determination of protein half-life by streptavidin-HRP blotting without the need of 
a fluorescence detector or the use of radioactivity. It is important to note that, aside from 
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alternative reagents, all the above immediate follow-up studies to my experimental work 
would utilize similar or exact techniques that were used throughout my thesis, allowing for 
the quick and straightforward assessment of these experiments.  
 Results from my thesis support further long-term investigation into alternative 
mechanisms beyond cytosolic HSPs that may regulate ChAT protein stability and function 
under physiological conditions and/or during cell stress and disease (Figure 4.2). First, in 
relation to my results detailing the effects of VCP inhibition, the stability and function of 
ChAT protein could be assessed in relation to ERAD-associated mechanisms. As discussed 
above, VCP is best known for its critical role in mediating ER-to-cytoplasm transfer of 
proteins ubiquitinated in the ER [441-442, 522], and furthermore inhibition of VCP by Eer1 
treatment has been previously shown to inhibit the degradation of ubiquitinated VCP and 
ERAD substrates [515-516]. Thus, as in my studies I showed that VCP inhibition prevented 
the degradation of ubiquitinated ChAT, it is possible that the basal ubiquitination of ChAT 
may be regulated through ERAD-related mechanisms. Though I found that the E3 ubiquitin 
ligase CHIP interacts with ChAT in situ, siRNA-mediated knock-down of CHIP had no 
effect on ChAT protein levels, and thus the E3 ligase/s responsible for ChAT ubiquitination 
remain to be elucidated. Ubiquitination of mammalian ERAD substrates is regulated by 
two differing ER-bound E3 ubiquitin ligases, gp78/AMFR and Hrd1/SYVN1 [573-575]. 
Importantly, these E3 ubiquitin ligases and their ubiquitinated substrates can interact with 
VCP through the ER-localized adaptor protein Ubx2 [576-577], acting together to mediate 
the retrotranslocation of ERAD substrates into the cytoplasm for degradation by the 26S 
proteasome [522-524]. Though pharmacological inhibitors of these E3 ubiquitin ligases are 
not commercially available, siRNA-mediated knock-down has been used in the past as an 
effective tool to study the functions of gp78 and Hrd1 and of their cellular substrates [578-
580]. Interestingly, gp78, Hrd1, and VCP act together downstream of GRP-78 and GRP-
94, two ER-localized molecular chaperones that are related-to and that share homologous 
functions to HSC/HSP70 and HSP90 respectively [525, 555, 575, 581-582]. Thus, given 
that my studies have demonstrated a role for the cytoplasmic chaperones HSC/HSP70 and 
HSP90 on ChAT protein stability and function, it is possible that the homologous and ER-
associated GRP-78 and/or GRP-94 may also chaperone nascent ChAT protein. Like gp78  
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Figure 4.2: Hypothetical model for the regulation of ChAT protein stability by the 
endoplasmic reticulum-associated degradation (ERAD) system. (1) Nascent ChAT 
protein interacts with and is chaperoned by the heat shock proteins GRP-78 and GRP-94 in 
the ER lumen. (2) Once localized to the cell cytoplasm, semi-folded ChAT protein interacts 
with HSC/HSP70 and HSP90 in order to produce fully-folded and conformationally-active 
ChAT enzyme. (3) If initial folding of nascent ChAT protein in the ER by GRP-78 and/or 
GRP-94 is unsuccessful, ChAT may be ubiquitinated by the ER-localized E3 ubiquitin 
ligases gp78/AMFR and/or Hrd1/SYVN1. (4) p97/VCP, linked to the ER by the adaptor 
protein Ubx2, regulates retrotranslocation of ER-ubiquitinated ChAT into the cytoplasm 
for degradation by the cytosolic 26S proteasome. VCP inhibition by Eeyarestatin I (Eer1) 
treatment prevents the degradation of ubiquitinated ChAT. (5) Cellular stresses, such as ER 
and/or oxidative stress (e.g. H2O2, Aβ), may promote the misfolding of ChAT protein and 
subsequent degradation of ChAT through ERAD and/or cytosolic HSP mechanisms.  
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and Hrd1, knock-down studies have been used in the past to elucidate the cellular functions 
and substrates of either GRP-78 [583-584] or GRP-94 [254, 585]. Therefore, alongside 
siRNA knock-down studies, I propose that co-IP and in situ PLA assays could be used to 
quickly and effectively assess whether ChAT may interact with various ERAD-associated 
chaperones and E3 ubiquitin ligases, and if so to determine if interaction with these ER 
proteins regulates ChAT protein stability in a manner consistent with their known ERAD-
related functions. These initial studies can then be expanded upon by investigating ChAT 
ubiquitination and degradation under conditions of ERAD impairment (i.e. knock-down) 
or in cells exposed to various ER stress-inducing small molecules, including tunicamycin, 
thapsigargin, and brefeldin A [586-587]. Lastly, one of the most well-studied roles for 
ERAD is as a central hub for multiple protein quality control mechanisms that act together 
to triage misfolded and mutated proteins for proteasomal degradation [588-589], and as 
such ERAD may represent a cellular pathway responsible for the enhanced ubiquitination 
and degradation of various CMS-related ChAT mutants.  
 Lastly, another important avenue for future investigation will be to identify the 
cellular mechanisms that may promote ChAT stability and function during cellular stress 
and disease. Results from my studies related to oxidative stress suggest that cytosolic HSPs, 
particularly HSC/HSP70, may chaperone ChAT during cellular stress so to prevent stress-
induced misfolding, loss of solubility, enhanced ubiquitination, and subsequent degradation 
of ChAT protein. Though these preliminary studies were completed using H2O2, a potent 
inducer of oxidative stress [590-591], alternative studies have demonstrated that ChAT 
activity is altered in cells acutely exposed to AD-related and oxidative Aβ1-42 oligomers 
[438-440]. Additionally, impairment of ChAT activity has been associated with the 
pathogenesis of AD [432-435], an age-related neurodegenerative disease characterized 
partly by the dysregulation of molecular chaperones, including HSPs, and various protein 
quality control mechanisms [10, 329]. As such, an important question that will need 
addressing is whether acute and/or prolonged cellular exposure to oxidative Aβ1-42 may 
promote the insolubilization and ubiquitination of ChAT protein like that observed in my 
studies following H2O2 treatment. Furthermore, a potential protective role for HSC/HSP70 
and/or HSP90 towards ChAT function during Aβ-stress could be assessed by co-treatment 
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of ChAT-expressing cells with Aβ1-42 in combination with inhibitors of either HSC/HSP70 
(e.g. PES and VER-155008) or HSP90 (e.g. 17-AAG). Following these treatments, the 
solubility, ubiquitination, and enzymatic activity of ChAT protein could be determined 
using similar techniques to those used in the thesis, including but not limited to Triton X-
100 fractionation, IP/co-IP assays, and radioenzymatic assay to determine cellular ChAT 
activity. Interestingly, multiple studies have reported on the potential therapeutic potential 
for either activation of HSF1 (i.e. the heat shock response) or enhancement of HSC/HSP70 
activity on the pathogenesis of protein misfolding neurodegenerative diseases, including 
AD [592-594], and as such it would be interesting to test if these strategies may help to 
ameliorate ChAT dysfunction during cellular stress and disease. It is important to note that, 
in addition to oxidative stress, another key feature of many age-related neurodegenerative 
diseases is heightened ER stress and ER dysfunction due to the accumulation of misfolded 
proteins [595-596], and subsequently studies have shown that cellular exposure to cytotoxic 
Aβ can directly induce ER stress [597-598]. Of significance, previous work from our 
laboratory has shown that interaction of ChAT with the ER-associated co-chaperone 
p97/VCP is enhanced in neural cells treated with Aβ1-42 [440], suggesting that the 
regulation of ChAT ubiquitination and function may be altered following exposure to ER 
and/or oxidative stress. Therefore, these proposed studies investigating the effects of Aβ-
stress on ChAT protein stability may be intimately linked with my other proposed studies 
assessing a potential role for ER-associated chaperones and ERAD-related mechanisms on 
the regulation of ChAT protein function (Figure 4.2).  
 
4.5: Significance and Concluding Remarks 
In summary, for this thesis I initially set out to determine a functional role for the highly-
conserved N-terminal proline-rich motif of human 69-kDa ChAT and found that both the 
cellular protein stability and enzyme activity of ChAT protein is dramatically reduced 
following alteration of this motif. In addition, I demonstrated for the first time that ChAT 
protein levels are modulated through the ubiquitin-proteasome system, and furthermore 
that the ubiquitination of catalytically-deficient ChAT, such as CMS-related V18M-ChAT, 
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is increased. In search for cellular mechanisms that may regulate ChAT protein stability 
and/or that are responsible for enhanced ubiquitination of mutant ChAT, I found evidence 
that a network of cytoplasmic and ER-associated chaperones, which included the heat 
shock proteins HSC/HSP70 and HSP90 along with the co-chaperone Cdc48/p97/VCP, 
regulates ChAT protein stability and function. The regulation of specific catalytically-
deficient ChAT mutants (i.e. P17A/P19A, V18M, and A513T-ChAT) by these chaperones 
is altered, suggesting a mechanism that may be relevant to other CMS-related ChAT 
mutants or to ChAT protein during cellular stress and disease. Subsequently, in preliminary 
experiments I observed evidence that HSC/HSP70 may play a role in the maintenance of 
ChAT protein solubility, stability, and function during cellular exposure to oxidative stress. 
For future studies, this thesis supports research into the mechanisms that regulate ChAT 
ubiquitination and the role that ubiquitination may play in relation to ChAT dysfunction 
during cellular stress. Lastly, my results merit additional assessment of the roles for various 
cytosolic and ER-associated HSPs, along with the co-chaperone VCP, on ChAT stability 
and function under both physiological conditions and during cellular stress and disease.  
In conclusion, this thesis has established and characterized the roles of various 
molecular chaperones and the ubiquitin-proteasome system on the regulation of human 69-
kDa ChAT protein stability and function. It is important to note that to date ChAT is the 
sole enzyme known to synthesize the neurotransmitter ACh, and thus is both critical to and 
necessary for the function of cholinergic neurons [390, 392, 599]. These neurons can be 
found throughout the central, peripheral, and somatic nervous systems, where they are 
involved in the regulation of numerous bodily functions. These processes include cognitive 
functions such as behaviour, attention, and learning/memory, as well as various autonomic 
(e.g. pupil dilation, heart rate, and gastric and renal function) and neuromuscular processes 
(i.e. movement and motor control) [389-390, 392, 599-600]. Consequently, dysregulation 
of ChAT function, ACh synthesis, and cholinergic neurotransmission has been observed in 
multiple neurodegenerative and neuromuscular disorders including AD and CMS [387-
388, 411, 457-458]. Thus, by gaining a deeper understanding of the factors that regulate 
ChAT protein stability and activity, the work presented within this thesis may have broader 
implications to the study of ChAT protein function during cellular stress and in disease. 
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APPENDICES 
Appendix A: Optimization of BioID in multiple mammalian cell lines. Comparison of 
ChAT-BirA* fusion protein expression and the levels of biotinylated cellular proteins in 
human HEK293 as compared to either human SH-SY5Y (A; n=2) or mouse SN56 cells (B; 
n=2) following BioID. Cells were transfected to transiently express either 69-kDa (A and 
B) or 82-kDa (B) ChAT-BirA* fusion proteins using either Lipofectamine 2000 (A) or 
3000 (A and B). Cells were treated for 24 h with 50 µM biotin to induce proximity-
dependent biotinylation of ChAT-interacting proteins prior to collection and lysis. Biotin-
treated control cells were transfected with empty pcDNA3.1+ vector or vectors encoding 
for untagged 69- or 82-kDa ChAT proteins. Altogether, transfection of human HEK293 
cells using Lipofectamine 3000 was found to be superior for both the transient expression 
of ChAT-BirA* and for the accumulation and detection of cellular biotinylated proteins as 
compared to either SH-SY5Y or SN56 cells. As such, this method was used to perform my 
BioID experiments as detailed earlier (Figures 3.17 – 3.23). Biotinylated cellular proteins 
from whole cell lysates were detected by blotting with HRP-conjugated streptavidin (Strep-
HRP). Relative expression of ChAT-BirA* fusion proteins and of untagged ChAT proteins 
were assessed by anti-ChAT immunoblotting. Anti-actin immunoblotting from whole cell 
lysates was completed as a loading control. Optimization experiments for BioID were 
completed by Sabin Rajkarnikar, B.Sc. 
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Appendix B: Optimization of siRNA-mediated knock-down of endogenous 
HSC/HSP70 and HSP90. (A) Anti-HSC70 and anti-HSP90 immunoblots from SN56 cells 
that were transfected for 72 h with 10-100 nM of either anti-HSC70 or anti-HSP90 siRNA. 
Control cells were mock-transfected or transfected with 50 nM of scramble-control siRNA. 
Following incubation with siRNAs an ~50% knock-down of either HSC70 and HSP90 was 
observed. Anti-actin immunoblotting was completed as a loading control (n=2). (B) siRNA 
knock-down of HSC70 promotes the stress-induced expression of both HSP70 and HSP90 
in SN56 cells. Accumulation of stress-induced HSP70 was preventable by co-transfecting 
cells with anti-HSP70 siRNA (n=2). (C) Knock-down of HSC70 either alone or together 
with stress-induced HSP70 reduces the viability of SN56 cells as compared to scramble-
control transfected cells (***p≤0.001; one-way ANOVA with Dunnett’s post-hoc test, 
mean ± SEM). Cell viability was measured by alamar blue assay after 72 h of siRNA 
incubation (n=2).  
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understanding that nowhere in the text is a previously published source 
acknowledged for all or part of this Wiley Material. Any third party content is 
expressly excluded from this permission. 
• With respect to the Wiley Materials, all rights are reserved. Except as expressly 
granted by the terms of the license, no part of the Wiley Materials may be copied, 
modified, adapted (except for minor reformatting required by the new Publication), 
translated, reproduced, transferred or distributed, in any form or by any means, and 
no derivative works may be made based on the Wiley Materials without the prior 
permission of the respective copyright owner.For STM Signatory Publishers 
clearing permission under the terms of the STM Permissions Guidelines only, 
the terms of the license are extended to include subsequent editions and for 
editions in other languages, provided such editions are for the work as a whole 
in situ and does not involve the separate exploitation of the permitted figures 
or extracts,You may not alter, remove or suppress in any manner any copyright, 
trademark or other notices displayed by the Wiley Materials. You may not license, 
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rent, sell, loan, lease, pledge, offer as security, transfer or assign the Wiley 
Materials on a stand-alone basis, or any of the rights granted to you hereunder to 
any other person. 
• The Wiley Materials and all of the intellectual property rights therein shall at all 
times remain the exclusive property of John Wiley & Sons Inc, the Wiley 
Companies, or their respective licensors, and your interest therein is only that of 
having possession of and the right to reproduce the Wiley Materials pursuant to 
Section 2 herein during the continuance of this Agreement. You agree that you own 
no right, title or interest in or to the Wiley Materials or any of the intellectual 
property rights therein. You shall have no rights hereunder other than the license as 
provided for above in Section 2. No right, license or interest to any trademark, trade 
name, service mark or other branding ("Marks") of WILEY or its licensors is 
granted hereunder, and you agree that you shall not assert any such right, license or 
interest with respect thereto 
• NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR 
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, 
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE 
MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED 
IN THE MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED 
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY 
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, 
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES 
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED 
BY YOU.  
• WILEY shall have the right to terminate this Agreement immediately upon breach 
of this Agreement by you. 
• You shall indemnify, defend and hold harmless WILEY, its Licensors and their 
respective directors, officers, agents and employees, from and against any actual or 
threatened claims, demands, causes of action or proceedings arising from any 
breach of this Agreement by you. 
• IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR 
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY 
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR 
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN 
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR 
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION, 
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, 
TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, 
WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, 
FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), 
AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE 
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POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY 
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY 
LIMITED REMEDY PROVIDED HEREIN.  
• Should any provision of this Agreement be held by a court of competent 
jurisdiction to be illegal, invalid, or unenforceable, that provision shall be deemed 
amended to achieve as nearly as possible the same economic effect as the original 
provision, and the legality, validity and enforceability of the remaining provisions 
of this Agreement shall not be affected or impaired thereby.  
• The failure of either party to enforce any term or condition of this Agreement shall 
not constitute a waiver of either party's right to enforce each and every term and 
condition of this Agreement. No breach under this agreement shall be deemed 
waived or excused by either party unless such waiver or consent is in writing 
signed by the party granting such waiver or consent. The waiver by or consent of a 
party to a breach of any provision of this Agreement shall not operate or be 
construed as a waiver of or consent to any other or subsequent breach by such other 
party.  
• This Agreement may not be assigned (including by operation of law or otherwise) 
by you without WILEY's prior written consent. 
• Any fee required for this permission shall be non-refundable after thirty (30) days 
from receipt by the CCC. 
• These terms and conditions together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein) form the entire agreement between you 
and WILEY concerning this licensing transaction and (in the absence of fraud) 
supersedes all prior agreements and representations of the parties, oral or written. 
This Agreement may not be amended except in writing signed by both parties. This 
Agreement shall be binding upon and inure to the benefit of the parties' successors, 
legal representatives, and authorized assigns.  
• In the event of any conflict between your obligations established by these terms and 
conditions and those established by CCC's Billing and Payment terms and 
conditions, these terms and conditions shall prevail. 
• WILEY expressly reserves all rights not specifically granted in the combination of 
(i) the license details provided by you and accepted in the course of this licensing 
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment 
terms and conditions. 
• This Agreement will be void if the Type of Use, Format, Circulation, or Requestor 
Type was misrepresented during the licensing process. 
• This Agreement shall be governed by and construed in accordance with the laws of 
the State of New York, USA, without regards to such state's conflict of law rules. 
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Any legal action, suit or proceeding arising out of or relating to these Terms and 
Conditions or the breach thereof shall be instituted in a court of competent 
jurisdiction in New York County in the State of New York in the United States of 
America and each party hereby consents and submits to the personal jurisdiction of 
such court, waives any objection to venue in such court and consents to service of 
process by registered or certified mail, return receipt requested, at the last known 
address of such party. 
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription 
journals offering Online Open. Although most of the fully Open Access journals publish 
open access articles under the terms of the Creative Commons Attribution (CC BY) 
License only, the subscription journals and a few of the Open Access Journals offer a 
choice of Creative Commons Licenses. The license type is clearly identified on the article. 
 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and 
transmit an article, adapt the article and make commercial use of the article. The CC-BY 
license permits commercial and non- 
 
Creative Commons Attribution Non-Commercial License 
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use, 
distribution and reproduction in any medium, provided the original work is properly cited 
and is not used for commercial purposes.(see below) 
Creative Commons Attribution-Non-Commercial-NoDerivs License 
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND) 
permits use, distribution and reproduction in any medium, provided the original work is 
properly cited, is not used for commercial purposes and no modifications or adaptations are 
made. (see below) 
 
Use by commercial "for-profit" organizations 
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes 
requires further explicit permission from Wiley and will be subject to a fee. 
Further details can be found on Wiley Online 
Library http://olabout.wiley.com/WileyCDA/Section/id-410895.html 
 
 
Other Terms and Conditions: 
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Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or 
+1-978-646-2777. 
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Dear Dr. Morey, 
 
Thank you for your email. 
 
I would like to confirm that under the Frontiers Terms and Conditions, authors retain the copyright to 
their work. All Frontiers articles are Open Access and distributed under the terms of the Creative 
Commons Attribution License (CC-BY 3.0), which permits the re-use, distribution and reproduction of 
material from published articles, provided the original authors and source are credited. 
 
Please keep in mind that if anything in the paper, such as a figure, was already under copyright 
restriction from any other third-party, then you would have to seek permission to reuse the item. 
 
I hope I have addressed your question. Please let me know if you have any other questions or 
concerns. 
Best regards, 
 
Iacopo 
Iacopo Marcon, PhD 
Journal Development Specialist 
 
Frontiers | Editorial Office - Journal Development Team 
Journal Manager: Stéphanie Maret, PhD 
 
---------- Forwarded message ---------- 
From: Frontiers Editorial Office <editorial.office@frontiersin.org> 
Date: Tue, Feb 27, 2018 at 9:22 AM 
Subject: Fwd: Permission to Use Copyrighted Material in a Doctoral/Master’s Thesis 
To: Frontiers Research Topics Neuroscience <neuroscience@frontiersin.org> 
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---------- Forwarded message ---------- 
From: Trevor Morey  
Date: Mon, Feb 26, 2018 at 5:57 PM 
Subject: Permission to Use Copyrighted Material in a Doctoral/Master’s Thesis 
To: editorial.office@frontiersin.org 
 
Hello, 
I am a University of Western Ontario graduate student completing my Doctoral / Master’s 
thesis entitled “Regulation of Human 69-kDa Choline Acetyltransferase Protein Stability and 
Function by Molecular Chaperones and the Ubiquitin-Proteasome System”. My thesis will be 
available in full-text on the internet for reference, study and / or copy. Except in situations 
where a thesis is under embargo or restriction, the electronic version will be accessible 
through the Western Libraries web pages, the Library’s web catalogue, and also through web 
search engines. I will also be granting Library and Archives Canada and ProQuest/UMI a 
non-exclusive license to reproduce, loan, distribute, or sell single copies of my thesis by any 
means and in any form or format. These rights will in no way restrict republication of the 
material in any other form by you or by others authorized by you. 
I would like permission to allow inclusion of figures and text from the following publication; the 
materials will be attributed through citation: 
 Morey, T.M., Winick-Ng, W., Seah, C., and Rylett, R.J. (2017). Chaperone-mediated 
regulation of choline acetyltransferase protein stability and activity by HSC/HSP70, 
HSP90 and p97/VCP. Front Mol Neurosci. 10:415. doi: 10.3389/fnmol.2017.00415. 
Please confirm in writing or by email that these arrangements meet with your approval. 
Sincerely  
Trevor Morey 
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CURRICULUM VITAE 
 
Trevor M. Morey 
PubMed ID: “Morey TM” 
 
 
Education: 
 
• Ph.D Physiology; Western University: 2012 – 2018. 
o Supervisor: Dr. R. Jane Rylett 
o Thesis: Regulation of Human 69-kDa Choline Acetyltransferase Protein 
Stability and Function by Molecular Chaperones and the Ubiquitin-
Proteasome System – Defended January 2018 
 
• M.Sc. Molecular and Cellular Biology; University of Guelph: 2009 – 2012. 
o Supervisor: Dr. Richard Mosser 
o Thesis: The Effect of Noxa serine-13 Phosphorylation on Hyperthermia-
induced Apoptosis – Defended January 2012.  
 
• B.Sc. Molecular Biology and Genetics; University of Guelph: 2005 – 2009. 
 
 
Scholarships and Awards: 
 
• Robarts Research Institute Trainee Award; awarded a platform presentation at Robarts 
Research Retreat – June 2016 
 
• Queen Elizabeth II Scholarship – Ontario Graduate Scholarship; $15,000 awarded 
annually; Awarded 2x: September 2013–2014, September 2014–2015 
 
 
Publications: 
 
1. Morey, T.M., Winick-Ng, W., Seah, C., and Rylett, R.J. (2017). Chaperone-mediated 
regulation of choline acetyltransferase protein stability and activity by HSC/HSP70, 
HSP90 and p97/VCP. Front. Mol. Neurosci. 10:415. doi: 10.3389/fnmol.2017.00415. 
 
2. Winick-Ng, W., Caetano, F.A., Winick-Ng, J., Morey, T.M., Heit, B., and Rylett, 
R.J. (2016). 82-kDa choline acetyltransferase and SATB1 localize to -amyloid 
induced matrix attachment regions. Sci. Rep. 6:23914. doi: 10.1038/srep23914. 
 
3. Morey, T.M., Albers, S., Shilton, B.H., and Rylett, R.J. (2016). Enhanced 
ubiquitination and proteasomal-degradation of catalytically-deficient human choline 
acetyltransferase mutants. J. Neurochem. 137, 630-646. 
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4. Morey, T.M., Roufayel, R., Johnston, D.S., and Mosser, D.D. (2015). Heat shock 
inhibition of CDK5 increases NOXA levels through miR-23a repression. J. Biol. 
Chem. 290, 11443-11454. 
 
 
Scientific Meetings and Conferences:  
 
• Robarts Research Retreat, London, Ontario, Canada; June 20, 2017 
o Poster: Ubiquitination and Protein Stability of Catalytically-deficient Human 
Choline Acetyltransferase Mutants are regulated by the molecular chaperones 
HSC70 and HSP90s  
o Authors: Trevor M. Morey, Claudia Seah, and R. Jane Rylett 
o Scope: Institutional 
 
• London Health Research Day; London, Ontario, Canada; March 28, 2017 
o Poster: Ubiquitination and Protein Stability of Catalytically-deficient Human 
Choline Acetyltransferase Mutants are regulated by the molecular chaperones 
HSC/HSP70 and HSP90s  
o Authors: Trevor M. Morey, and R. Jane Rylett 
o Scope: Institutional 
o Facilitator for Salon B Platform Presentations, morning session 
 
• Physiology and Pharmacology Annual Research Day; London, Ontario, Canada; 
November 1, 2016. 
o Poster: Regulation of Catalytically-deficient Human Choline 
Acetyltransferase Mutants by the Heat Shock Family of Molecular 
Chaperones and the E3 Ubiquitin Ligase CHIP  
o Authors: Trevor M. Morey, Warren Winick-Ng, and R. Jane Rylett 
o Scope: Departmental 
o Awarded first place prize - Neurosciences 
 
• Robarts Research Retreat, London, Ontario, Canada; June 13, 2016 
o Platform Presentation: Enhanced Ubiquitination and Proteasomal-
degradation of Catalytically-deficient Human Choline Acetyltransferase 
Mutants  
o Authors: Trevor M. Morey, Shawn Albers, and R. Jane Rylett 
o Scope: Institutional  
 
• London Health Research Day; London, Ontario, Canada; March 29, 2016. 
o Platform Presentation: Enhanced Ubiquitination and Proteasomal-
degradation of Catalytically-deficient Human Choline Acetyltransferase 
Mutants 
o Authors: Trevor M. Morey, Shawn Albers, and R. Jane Rylett 
o Scope: Institutional 
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• Physiology and Pharmacology Annual Research Day; London, Ontario, Canada; 
November 3, 2015. 
o Poster: Decreased Activity and Increased Ubiquitin-Mediated Degradation of 
Human Choline Acetyltransferase by Mutation of an N-terminal Proline-Rich 
Motif. 
o Authors: Trevor M. Morey, Shawn Albers, Brian H. Shilton, and R. Jane 
Rylett 
o Scope: Departmental 
o Awarded first place prize - Neurosciences 
 
• Neuroscience 2015; Society for Neuroscience, Chicago, Illinois, USA; October 17-21, 
2015. 
o Poster: Decreased Activity and Increased Ubiquitin-Mediated Degradation of 
Human Choline Acetyltransferase by Mutation of an N-terminal Proline-Rich 
Motif. 
o Authors: Trevor M. Morey, Shawn Albers, Brian H. Shilton, and R. Jane 
Rylett 
o Scope: International 
 
• Robarts Research Retreat; London, Ontario, Canada; June 8, 2015. 
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a 
N-terminal Proline-rich Motif. 
o Authors: Trevor M. Morey, R. Jane Rylett 
o Scope: Institutional 
 
• London Health Research Day; London, Ontario, Canada; April 1, 2015. 
o Platform Presentation: Regulation of Human Choline Acetyltransferase 
Protein Stability and Enzyme Activity by an N-terminal Proline-rich Motif. 
o Authors: Trevor M. Morey, R. Jane Rylett 
o Scope: Institutional 
 
• Physiology and Pharmacology Annual Research Day; London, Ontario, Canada; 
November 4, 2014. 
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a 
N-terminal Proline-rich Motif. 
o Authors: Trevor M. Morey, R. Jane Rylett 
o Scope: Departmental 
o Awarded first place prize - Neurosciences 
 
• Canadian Student Health Research Forum; Winnipeg, Manitoba, Canada; June 10-12, 
2014. 
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a 
N-terminal Proline-rich Motif. 
o Authors: Trevor M. Morey, R. Jane Rylett 
o Scope: National; invite-only 
o Awarded an honorable mention 
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• Robarts Research Retreat; London, Ontario, Canada; June 9, 2014. 
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a 
N-terminal Proline-rich Motif. 
o Authors: Trevor M. Morey, R. Jane Rylett 
o Scope: Institutional 
 
• Southern Ontario Neuroscience Association; London, Ontario, Canada; May 5, 2014. 
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a 
N-terminal Proline-rich Motif. 
o Authors: Trevor M. Morey, R. Jane Rylett 
o Scope: Regional 
 
• London Health Research Day; London, Ontario, Canada; March 18, 2014. 
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a 
N-terminal Proline-rich Motif. 
o Authors: Trevor M. Morey, R. Jane Rylett 
o Scope: Institutional 
o Awarded first place prize – Neuroscience and Mental Health  
 
• Physiology and Pharmacology Annual Research Day; London, Ontario, Canada; 
November 4, 2013. 
o Poster: Regulation of Human Choline Acetyltransferase Protein Stability by a 
N-terminal Proline-rich Motif. 
o Authors: Trevor M. Morey, R. Jane Rylett 
o Scope: Departmental 
 
• Molecular and Cellular Biology Annual Research Day; Guelph, Ontario, Canada; 
April 2009. 
o Poster: The Effect of Noxa Serine-13 Phosphorylation on Hyperthermia-
induced Apoptosis. 
o Authors: Trevor M. Morey, Richard Mosser 
o Scope: Departmental 
 
 
Scientific and Technical Expertise: 
 
• Mammalian cell culture: 
o Culture and maintenance of primary murine cells and mammalian cell lines. 
o Plasmid transfection of adherent and non-adherent human cells lines. 
o Generation of stably-expressing mammalian cells lines. 
o Pharmacological experimentation. 
 
• Molecular techniques: 
o Plasmid design and generation: PCR (for both insertion and mutagenesis 
cloning), restriction digestion and purification, plasmid ligation. 
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o Plasmid preparation: Bacterial transformation, plating, growth, and 
purification. 
o Immunoblotting: Mammalian cell lysis, protein sample preparation, 1D SDS-
PAGE, electroblotting, and protein detection by chemiluminescence using film 
or ChemiDoc. 
o Immunoprecipitation, co-immunoprecipitation, and affinity purification. 
o Confocal microscopy 
o Advanced techniques: BioID, PLA, SDD-AGE. 
o Fluorescent and colorimetric plate-reader assays. 
o Radioenzymatic assays, 32P-orthophosphate live-labeling and detection. 
o Generation of novel assays (i.e. SPAAC pulse-chase). 
 
• Biochemical techniques: 
o Recombinant protein purification: Expression in E. coli BL21, bacterial lysis, 
Ni2+ affinity purification, TEV digestion, dialysis, cation exchange 
purification. 
o Biochemical plate-reader assays: enzymatic assays. 
o Circular dichroism with tandem thermal denaturation for measurement of in 
vitro protein structure and thermal stability. 
o MALDI and ESI mass spectrometry to identify protein-protein interactors 
 
 
Teaching Experience: 
 
• Phys1020 – Human Physiology, Western University, Sept. 2015 – April 2016. 
o Supervisor: Christine Bell 
o Position: Teaching Assistant 
 
• Phys1020 – Human Physiology, Western University, Sept. 2014 – April 2015. 
o Supervisor: Christine Bell 
o Position: Teaching Assistant 
 
• Phys1020 – Human Physiology, Western University, Sept. 2013 – April 2014. 
o Supervisor: Tom Stavraky 
o Position: Teaching Assistant 
 
• Phys3130y – Physiology Laboratory, Western University, Sept. 2013 – April 2013. 
o Supervisor: Tom Stavraky 
o Position: Teaching Assistant 
 
• Biol1090 – Introduction to Molecular and Cellular Biology, University of Guelph, 
Jan. 2011 – April 2011. 
o Supervisor: Kim Kirby 
o Position: Teaching Assistant 
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• MCB4010 – Advanced Cell Biology, University of Guelph, Jan. 2011 – April 2011; 
Jan. 2010 – April 2010. 
o Supervisor: Dr. Richard Mosser 
o Position: Teaching Assistant 
 
• MBG2000 – Introductory Genetics, University of Guelph, Sept. 2010 – Dec. 2010; 
May 2010 – Aug. 2010; Sept. 2009 – Dec. 2009. 
o Supervisor: Christine Schisler 
o Position: Teaching Assistant 
 
 
 
